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Although leukaemia specific antigens have been identified that are recognisable by
cytotoxic T lymphocytes (CTLs), there is little evidence to suggest that clinically
relevant immunity, directed against these antigens, develops in patients with acute
myeloid leukaemia (AML). A major reason for this is believed to be a consequence
of the lack of expression of costimulatory molecules by leukaemia cells. Studies
examining mechanisms of T cell activation have demonstrated the crucial role that
costimulatory molecules have in providing the signals necessary for the induction of
T lymphocyte activation and proliferation following initial T cell receptor
engagement of the MHC-peptide complex. A further reason for this failure to
develop leukaemia specific immunity is believed to be that the leukaemia
microenvironment is one in which the local production of immunosuppressive
cytokines and other soluble factors favours immune escape rather than control.
The hypothesis represented within this study is that modification of leukaemia cells
in order to allow expression of costimulatory molecules and/or production of
immunostimulatory cytokines would render these cells capable of generating
autologous leukaemia reactive CTLs. Two main approaches were employed in an
attempt to test this hypothesis. The first was based on the transfer of genes encoding
costimulatory molecules and immunostimulatory cytokines to leukaemia cells. The
second approach was the attempted induction of differentiation of leukaemia cells to
dendritic-like cells through the use of specific cytokine combinations.
A critical requirement for the success of any gene transfer strategy, in a clinical
setting, is a highly efficient and robust system of gene transfer to primary leukaemia
cells. Using Green Fluorescence Protein as a reporter gene a variety of gene transfer
methodologies were evaluated in myeloid leukaemia cell lines and primary cells. All
the physical and chemical methods tested generally had a low efficiency of gene
transfer. Two viral vector systems were evaluated. Although a retroviral vector
yielded high gene transfer efficiencies in 3 of 4 leukaemia cell lines efficiency was
very low in primary cells. An adenoviral vector similarly was efficient at gene
transfer in the myeloid leukaemia cell lines but gave a very variable level of gene
transfer in primary leukaemia cells. None of the methods tested was felt to fulfil the
requirements of a clinically useful gene transfer system.
The second approach involved the attempted differentiation of leukaemia cells to
dendritic-like cells (DLLC) by the use of specific cytokine combinations. Leukaemia
cells from 42 patients with AML were tested for evidence of differentiation
following their culture with cytokines GM-CSF, IL-4 and TNFa/CD40 ligand. In 22
cases the leukaemia cells were deemed to have undergone DLLC differentiation
based on upregulation of expression of costimulatory molecules and dendritic cell
associated markers, as measured by flow cytometry, and the acquisition of a
dendritic-cell like morphology. Antigen presenting function was measured in mixed
leukaemia lymphocyte reactions where DLLC were found to be potent stimulators of
allogeneic T lymphocyte proliferation. In 2 cases co-culture of DLLC with
autologous T lymphocytes led to the generation of CTLs that were capable of
xi
recognising and destroying unmodified cells in cytotoxicity assays. In 4 cases the
leukaemic cells had poor viability over the culture period and were therefore not
evaluable. In the remaining 16 cases the leukaemia cells were deemed to be resistant
to cytokine induced differentiation. Examination of the clinical features of these
cases showed a preponderance of poor risk karyotypic features. A variety of
differentiating agents were used in combination with cytokines in an attempt to
overcome differentiation resistance. Bryostatin-1 was found to be successful in
permitting DLLC differentiation to proceed but only in a proportion of the resistant
cases.
In summary DLLC derived from leukaemia cells by cytokine induced differentiation




1.1 Limitations of current treatment approaches in acute myeloid leukaemia
Acute myeloid leukaemia (AML) is a disease characterised by a clonal neoplastic
proliferation of cells of haematopoietic origin. Without treatment patients will
usually succumb to the complications of leukostasis or bone marrow failure within
days to weeks of the diagnosis being made. Conventional therapy aims at inducing
remission (defined as <5% blasts in the bone marrow) through intensive multi-agent
chemotherapy, followed by further blocks of consolidation chemotherapy. With this
type of approach it is possible to induce a morphological remission in >60% of
patients (Bennett et al, 1997). However, despite this, only a small number of patients
enjoy long-term survival, with the majority relapsing and eventually succumbing to
the disease or complications arising from its treatment. A review of the data from the
Eastern Cooperative Oncology Group trial serves to illustrate this, with of the 62% of
patient's who achieved complete remission, 70% subsequently relapsing and dying
from their leukaemia (Bennett et al, 1997). The major cause for relapse is due to the
presence of small amounts of residual morphologically undetectable leukaemic cells,
so-called minimal residual disease (MRD). In MRD the leukaemic blasts are often
resistant to the majority of the chemotherapeutic agents used to treat AML, thus
enabling them to survive through further courses of treatment. In an attempt to
eradicate MRD dose escalation has been employed, with autologous or allogeneic
haematopoietic stem cells being given to 'rescue' patients following myeloablative
chemotherapy. Autologous transplantation in AML confers some degree of benefit in
respect of improved disease-free survival but is associated with high rates of
treatment-associated mortality (Burnett et al, 1998; Ravindranath et al, 1996).
Allogeneic haematopoietic stem cell transplantation (SCT) has a more established
role in the treatment of AML (Casper et al, 1995). The improved disease-free
survival rates observed with allogeneic compared with autologous transplantation is
due, in large part, to a 'graft versus leukaemia' (GVL) effect (Korngold et al, 1994).
In GVL donor T lymphocytes are able to recognise and destroy host allogeneic
leukaemia cells (Falkenburg et al, 1997). In an attempt to harness this GVL effect,
donor lymphocyte infusion (DLI) has been used to treat relapse following allogeneic
haematopoietic SCT (Helg et al, 1998; Johnson & Truitt, 1995; Kolb et al, 1995;
Kolb, 1998; Mackinnon et al, 1995; Pati et al, 1995; Porter & Antin, 1995; Slavin et
al, 1993). DLI has had most success in patients with relapsed chronic myeloid
leukaemia (CML) but complete remission of relapsed AML has also been reported
with DLI alone (Helg et al, 1998; Kolb et al, 1995; Pati et al, 1995; Porter & Antin,
1995). Unfortunately GVL is almost invariably associated with the related but
distinct phenomenon of graft versus host disease (GVHD). In this condition normal
host tissues are attacked by donor T lymphocytes leading to a severe and potentially
life threatening multi-system disorder. It has not as yet proven possible to separate
the beneficial GVL effects from those of GVHD. However the presence of GVL
provides evidence that immunological control of AML is achievable, albeit within
the context of an allogeneic stem cell transplantation setting. Further laboratory
evidence supporting the importance of host cell-mediated immunological responses
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in the defence against leukaemia derives from a study examining the frequency of
cytotoxic T lymphocytes (CTL) specific for a leukaemia-specific antigen, PR1, in
patients with CML (Molldrem et al, 2000). PR1 specific CTL were only found in
patients who had received treatment that potentially could have stimulated host
immunity against leukaemia i.e. only in patients who had received
immunomodulatory therapies such as allogeneic haematopoietic SCT or IFNa, but
not in patients receiving chemotherapy alone. In addition the presence of these PR1
specific CTL correlated with clinical responses and survival. Patients with higher
numbers of circulating PR1 specific CTLs enjoyed more favourable clinical
outcomes (Molldrem et al, 2000).
Given the limitations of current conventional AML therapies and based on the
evidence suggesting that in certain settings immunological control of leukaemia is
possible, there is a need to develop novel immunotherapeutic strategies. Any new
therapy would need to fulfil three basic criteria:
• Specifically target the leukaemia cells
• Little or no toxicity against normal tissues
• Be able to eradicate MRD
Creating a tumour vaccine by modification of autologous leukaemic cells might
potentially offer a novel treatment approach that would fulfil these criteria (Arceci,
1998).
1.2 Early studies of immunotherapy in acute leukaemia
Early human studies that attempted to harness the immune system against cancer
gained inspiration from observations such as those of Coley-Nauts and colleagues,
which showed that exposure to bacterial toxins would sometimes induce a regression
in cancer patients (Coley-Nauts et al, 1946). These human studies, in addition to
results obtained from animal studies, led investigators to reason that it might be
possible to enhance the immune system of patients to eradicate tumour cells
especially in the MRD state. The first clinical trials in leukaemia were performed
using bacilli Calmette-Guerin (BCG) adjuvants which were believed to enhance
overall immune activity and possibly generate anti-tumour responses in the process.
In 1969 Mathe et al reported that immunisation with BCG following remission-
induction chemotherapy prolonged first remission in children with Acute
Lymphoblastic Leukaemia (ALL) (Mathe et al, 1969). Although subsequent studies
failed to confirm these findings other investigators tried immunotherapeutic based
treatment approaches in patients with AML (Gutterman et al, 1974; Powles, 1974;
Powles et al, 1975). Cellular vaccination using autologous and allogeneic leukaemia
blasts, either intact or as subcellular extracts, resulted in some studies in a minimal
prolongation of remission and survival (Foon et al, 1983; Zuhrie et al, 1980).
Laboratory support for the use of vaccine immunotherapy in patients with AML
derived from studies that showed that autoimmunisation of patients in remission with
irradiated leukaemia cells resulted in an increased in vitro response to leukaemic
blasts (Powles et al, 1971). However a review based on 1491 patients treated in
various vaccination studies concluded that overall this form of immunotherapy
conferred no definite clinical benefit (Foon et al, 1983).
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In all these studies the assumption was made that immunostimulatory antigens
existed in AML, although the nature of these antigens was unknown. Improved
understanding into the molecular and cell biology of tumour cell antigens and into
the mechanisms of T lymphocyte activation paved the way for the next wave of cell
based anti-tumour vaccines.
1.3 Identification of Immunostimulatory Antigens
Using techniques of cytotoxic T cell detection of immunostimulatory antigens in
combination with recombinant DNA procedures for expression cloning of genes it
has been possible to identify a range of different tumour antigens (Boel et al, 1995;
Boon, 1993; Boon et al, 1994; Boon et al, 1995; Cheever et al, 1995; Coulie et al,
1995; Coulie, 1995; Ostrand-Rosenberg, 1994; Pardoll, 1994; Slingluff et al, 1994;
Van Pel et al, 1995). Most of the immunostimulatory tumour antigens recognised by
CTL are short peptides (8-12 amino acids) held in the groove of Major
Histocompatibility Complex (MHC) class I molecule on the tumour cells. The
majority of tumour antigens have been MHC class I restricted and provide
stimulation for CTL responses. However class II MHC restricted T helper cell
responses have been shown to be important in anti-tumour responses observed in a
murine sarcoma model (Baskar et al, 1993). Immunostimulatory tumour antigens
thus far identified fall into several major classes of genes including:
1.4 Mechanisms of T cell activation
In order for T cell activation to take place there are a number of essential
requirements:
• Cell-cell adhesion
• Antigen presentation usually by MHC class I or II molecules
• T lymphocyte recognition of antigen and signaling through the T cell receptor
TCR (termed signal 1)
• A costimulation signal involving specific cell surface receptors on antigen
presenting cells (APC) and T cells (termed signal 2)
• Induction of interleukin-2 (IL-2) and its receptor by activated T cells resulting in
their proliferation and terminal effector function.
If adhesion or antigen presentation is blocked then T cell activation does not develop.
However subsequent re-challenge of T cells with antigen results in a normal immune
response. In contrast if antigen presentation (signal 1) occurs in the absence of the
second costimulatory signal, then antigen-specific hypo-responsiveness or anergy
results. This means that a subsequent antigen challenge does not lead to specific T
cell proliferation and function. Importantly this condition of anergy can in part be
overcome by continuous exposure of T cells to IL-2 in the presence of antigen
(Beverly et al, 1992).
One especially well-studied costimulation pathway involves the B7 family of
antigen-presenting cell surface molecules and their T cell receptors CD28 and
CTLA-4. Recent studies have demonstrated the pivotal importance of the B7
pathway in tumour-mediated costimulation. B7-1 (CD80) was first described as a
30kDa membrane protein appearing on B cells following activation (Freedman et al,
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• Normal differentiation antigens.
• Genes expressed during early embryonic development that are re-expressed
following malignant transformation (onco-foetal antigens).
• Mutated proto-oncogenes or fusion proteins that are created secondary to
chromosomal translocations.
• Viral derived proteins.
Although the majority of studies on tumour antigens have focused on solid tumours a
number of putative leukaemia-specific antigens have also been identified, based on
their ability to generate specific CTL responses. These include the AML-associated
DEK-CAN fusion peptide (Ohminami et al, 1999), the peptide BCR1/25, which
encompasses the fusion region of the hybrid molecule PML/RAR alpha and is
selectively expressed by blast cells in acute promyelocyte leukaemia (APL)
(Gambacorti-Passerini et al, 1993), the Wilm's tumour gene encoded transcription
factor, WT-1 (Gao et al, 2000; Gaiger et al, 2000; Inoue et al, 1997; Menssen et al,
1995; Ohminami et al, 2000) and PR1, a peptide derived from proteinase-3 found in
the primary granules of myeloid leukaemia cells (Molldrem et al, 1996; Molldrem et
al, 2000).
The identification of immunostimulatory antigens has been an important advance in
understanding anti-tumour immunity. However the mechanisms through which
malignant cells evade immune recognition and eradication, despite their expression
of immunostimulatory antigens, have only recently become evident. Critical
observations on antigen recognition and T cell activation have now emerged that
have allowed insight into the process through which T cells become activated.
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1987; Yokochi et al, 1982) as well as on other antigen-presenting cells (APC) such
as monocytes, macrophages, Langerhans cells and dendritic cells (Hathcock et al,
1993). CD80 can be induced by a variety of stimuli; for B cells this includes anti¬
immunoglobulin cross-linking (Hathcock et al, 1994) and stimulation with IL-4
(Valle et al, 1991) or IL-7 (Yssel et al, 1993) and for macrophages stimulation with y
interferon (Hirano et al, 1996). A second B7 family gene was cloned and termed B7-
2 (CD86) (Freeman et al, 1993; Freeman et al, 1993; Hathcock et al, 1993). CD86 is
constitutively expressed on monocytes and upregulated within 24 hours on B cells
following activation, in comparison to CD80, which is expressed on APC only
following activation (Azuma et al, 1993; Boussiotis et al, 1993; Freeman et al, 1993;
Hathcock et al, 1993). Thus CD86 may provide a very early costimulation signal
and CD80 contributes a subsequent signal. Further studies have shown that CD80
and CD86 may provide signals leading to both qualitative and quantitative
differences in the immune repertoire (Kuchroo et al, 1995; Thompson, 1995). In
animal models costimulatory vaccines utilising CD80 and CD86 have led to quite
different degrees of anti-tumour responses (Gajewski, 1996; Yang et al, 1995). The
primary receptor for the B7 costimulatory molecule is a 44kda homodimeric cell
surface glycoprotein named CD28, which is found on T cells (Aruffo & Seed, 1987).
Increased surface expression of CD28 occurs following TCR binding to antigen
(Hara et al, 1985; June et al, 1987; Ledbetter et al, 1985; Linsley & Ledbetter, 1993;
Turka et al, 1992). Following TCR activation alone T cells are able to undergo
minimal amounts of proliferation and cytokine secretion. However following the
additional engagement of the CD28 receptor, T cell proliferation, function and
cytokine secretion become maximally stimulated (Schwartz, 1992).
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It has been hypothesized that tumour cells may escape immune recognition and
subsequent eradication by failing to satisfy one or more of the above requirements
for T cell antigen recognition and activation (Bluestone, 1995; Bluestone, 1996;
Chen et al, 1992; Chen et al, 1993; Guinan et al, 1994; June et al, 1994). Thus if
antigen presentation does not occur because of low or absent expression ofMHC or
lack of a recognisable tumour antigen, then tumour cells would not be recognised.
On the other hand, if antigen recognition occurs by T cells but tumour cells do not
express a costimulatory molecule, then T cells become anergic. Studies examining
costimulatory molecule expression in AML have demonstrated that in a minority of
AML cases the leukaemia cells do express CD86 but in no cases was significant
expression of CD80 seen (Brouwer et al, 2000a; Costello et al, 1998; Hirano et al,
1996; Maeda et al, 1998; Zheng et al, 1998). Therefore, based on the evidence from
these studies, the leukaemia cells in AML would be incapable of stimulating T cell
mediated anti-leukaemia immunity because of their lack of expression of
costimulatory molecules. A potential strategy for eliciting a specific anti-leukaemia T
cell response would be to modify autologous leukaemia cells in such a way that they
express the costimulatory molecules that are critical in providing the second signal
necessary for T cell activation and proliferation (Figure 1.1).
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Figure 1.1 Mechanisms of T cell Activation
A. Recognition of MHC/peptide complexes on the surface of an antigen presenting
cell by TCR in the presence of a second costimulatory signal mediated by B7 leads
to T cell activation and proliferation.
B. Absence of B7 expression by leukaemia cells means that there is no
costimulatory signal following TCR binding of MHC/peptide complex with
consequent T cell anergy
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1.5 The Influence of the cytokine microenvironment
Although the decision to initiate an immune response is dependent upon antigen
recognition by the TCR in conjunction with costimulatory molecule signalling, the
cytokine microenvironment plays an important role in determining the nature of any
response generated (Buggins et al, 1999). Leukaemia cells have been shown to
produce a number of soluble factors that can prevent or undermine T cell activation
(Buggins et al, 1999; Chouaib et al, 1997). Immunosuppressive factors produced by
tumour cells, including leukaemia cells, include vascular endothelial growth factor
(Aguayo et al, 1999; Gabrilovich et al, 1996), TGFp (de Visser & Kast, 1999;
Espevik et al, 1987; Espinoza-Delgado et al, 1994), IL-10 (Akdis et al, 1998; de
Waal et al, 1992; Groux et al, 1996) and soluble Fas ligand (Buzyn et al, 1998;
Buzyn et al, 1999). Therefore if a tumour vaccine is to be effective it must be
capable of altering the cytokine microenvironment so as to favour an appropriate T
cell response. Dendritic cells (DC) are professional APC that play a crucial role in
the initiation of immunity (Avigan, 1999; Banchereau & Steinman, 1998; Colaco,
1999; Hart, 1997; Reid, 1998; van Schooten et al, 1997). The cytokine profile
produced by DC at the time of antigen presentation dictates the nature of T cell
activation through influencing the Thl/Th2 decision during T cell differentiation
(Kalinski et al, 1999a; Vieira et al, 2000). One of the most important cytokines in the
development of T cell responses is IL-12, a heterodimeric disulphide-linked
glycoprotein consisting of a 35 and a 40kD subunit (Kobayashi et al, 1989). It has
been shown to be a potent immunostimulatory cytokine that mediates a number of
biological important properties. These include stimulation of cytotoxicity and
proliferation of NK cells and CTL, induction of cytokine and chemokine secretion,
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especially IFN-y, and generation of T helper type 1 (Thl) cells (Brunda, 1994;
Trinchieri, 1994; Trinchieri, 1998). DC that produce high levels of IL-12 cause
polarization of T cells towards a Thl phenotype whereas DC that produce low levels
of IL-12 generate T cells with a Th2 phenotype (Brunda et al, 1995; Kalinski et al,
1999a; Macatonia et al, 1995; Palm et al, 1996; Vieira et al, 2000). Effective anti-
leukaemia immunity is generally considered to require a cell-mediated Thl response.
In order for DC to produce high levels of IL-12 they must first have undergone
maturation. One of the most important pathways for DC maturation involves the
binding of the cell surface receptor CD40 by its ligand CD40 ligand (CD40L) present
on activated T cells (Van Kooten & Banchereau, 1997; Van Kooten & Banchereau,
2000). CD40, is a 50kD molecule expressed on B cells, DC and other professional
APC (Van Kooten & Banchereau, 1997; Van Kooten & Banchereau, 2000). Binding
of CD40L to CD40 on DC leads to the up-regulation of costimulatory molecule
expression and to the production of IL-12 (Caux et al, 1994; Cella et al, 1996;
Mackey et al, 1998; Mosca et al, 2000; Van Kooten & Banchereau, 1997; Van
Kooten & Banchereau, 2000) and IL-15 (Kuniyoshi et al, 1999). Other maturation
stimuli that promote IL-12 production by DC include IFN-y (Kalinski et al, 1999a;
Kalinski et al, 1999b; Vieira et al, 2000 and TNF-a (Sallusto & Lanzavecchia,
1994). Following maturation induction DC become potent immunostimulators
capable of initiating Thl responses (Mackey et al, 1998; Terheyden et al, 2000). It is
this ability to alter the cytokine microenvironment at the time of antigen presentation
and so determine the nature of subsequent T cell immune responses that makes DC
such effective APC.
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1.6 Development of vaccines by modification of autologous leukaemia cells
The principle of vaccination with autologous leukaemia cells is based on the
assumption that leukaemia cells possess antigens recognisable by autologous T cells
and that it is solely due to a lack of costimulatory molecule expression that immune
activation fails to take place. Therefore if the leukaemia cells could be modified in
such a way that they gain expression of the required costimulatory molecules and/or
produce immunostimulatory cytokines then they might become capable of
stimulating autologous T cells to recognise and destroy unmodified leukaemia cells
(Allison et al, 1995; Bruserud & Gjertsen, 2000). This could be achieved by either:
• Gene transfer of costimulatory molecules and/or cytokines
• Induction of differentiation thereby leading to upregulation of costimulatory
molecule expression
1.6.1 Gene transfer of costimulatory molecules or cytokines
Immune gene transfer strategies are all reliant on a robust and efficient gene transfer
method for success. The gene transfer technique needs to fulfil a number of
requirements in order to be suitable for use in an immunotherapeutic strategy. It must
give a high efficiency of gene transfer to the target cell, with low toxicity, and
transgene expression must be sufficiently high and of long enough duration to allow
the modified cell vaccine to stimulate an immune response.
Gene transfer technologies can be broadly divided into three types:
• Physical methods e.g. electroporation
• Chemical methods e.g. polycationic liposomes, activated dendrimers
• Viral methods e.g. retroviral vectors, adenoviral vectors
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1.6.1.1 Gene transfer methods
i/ Electroporation
Electroporation involves using a short duration high voltage pulse that causes the
membrane potential of the cells to break down. As a result pores are formed through
which macromolecules such as DNA can enter. The main advantage of
electroporation is its applicability for transient and stable transfection in all cell
types. A major drawback however is the high cell mortality that can result, typically
in the region of 50-70% cell death.
ii/ Cationic liposomes
Feigner and colleagues first introduced liposomes in 1987 (Feigner et al, 1987).
Liposomes typically contain a mixture of cationic and neutral lipid, the latter often
being L-dioleoyl phosphatidyl ethanolamine (DOPE). The cationic portion of the
lipid molecule associates with the negatively charged nucleic acid, resulting in a
liposome/DNA complex. The overall net positive charge of the liposome/DNA
complex generally results in high transfer efficiencies because it allows closer
association of the complex with the negatively charged cell membrane. The uptake of
the liposome/DNA complex is then thought to take place by endocytosis.
iii/ Activated dendrimers
Dendrimers are highly branched spherical molecules with branches radiating from a
central core molecule and terminating at amino groups (Tang & Szoka, 1997).
Activation of newly synthesised dendrimers involves complete removal of some of
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the tertiary amines, resulting in a molecule with a higher degree of flexibility (Tang
et al, 1996). Activated dendrimers assemble DNA into compact structures through
interaction of the negatively charged phosphate groups of nucleic acids with the
positively charged amino groups of the dendrimers. The resulting DNA-activated
dendrimer complexes possess a net positive charge on the surface molecules of the
cell membrane. The transfection complexes are taken up by non-specific
endocytosis.
iv/ Retroviral vectors
Retroviruses are a class of enveloped viruses containing a single stranded RNA
molecule as a genome. Following infection the viral genome is reverse transcribed
into double stranded DNA, which is integrated into the host genome and expressed
as proteins (Figure 1.2). The viral genome is approximately 10Kb, containing at least
three genes, gag (coding for core proteins), pol (coding for reverse transcriptase) and
env (coding for envelope protein). At each end of the genome long terminal repeats
(LTR), which include promoter/enhancer regions and sequences involved in
integration (Figure 1.3). In addition there are sequences required for packaging the
viral DNA (\j/) and RNA splice sites in the envelope.
Vector systems based on retroviruses can be divided into two components, the
retroviral vector and the packaging cells. The retroviral vector is manipulated in its
DNA form as part of a bacterial plasmid. The vector does not encode viral proteins
but serves as a vehicle for the genes to be transferred. The retroviral packaging cells
provide all the viral proteins necessary for encapsidation of the vector RNA into
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virions and for subsequent infection, reverse transcription and integration of the
vector into the genomic DNA of cells (Figure 1.2).
The design of retrovirus packaging cell line has evolved to address the problem of
spontaneous helper production such that gag-pol and env viral proteins are separated
on different expression plasmids that are independently transfected into the
packaging cells, meaning that three recombination events are necessary for wild type
virus production (Figure 1.3).
Retroviral vectors are most frequently based on the Moloney-murine leukaemia virus
(Mo-MLV), which is an amphotrophic virus capable of infecting mouse and human
cells. Attachment of the retrovirus to a target cell is dependent upon the binding of
retroviral envelope protein with specific target cell receptors. Different viruses differ
with respect to their tropisms therefore by replacing the env gene with that of another
virus the host range can be extended in a technique known as pseudo-typing
(Karavanas et al, 1998). An example of this is the vesicular stomatitis virus-G (VSV-
G) protein which has been incorporated into a Mo-MLV derived vector thereby
markedly broadening the vector's host range (Yee et al, 1994). Transgene expression
can be driven by the promoter/enhancer region in the 5' LTR or by an alternative
viral (e.g. Cytomegalovirus) promoter. The available carrying capacity for retroviral
vectors is approximately 7.5kb, which is too small for some genes even if cDNA is
used (Verma & Somia, 1997). A requirement for retroviral integration and
expression of viral genes is that the target cells must undergo at least one round of
cell division. This limits the use of these vectors to proliferating cells.
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Figure 1.2 Retroviral life-cycle and production of recombination retroviral vectors
by packaging cell lines
A. Retroviral replication cycle. Binding of the virus to the host cell takes place by the
interaction between viral envelope proteins and specific receptors on the host cell
surface. This is followed by viral internalisation and release of the viral core into the
cytoplasm. Viral RNA is uncoated, reverse transcribed and transported to the
nucleus. The viral DNA is then stably integrated into the host genome. During DNA
synthesis viral RNA is produced and translated to produce viral proteins and
enzymes. Mature virons are formed following encapsidation of the viral core
proteins. The virions are released from the cell where they are able to infect other
cells.
B. Retroviral packaging cell line and viral vector production. Viral genes encoding
retroviral structural and enzymatic proteins are stably introduced into cells. When a
retroviral vector is introduced into the cell, the viral vector RNA can be packaged
resulting in the production of a infectious virus particle. These viral particles can be
harvested and used to infect a target cell in order to introduce a foreign gene on the
vector into the cells.
Reproduced (following modification), with permission, from Development of
lentiviral vectors for gene therapy of human diseases Blood 2000;95:2499-2504
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Figure 1.3 Comparison of wild type retrovirus and replication-incompetent retroviral
vector
A. Generic helper virus-Mo-MLV is shown
B. Generic retroviral vector with non-viral sequences inserted into the vector
\|/ indicates the retroviral packaging signal
Gag, pol and env represent the viral genes
SD and SA are the splice donor and acceptor used for expression of the env gene
Promoters are indicated by boxes with arrows pointing in the direction of
transcription
PA indicates the polyadenylation site
LTR indicates the retroviral long terminal repeat
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v/ Lentiviral vectors
Lentiviruses are a subclass of retroviruses, which are able to infect both proliferating
and non-proliferating cells (Buchschacher, Jr. & Wong-Staal, 2000; Naldini et al,
1996; Uchida et al, 1998). Their genome is considerably more complex than simple
retroviruses containing an additional six proteins; tat, rev, vpr, nef and vif. Because
of this ability to infect non-dividing cells there has been great interest in the
development of lentivirus vectors for use in clinical gene transfer studies
(Buchschacher, Jr. & Wong-Staal, 2000). However the complex genome and
replication cycle of lentiviruses, best exemplified by HIV-1, has meant that
development of vectors and packaging cell lines has been more difficult in
comparison with retroviruses. With recent advances in the understanding of HIV
replication it has been possible to generate relatively high-titre lentivirus vectors
(Stripecke et al, 2000). Lentivirus vectors based on other primate viruses, such as
HIV-2 and simian immunodeficiency virus, and non-primate lentiviruses such as
feline immunodeficiency virus have also been designed.
vi/ Adenoviral vectors
Adenovirus is a non-enveloped icosahedral structure with 20 triangular surfaces, 12
vertices and a diameter of around 70nm (Morsy & Caskey, 1999). The capsid
proteins are composed of 20 hexons, 12 pentons and a fibre protein. The fibre
protein is a rod like structure that protrudes from each penton base. The viral genome
comprises linear, double stranded DNA (around 36kb) which encodes early- and
late- expressed genes; their replication is early or late in relation to the onset of viral
replication (Morsy & Caskey, 1999). All viral proteins can be supplemented in trans,
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thus coding sequences can be eliminated. The only essential cis elements required for
viral propagation and packaging are the packaging signal sequences and the inverted
terminal repeats (Yeh & Perricaudet, 1997). The most important advance in the
development of adenoviral vectors was the finding that replication defective
adenoviruses lacking portions of the El region of the viral genome could be
propagated in cells engineered to express the El genes (Jones & Shenk, 1979). Most
of the adenovirus vectors currently in use carry deletions in the E1A-E1B and E3
regions of the viral genome. The elimination of adenovirus coding sequences allows
generation of vectors that lack expressed viral proteins thus giving a greater safety
profile, reduced immunogenicity and a large insert capacity (up to 37kb) (Yeh &
Perricaudet, 1997). Expression of the inserted sequence is usually promoted either by
the ElA promoter, the major late promoter (MLP) and associated leader sequences,
the E3 promoter or exogenously added promoter sequences. Adenoviruses attach to
the cell surface and are endocytosed via two receptors, the coxsackie and adenovirus
receptor (CAR) and the integrin cell surface receptor (Bergelson et al, 1997). Vectors
based on adenovirus are able to infect non-dividing cells. In contrast to retrovirus
vectors, transgene expression is not dependent upon integration with the host
genome. In fact integration of adenoviral DNA sequences into the chromosomal
DNA of a target cell is an uncommon event and as a consequence transgene
expression is not permanent.
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1.6.1.2 Comparative Studies of Gene Transfer Methodologies
As stated above the success of any immune gene transfer strategy is critically
dependent upon a highly efficient gene transfer technique. There have been no
comparative studies examining different gene transfer methods to leukaemia cells
from patients with AML, but there has been a single such study in ALL
(Mascarenhas et al, 1998). In this study a variety of gene transfer approaches were
tested in the precursor B ALL cell lines, Nalm-6 and Reh, and in human primary
ALL blasts. The gene transfer methods used were electroporation, polycationic
liposomes, activated dendrimers, retrovirus and lentivirus vectors.
In order to determine gene transfer efficiency (GTE) a reporter gene coding for the
enhanced form of green fluorescent protein (GFP) was used. GFP is derived from the
jellyfish Aequora victoria. It absorbs blue light (absorption wavelength peak 395nm)
and emits green light (emission wavelength peak 508nm), which is detectable using a
fluorescence microscope or by flow cytometric analysis. Enhanced GFP is a red
shifted variant of GFP that contains two mutations, S65T and P64L (Zhang et al,
1996). In addition enhanced GFP has been re-engineered with more than 190 silent
base changes corresponding to human codon usage preferences (Zhang et al, 1996).
The GFP variant exhibits higher expression and fluorescence intensity than wild type
GFP (Yang et al, 1996). The combined effect of these changes results in an increased
sensitivity of up to 350 times over wild type GFP when excited at 488nm thus
making detection more sensitive (Cormack et al, 1996).
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By flow cytometric measurement of enhanced GFP expression the GTE for each of
the gene transfer methods was determined in ALL leukaemia cells. Gene transfer to
leukaemia cells derived from the ALL cells lines, Nalm-6 and Reh cells, by
electroporation was minimal and associated with significant cell mortality. No
measurable gene transfer was achieved with the activated dendrimer (Superfect). Of
the polycationic liposomes used only one, Cellfectin, produced reproducible low-
level gene transfer. Retroviral vectors based on the Mo-MLV, pseudotyped with
VSV-G envelope, transduced Nalm-6 cells more efficiently than Reh. High levels of
stable gene transduction could be achieved in Nalm-6 cells by co-cultivation with
murine packaging cells and using cell free virus supernatant on either bone marrow
stroma or with the recombinant fibronectin fragment, CH-296 (Mascarenhas et al,
1998). The highest level of gene transfer in both Nalm-6 and Reh cells was achieved
using lentivirus vectors pseudotyped with the VSV-G envelope. Primary B-precursor
ALL cells from 5 patients were found to be efficiently transduced by both Mo-MLV
based (range 4.1-74%, mean 35.1%) and lentivirus based vectors (range 29.1-43.3%,
mean 31.1%) (Mascarenhas et al, 1998).
Although no comparable study exists for primary AML leukaemia cells studies have
been performed in which the GTE for individual gene transfer methods has been
assessed. Leukaemia cells from a single patient with AML underwent electroporation
in the presence of plasmid DNA containing the cDNA for CD80 (Mutis et al, 1998).
Expression of CD80 by the leukaemia cells, measured by flow cytometry, was of a
low level and transient. All other studies examining gene transfer to AML cells have
utilised viral-based vector systems (Summarised in Table 1.1).
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Gene transfer to primary human AML blasts derived from 10 patients, using a Mo-
MLV-based retroviral vector containing the cDNA for CD80, gave a GTE ranging
from 0.3-8.2% (mean 1.5%) (Hirst et al, 1997). Because of the requirement for the
target cell to be in cycle to allow transgene expression to take place, the cytokines
IL3, GM-CSF and SCF were used to stimulate cell division. This led to an increase
in mean GTE to 3.9%. However there was no apparent correlation between the GTE
and the degree of cellular proliferation as measured by bromodeoxyuridine uptake
(Hirst et al, 1997).
There have been two studies in which lentiviral vectors were used for gene transfer
to primary AML blasts. In the first of these a lentiviral vector containing the cDNA
for CD80 was used to infect leukaemic cells from 5 patients with AML (Stripecke et
al, 2000). GTE ranged from 61.7-87.6% (mean 77.6%) (Stripecke et al, 2000). In the
second study, using a lentiviral vector containing cDNA coding for GFP, GTE in
leukaemia cells from 5 AML cases ranged from 12.6-32% (mean 19.5) (Biagi et al,
2001). In both these studies the lentiviral vectors were pseudotyped with VSV-G
envelope protein. Although cell division is not a requirement for lentiviral vector
expression leukaemia cells were cultured in growth-stimulating cytokines prior to
infection in both studies (Table 1.1).
GTE to primary AML blasts using adenoviral vectors has been examined in one
study. Using an adenoviral vector containing the cDNA for B-galactosidase as a
reporter gene, GTE in leukaemia cells from 25 AML cases was highly variable,
ranging from 0-74.7% (mean 10.26%) (Gonzalez et al, 1999). Previous studies
examining adenoviral infection of haematopoietic cells provide insight into why
adenoviral vectors should show such variability in GTE to leukaemia cells.
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Haematopoietic cells do not express the main adenovirus receptor CAR and viral
attachment is therefore dependent upon binding to integrins (Huang et al, 1996). In
general haematopoietic cells have low levels of expression of the avp3 and avp5
integrins, which mediate adenovirus internalisation by binding to the adenoviral
penton base via a RGD motif (Huang et al, 1995).
In an attempt to improve adenovirus vector attachment, and therefore GTE, in
haematopoietic cells various approaches have been tried. Combining adenoviral
vectors with polycationic lipids has been shown to improve GTE in haematopoietic
cells (Clark et al, 1999; Dietz & Vuk-Pavlovic, 1998; Fasbender et al, 1997). An
alternative approach is to modify the adenoviral vector by retargeting it to bind to
different cell surface receptors (Douglas et al, 1996; Douglas et al, 1999; Smith et al,
1999; Wickham et al, 1996). Wickham et al described an adenoviral vector
AdZ.F(pk7) containing a modified fibre protein where polylysine had been added to
the c-terminal end of the fibre (Wickham et al, 1996). This vector, through binding
of polylysines to heparan-sulphate containing receptors, could increase virus
adsorption and GTE in cell types expressing low levels of adenovirus receptors. As it
is known that haematopoietic stem cells express heparan-sulphate receptors the
AdZ.F(pk7) vector was evaluated in primary AML cells. Leukaemic cells from 25
patients with AML were infected at multiplicity of infection (MOI) of 100 with the
AdZ.F9(pk7) vector containing the cDNA for B-galactosidase (Gonzalez et al,
1999). GTE ranged from 70-100% (mean 94.3%) (Gonzalez et al, 1999). The
addition of cytokines SCF, IL-3 and GM-CSF was essential as their omission led to a
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1.6.1.3 Immunostimulatory properties following gene transfer
In vitro studies, based on the gene transfer of cDNA coding for CD80 to primary
human AML blasts, have shown that leukaemia cells expressing CD80 are capable of
stimulating the proliferation of allogeneic T lymphocytes (Hirst et al, 1997).
A number of in vivo studies have been performed with murine leukaemia models.
Using the Ml murine leukaemia model, leukaemia cells were transduced with CD80
and then tested for their ability to induce anti-leukaemia immunity (Hirano et al,
1997). When syngeneic, immunocompetent SL mice were injected with two
independent CD80 transduced monoclonal sublines, Ml-B7-l/F/clone F20 and Ml-
B7-l/F/clone F7, 57% and 43% of mice, respectively, were able to reject the
modified leukaemia cells. In vivo depletion of T cell subsets showed that both CD4+
and CD8 T cells were indispensable for the development of anti-leukemic immunity.
Although a single exposure of irradiated monoclonal M1-B7/1/F cells was not fully
effective, multiple exposures induced protective immunity against subsequent
challenge with parental Ml cells (Hirano et al, 1997). Furthermore, multiple
vaccinations with irradiated monoclonal Ml-B7-l/F/clone F7 cells could cure 67%
ofmice previously injected with a lethal number ofMl cells.
Other investigators have utilised a radiation/dexamethasone-induced murine
leukaemia model that closely mimics AML in humans (Resnitzky et al, 1985). Initial
studies using this model involved the transduction of leukaemic cells with a
retroviral vector containing the cDNA coding for CD80. Infusion of CD80
transduced mAML cells into a syngeneic host led to complete eradication of the
leukaemia if less than 106 cells were infused but if greater than 106 cells were infused
although time till death was prolonged animals were not cured (Dunussi-
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Joannopoulos et al, 1996). CD80 transduced mAML cells were also capable of
protecting animals from the development of leukaemia when later challenged with
unmodified mAML leukaemia cells. In animals immunised intravenously with 105
irradiated CD80 transduced mAML cells subsequent infusion of 105 unmodified
mAML cells did not result in the development of leukaemia (Dunussi-Joannopoulos
et al, 1996). This anti-leukaemic immune response was dependent on the interaction
of CD80 and the T cell CD28 receptor as blocking of this with CTLA4/Ig eliminated
the efficacy of the vaccine (Dunussi-Joannopoulos et al, 1996). To test whether this
approach would be successful in treating established disease animals were first
inoculated with unmodified mAML cells and allowed to develop leukaemia. Mice
were then infused with CD80 transduced mAML cells. If given early in the course of
the disease the tumour vaccine led to cure of the animals, however, in late-stage
disease although time to death was prolonged animals were not cured (Dunussi-
Joannopoulos et al, 1996; Dunussi-Joannopoulos et al, 1997). When vaccination with
CD80 transduced mAML cells was given to treat animals with established leukaemia
following prior cytoreductive therapy, it proved more effective in eliciting cure than
chemotherapy or vaccination alone (Dunussi-Joannopoulos et al, 1997). This
suggests that the setting for such a strategy would be following remission-induction
therapy when there is a relatively low tumour burden.
Using this model the same group of investigators evaluated the efficacy of vaccines
based on leukaemia cells transduced with the cDNA for a variety of
immunostimulatory cytokines. Vaccination with mAML cells transduced with cDNA
for GM-CSF led to improved cure of established disease in comparison with CD80
transduced mAML cells (Dunussi-Joannopoulos et al, 1998). The effectiveness of
-27-
the GM-CSF transduced mAML based vaccine did not appear to be dependent upon
the presence of T cells and it was hypothesized that the production of GM-CSF by
the leukaemic blasts might have promoted direct leukaemia killing through the
recruitment of immune effectors such as activated natural killer cells, macrophages,
neutrophils and eosinophils (Dunussi-Joannopoulos et al, 1998). More recently IL-12
transduced mAML cells have been evaluated using this model (Dunussi-
Joannopoulos et al, 1999). Vaccination with IL-12 transduced mAML cells was able
to cure established leukaemia and generate long-lasting leukaemia-specific immunity
(Dunussi-Joannopoulos et al, 1999). This effect was shown to be dependent upon the
presence of IL-12 as use of blocking anti-IL-12 monoclonal antibodies (mAb)
abrogated the therapeutic effect. It was shown that IL-12 mediated its effect through
stimulating the local production of IFN-y, as depletion of IFN-y also abolished the
efficacy of the vaccine (Dunussi-Joannopoulos et al, 1999).
These in vivo studies with cytokine gene transduced leukaemia vaccines provide
evidence in support of the hypothesis that the generation of therapeutic immunity is
dependent upon the creation of a suitable immunostimulatory cytokine
microenviroment. Based on the studies that suggest that the leukaemia
microenvironment is immunosuppressive, tumour vaccines based solely on the gene
transfer of costimulatory molecules might prove to be ineffective at promoting anti-
leukaemia immunity, as they would be incapable of favourably altering the cytokine
microenvironment. In an attempt to address this problem vaccines have been
designed in which the tumour cells are transduced with vectors that contain cDNA
for both a costimulatory molecule and an immunostimulatory cytokine, for example
CD80 combined with IL-12 (Zitvogel et al, 1996) or GM-CSF (Stripecke et al,
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1999). In a murine ALL model higher leukaemia rejection rates were achieved using
leukaemia cells transduced with the cDNA for both CD80 and GM-CSF in
comparison with leukaemia cells transduced with CD80 alone (Stripecke et al, 1999).
1.6.2 Differentiation induction in human myeloid leukaemia cells
An alternative way of modifying leukaemia cells in such a way as to increase their
immunostimulatory properties is by inducing leukaemia cell differentiation. AML is
characterised by a block in normal haematopoietic differentiation with the
consequence that there is an accumulation of leukaemia cells showing differentiation
up to but not beyond the stage of the arrest. In the FAB classification of AML there
is a subdivision into seven categories depending on morphological and phenotypic
evidence for myeloid, monocytic, erthyroid or megakaryocytic differentiation and on
the degree of subsequent cell maturation (Fig 1.4). Recent studies have advanced our
understanding of the molecular mechanisms underlying this differentiation arrest.
Several lines of evidence point towards a common theme in the molecular
pathogenesis of AML namely that the end result of many of the common
chromosomal rearrangements found in AML is the transcriptional repression of
genes involved in haematopoietic differentiation (Redner et al, 1999). In the case of
three of these chromosomal rearrangement; t(15;17), t(8;21) and inv(16), the fusion
protein products exert their repressive effect by altering histone acetylation status
thereby leading to transcriptional inactivation. Despite the differentiation block it is
still possible to induce leukaemia cell differentiation by using differentiating agents




































Figure 1.4 FAB classification of Acute Myeloid Leukaemia
-30-
1.6.2.1 Differentiating agents
Studies have shown that a variety of agents are capable of inducing differentiation in
leukaemia cells. Examples of differentiating agents include vitamin D3 (Miyaura et
al, 1981; Olsson et al, 1983), retinoic acid (Breitman et al, 1980), azacytidine (AZA)
(Attadia, 1993; Lubbert, 2000; Pinto et al, 1984), trichostatin (TSA) (Kosugi et al,
1999; Wang et al, 1999; Yoshida et al, 1987; Yoshida et al, 1990), bryostatin
(BRYO) (Kaneki et al, 1999; Steube & Drexler, 1993) and calcium ionomycin (CI)
(Engels et al, 1998; Engels et al, 1999; Koski et al, 1997; Koski et al, 1999a; Koski
et al, 1999b) (Summarised in Table 1.2).
Only the retinoic acid derivative, ATRA, has thus far proven to be clinically useful
(Fenaux et al, 1993; Grimwade et al, 1998). At pharmacological doses ATRA is able
to relieve the transcriptional repression mediated by the PML-RARA fusion protein,
present in t(l 5; 17) APML, thereby causing the differentiation of leukaemia cells into
mature granulocytes (Zhang et al, 2000). In combination with chemotherapy the
treatment of patients with t(l 5; 17) APML with ATRA has lead to leukaemia-free 5
year survival rates of greater than 70% (Grimwade et al, 1998).
The rationale for using TSA and AZA to induce leukaemia cell differentiation is
based on studies that have demonstrated the important role that histone acetylation
and DNA methylation status have in controlling transcriptional activity and on
evidence that many of the chromosomal and molecular rearrangements characterising
acute leukaemia act by repressing transcription of genes involved in haematopoietic
differentiation through the recruitment of histone deacetylases and DNA methylaters.
AZA is able to induce differentiation in myeloid leukaemic cells by relieving
transcriptional repression caused by increased DNA methylation (Attadia, 1993;
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Lubbert, 2000; Pinto et al, 1984). TSA, a specific histone deacetylase inhibitor
(HDAI), has been shown to relieve transcriptional repression caused by histone
deacetylation thereby allowing differentiation to proceed (Kosugi et al, 1999; Wang
et al, 1999; Yoshida et al, 1987; Yoshida et al, 1990). In a study examining the
effects of TSA on differentiation in AML, treatment of leukaemia cells with TSA,
and other HDAIs, was shown to lead to induction in the expression of the
costimulatory molecule CD86 (Maeda et al, 2000).
A different class of differentiating agent, BRYO, exerts its action by interfering with
protein kinase C activity. BRYO has been shown to be able to induce monocytic
differentiation in myeloid leukaemia cells (Kaneki et al, 1999; Steube & Drexler,
1993).
CI, a calcium ionophore has been shown to induce the differentiation of
haematopoietic cells into dendritic-like cells (Engels et al, 1998; Koski et al, 1999a;
Koski et al, 1999b). The mechanism of action of CI is thought to be through
increased calcium mobilisation thereby leading to activation of calcium-dependent
signaling pathways, which trigger DC differentiation. CI was found to induce the
differentiation of leukaemia cells derived both from patients with CML and the
myeloid leukaemia cell line, HL60, into dendritic-like cells based on costimulatory
molecule and CD83 expression and on the acquisition of a DC-like morphology
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1.6.2.2 Cytokine-induced differentiation
One of the earliest studies in AML differentiation induction showed that in the
murine myeloid leukaemia cell line, Ml, differentiation into mature granulocytes and
macrophages was possible using the cytokine IL-6, but only in certain subclones
(Fibach et al, 1972; Sachs, 1978). More recent investigations into cytokine-induced
differentiation in AML have been stimulated by studies showing that it is possible to
induce the differentiation of peripheral blood monocytes and CD34+ haematopoietic
progenitor cells into DC by culture with certain cytokine combinations (Brossart et
al, 1998; Caux et al, 1994; Hart, 1997; Reid et al, 1992; Reid, 1998; van Schooten et
al, 1997). Culture of CD34+ bone marrow haematopoietic progenitor cells or CD14+
PB monocytes with cytokines GM-CSF and IL-4 induces their differentiation into
functional DC (Romani et al, 1994; Sallusto & Lanzavecchia, 1994). DC generated
in this way are considered 'immature' and are efficient at antigen uptake and
processing but are relatively inefficient at antigen presentation (Sallusto &
Lanzavecchia, 1994; Zhou & Tedder, 1996). Immunophenotypically 'immature' DC
express the DC-associated cell marker CD la, but have relatively low levels of
expression of costimulatory molecules CD40, CD80 and CD86 and HLA class II
molecules. CD la is a type I transmembrane protein that associates non-covalently
with p2 microglobulin (Bauer et al, 1997). Expression of CD la has been used as a
marker for DC populations although its expression is not restricted to this cell type.
Its function is believed to be in the presentation of foreign lipids, such as those
derived from mycobacteria, to T cells. Following culture of 'immature' DC in TNFa
or CD40L there is down-regulation in the DC ability to take up and process antigen
(Figure 1.4). In contrast matured DC show upregulation of CD54, HLA class II
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molecules, CD80 and CD86 and gain expression of CD83. CD83 is a type I
membrane glycoprotein and is a member of the immunoglobulin superfamily (Zhou
1992). Its expression is highly restricted to mature DC (Kozlow et al, 1993). The
function of CD83 has been unknown but a recent study presents evidence to suggest
that it is an adhesion receptor that binds to a ligand present on circulating monocytes
and a fraction of activated and/or stressed CD8+ T cells. Based on the evidence in
this study it has been suggested that it may have a role in intracellular
communications involving DC, circulating monocytes and certain populations of
activated and/or stressed T lymphocytes. In parallel with the upregulation of
costimulatory and HLA class II expression mature DC possess increased antigen-
presenting function as defined by enhanced allostimulatory capacity (Sallusto &
Lanzavecchia, 1994; Zhou & Tedder, 1996). DC play a crucial role in the control of
immunity based on their ability to initially process and then present antigen to T cells
in order to generate antigen-specific immunity (Avigan, 1999; Banchereau &
Steinman, 1998; Barratt-Boyes et al, 2000; Colaco, 1999; Hart, 1997; Labeur et al,
1999; Macatonia et al, 1995; van Schooten et al, 1997).
As DC and leukaemia cells share the same common myeloid progenitor cells this
prompted investigators to study whether leukaemia cells could be driven to
differentiate to dendritic-like cells using cytokine combinations similar to those used
in DC differentiation induction. The first studies involved leukaemia cells derived
from patients with CML (Choudhury et al, 1997; Heinzinger et al, 1999; Smit et al,
1997; Wang et al, 1999). In vitro studies of the cytokine-induced differentiation of



























Figure 1.5 Generation of dendritic cells.
Culture of CD14+ PB monocytes or CD34+ BM progenitors with GM-CSF and IL-4
for 4-7 days induces differentiation to CD1a+ CD83- 'immature' DC. Following
maturation the DC become CD83+ and show high levels of expression of CD80,
CD86 and FILA class II molecules.
Reproduced (following modification), with permission, from The biology and
clinical applications of dendritic cells Transfusion Medicine 1998;8:77-86
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In summary these studies have shown that following culture with GM-CSF, IL-4 and
TNFa/CD40L leukaemia cells derived from patients with AML developed
immunophenotypic and morphological features characteristic of DC (Boyer et al,
2000; Brouwer et al, 2000a; Brouwer et al, 2000b; Charbonnier et al, 1999;
Choudhury et al, 1999; Cignetti et al, 1999; Costello et al, 2000; Kohler et al, 2000;
Oehler et al, 2000; Robinson et al, 1998). Immunophenotypically dendritic-like
leukaemia cells (DLLC) show expression of costimulatory molecules CD40, CD80
and CD86, the cell adhesion molecule, ICAM-1, the dendritic cell-associated
markers, CD la and CD83 and both HLA class I and II molecules (Boyer et al, 2000;
Brouwer et al, 2000a; Brouwer et al, 2000b; Charbonnier et al, 1999; Choudhury et
al, 1999; Cignetti et al, 1999; Costello et al, 2000; Kohler et al, 2000; Oehler et al,
2000; Robinson et al, 1998). Morphologically DLLC possess the characteristic veils
and processes of 'classical' DC. IL-12 production by DLLC, a characteristic of
matured DC, has only been tested in one study (Charbonnier et al, 1999). A high
level of IL-12 production by DLLC was detected in seven AML cases all of which
were monocytic in nature (Charbonnier et al, 1999). Evidence that the DLLC are
derived from the leukaemic clone, and not contaminating monocytes, has been
provided by FISH analysis, which demonstrates that the DLLC retain the
chromosomal rearrangement characterising the original leukaemia (Boyer et al,
2000; Brouwer et al, 2000b; Choudhury et al, 1999; Kohler et al, 2000; Oehler et al,
2000; Robinson et al, 1998). Functional studies have also confirmed the dendritic
like nature of the differentiated leukaemia cells. In MLLR DLLC have been shown
to be potent stimulators of allogeneic T lymphocytes (Brouwer et al, 2000b;
Choudhury et al, 1999; Robinson et al, 1998). It has been shown that by co-culture
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of autologous T lymphocytes with DLLC, CTL can be generated that can specifically
recognise and destroy unmodified leukaemia cells in vitro (Charbonnier et al, 1999;
Choudhury et al, 1999). Table 1.3 summarizes the immunophenotypic and functional
similarities between monocyte derived DC and DLLC.
In the majority of these studies generation of DLLC from leukaemia blasts was
possible in around a half to two thirds of AML cases (Brouwer et al, 2000b;
Choudhury et al, 1999; Cignetti et al, 1999; Robinson et al, 1998). What factor(s)
prevent differentiation in resistant cases has not been identified. It does not appear to
be related to FAB subtype as DLLC have been generated from leukaemia cells of all
seven FAB subtypes (Boyer et al, 2000; Brouwer et al, 2000a; Brouwer et al, 2000b;
Charbonnier et al, 1999; Choudhury et al, 1999; Cignetti et al, 1999; Costello et al,
2000; Kohler et al, 2000; Oehler et al, 2000; Robinson et al, 1998).
1.7 Murine models of dendritic cell differentiation
Cytokine-induced dendritic cell differentiation from murine peripheral blood (PB)
monocytes and bone marrow (BM) derived haematopoietic progenitors has been
performed using cytokine combinations broadly similar to those used in human
studies (Masurier et al, 1999; Schreurs et al, 1999; Zhang et al, 1997; Zhang et al,
1998). There has only been one study examining cytokine-induced differentiation of
murine leukaemia cells to DLLC. In this study culture of murine erythroleukaemia
cells with GM-CSF was reported to induce dendritic cell differentiation in the
leukaemia cells (Cao et al, 1998).
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Immunophenotype Cytokinesproduced Functionalproperties
Monocyte-derivedDC HLAl/lI++ CD40++ CD80+ CD86++ CD1a+ CD83+ CD54++ IL-12 IL-15 PotentstimulatorsfTc llsinalloge eicMLR GenerateautologousCTLsthac nrecog ise novelandrecalntigens
DLLC HLAl/ll++ CD40+ CD80+/- CD86+ CD1a+/- CD83+/- CD54++ IL-12 IL-15? PotentstimulatorsfTc llsinalloge eicMLR GenerateautologousCTLsthatc nrecognise leukaemiasp cif cantigens
Table1.3AComparisonfthefe tu esMonocyte-DerivedDendriticellandendritic-LikeL uk mia
1.8 Study Objectives
The aim of this study was the development of a method for engineering leukaemia
cells in order to make them suitable for use as autologous vaccines in the
immunotherapy of AML. Two main approaches were to be employed to achieve this
aim:
1 Gene transfer of costimulatory molecules and immunostimulatory cytokines
to leukaemia cells
2 Cytokine-induced differentiation of leukaemia cells to dendritic-like cells
The first approach was to attempt the genetic modification of leukaemia cells by the
gene transfer of cDNA coding for costimulatory molecules or immunostimulatory
cytokines. An important prerequisite of this approach was a gene transfer system that
gave sufficiently high level of gene transfer efficiency in primary leukaemia cells so
as to be useful in a clinical setting. Therefore initial experiments were the evaluation
of GTE, in myeloid leukaemia cell lines and in primary AML blasts, of a variety of
physical, chemical and viral gene transfer systems. Whichever system proved to give
the highest level of reproducible GTE was to be selected for use in the gene transfer
of costimulatory molecules and/or immunostimulatory cytokines to primary
leukaemia cells in order to enhance their T cell immunostimulatory properties.
The second approach involved the cytokine-induced differentiation of leukaemia
cells to DLLC. Confirmation that differentiation to DLLC had taken place was to be
based on the morphological and immunophenotypic characteristics of the cytokine
cultured leukaemia cells.
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The functional properties of these engineered leukaemia cells in terms of their
antigen presenting capacity was to be tested for by measurement of their
allostimulatory properties in MLLR. The ability of these cells to prime autologous T
cells to recognise and destroy unmodified leukaemia cell targets was to be evaluated
by means of cytotoxicity assays.
Finally whichever of these two approaches proved to be the more promising in terms
of potential clinical utility was to be translated into a murine AML model in order to
determine whether a vaccination strategy based on modified leukaemia cells would
generate significant in vivo anti-leukaemia responses.
It was hoped that these pre-clinical studies would pave the way for subsequent phase




2.1 Cells and cell culture techniques
2.1.1 Culture conditions
All cultures were incubated at 37°C in a humidified incubator (Heraeus) containing 5%
C02.
2.1.2 Origin and maintenance of cell lines and primary leukaemia cells
2.1.2.1 Myeloid leukaemia cell lines
Four myeloid leukaemia lines were used in the study; KGla, U937, K562, and HL60 (all
ATCC, Rockville, MD, USA). Cells were cultured in RPMI 1640 medium with 10%
hiFCS (GlobePharm, Guildford, UK), L-glutamine (2mM/L), penicillin/ streptomycin
(50U/ml) and amphoteracin B 250 pg/ml (all GIBCO BRL, Paisley, UK) (cRPMI) in
25cm flasks, unless otherwise specified. Medium was replaced every 3-4 days with cell
density adjusted to between Ixl05-lxl06/ml in order to maintain the cells in exponential
growth phase.
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2.1.2.2 Retroviral vector packaging cell lines
The three retroviral packaging cell lines used TeflyMLV-A, TeflyRDlM and
TeflyGALV (Genethon, Evry, France) differ based on the specificity of the envelope
protein present on the virions (Cosset et al, 1995; Porter et al, 1996). TeflyMLV-A
carries the gene for the murine amphotrophic envelope protein, TeflyRDlM, the feline
endogenous retrovirus envelope protein and TeflyGALV the gibbon ape leukaemia virus
envelope protein (Eglitis & Schneiderman, 1997; Porter et al, 1996). These cell lines
were cultured in DMEM with 10% hiFCS, L-glutamine (2mM/L), Glucose 4.5gm/l
(GIBCO BRL), penicillin/ streptomycin (50U/ml) and amphoteracin B 250 pg/ml
(cDMEM) in 25cm flasks unless otherwise specified. Medium was replaced every 3-4
days. Once the monolayer was confluent cells were split. The medium was aspirated and
the monolayer washed with 5mls sterile tissue culture grade Phosphate buffered saline
(PBS) (GIBCO BRL). The PBS was then aspirated and 2mls of 0.1% trypsin (GIBCO
BRL) was added. After 30 seconds 1.5mls of the trypsin solution was aspirated and cells
were incubated for a further 2 minutes at which point the monolayer was starting to lose
adherence. The flask was then tapped lightly to fully detach the cells. 5mls of cDMEM
was added and cells were pelleted by centrifugation at 400g for 4 minutes. 1ml of
cDMEM was added and a cell count was performed. A new 25cm flask was reseeded
with 10" cells with the remainder being frozen for later use.
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2.1.2.3 Adenoviral propagating cell line
The HEK 293 cell line (F. Farzaneh, King's College School of Medicine and Dentistry,
London), a fibroblast-like cell line was cultured and maintained under identical
conditions to the retroviral packaging cell lines.
2.1.2.4 Gene transfer target cell lines
The TE6.71, CHO and COS (all ATCC, USA) target cell lines were cultured and
maintained under identical conditions to the retroviral packaging cell lines.
2.1.4 Primary human leukaemia cells
Primary AML cells were obtained, with written informed consent using a study protocol
that had received prior approval from Lothian research ethics committee, from BM
marrow or PB samples of patients with newly diagnosed or relapsed AML. Diagnosis
was established both by cytological criteria based on the FAB classification and by
immunophenotypic analysis following staining of leukaemia cells with a panel of mAb.
This acute leukaemia diagnostic panel comprised ofmAb directed against CD 13, CD 14,
CD15, CD33, CD34, and HLA class II molecules. Karyotypes were defined according to
criteria of the International System for Fluman Cytogenetic Nomenclature. Samples
were taken into tubes containing lOOu/ml of preservative free heparin (Leo, Risborough,
UK). An equal volume of RPMI was added to the PB or BM samples and the resulting
cell suspension was overlain over Lymphoprep (Nycomed, Amersham, UK) at a 4:1
ratio in 50ml conical tubes. The tubes were then centrifuged at 650g for 25 minutes.
Cells at the interface were aspirated and transferred to 15mls conical tubes and washed
-44-
with 4mls cRPMI. Following centrifugation at 400g for 4 minutes cells were
resuspended in 1ml cRPMI and a viable cell count performed. Cell density was adjusted
to 107/ml and cells were then frozen for later use.
2.1.3 Cryopreservation
All primary cells and cell lines, with the exception of the HL60 cell line, were
cryopreserved in cRPMI to which was added 10% tissue culture grade DMSO (Sigma-
Aldrich. Gillingham, UK). The FIL60 cells were cryopreserved in cRPMI and 10%
glycerol (Fisher Scientific, Loughborough, UK) because of the differentiating properties
of DMSO in this cell line. Cells suspensions in the freeze mixture were added in 1 ml
volumes to cryovials (cryotube™, Nunc, Denmark) and placed in a -70°C freezer. After
24 hours they were transferred to a -140° freezer for storage prior to use.
2.1.4 Thawing
Cryopreserved cells were thawed rapidly at 37°C in a water bath. The cell suspension
was washed in 5 mis cRPMI and then centrifuged at 400g for 4 minutes. The resulting
supernatant was then discarded and the pellet was resuspended in medium the nature of
which was dependent on the cell type and the purpose for which the cells were to be
used.
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2.1.5 Counting of viable cell numbers
lOpl of cell suspension to be counted was mixed with 90pl of 0.4% trypan blue. 10pl of
the subsequent dilution was placed in a Neubauer haemocytometer. The numbers of cells
excluding trypan blue in 16 squares were counted. Viable cell count/ml = number of
cells in 16 squares x 104 xlO.
2.2 Gene transfer methods
2.2.1 Qualitative comparison of GFP containing plasmid vectors
The calcium phosphate precipitation method was used for a qualitative comparison of a
variety of gene transfer vectors encoding GFP as a means of selecting the most suitable
for use in the comparative evaluation of gene transfer methods in myeloid leukaemia







Table 2.1 A qualitative comparison of five different GFP containing plasmid vectors
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CHO and COS-7 cells were harvested when in log growth phase and seeded into 3mls
cDMEM and added to the wells of a 6-well plate. Gene transfer by CaPC>4 precipitation
was performed once the monolayer had achieved two-thirds confluence. TE buffer
(ImM Tris HCL + 0.05mM EDTA, pH 7.5) was added to 5pg of plasmid DNA in a
bijoux tube to give a final volume of 187.5pl. Aliquots of 250pl 2xHBS (16gm NaCl,
lOgm HEPES, 0.23gm NaPC>4 in 11 distilled EfO, pH 7.1) were then dispensed into
another sets of bijoux tubes. 62.5|ul 1M CaCh was added drop wise to the DNA
containing tubes whilst vortexing at the same time. The DNA-CaC^ solution was then
added drop wise to tubes containing 2x HBS again vortexing at the same time. The
precipitate was allowed to form for 30 minutes at room temperature. The mixture was
then added drop wise to the media, in the wells containing the target cell line, and
distributed evenly by gently rotating the plate. The cells were incubated with the DNA-
CaPC>4 precipitates for 24 hours at 37°C, 5%C02. The supernatant was then aspirated
and the cells were washed with 3mls of sterile tissue culture grade PBS. 3 mis cDMEM
were then added and the plates were incubated at 37°C, 5%C02 for 48 hours. A
qualitative analysis of the efficiency of gene transfer for each of the plasmid vectors was
performed by examination of the wells under fluorescence microscopy (Zeiss Axiovent
25, Zeiss, Germany). Wells corresponding to different vectors were graded according to
the degree of green fluorescence exhibited by the target cells.
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2.2.2 Plasmid DNA preparation
A Mo-MLV vector encoding enhanced GFP was constructed by T. Paterson by cloning
the cDNA for enhanced GFP (Clontech, Basingstoke, UK) into the pBabe.puro vector
plasmid (H.Land, ICRF, London)(Morgenstern & Land, 1990). The transgene is
expressed from the Mo-MLV 5' LTR promoter. This vector, pBabe.puroEGFP, was used
in all subsequent physical, chemical and retroviral transfection experiments.
From frozen stocks of DH5a E.coli containing pBabe.puroEGFP plasmid a single
colony was picked from freshly streaked selective plate and inoculated into a starter
culture of 5mls of Luria Bertani (LB) medium (Tryptone lOgm + 5gm Yeast extract
+ 10gm NaCl in 11 distilled H2O) containing ampicillin lOOpg/ml. This was placed into
an orbital incubator at 200rpm 37°C for 6 hours. 5mls was then transferred to a 21
conical flask containing 500 mis LB medium with 100pg/ml ampicillin and then placed
in an orbital incubator at 32°C at 200 revs/minute overnight. Cells were harvested by
centrifugation at 6000g for 15 minutes at 4°C and the supernatant decanted. Purification
of plasmid DNA was performed using Qiagen-tip 500 kits (Qiagen, Crawley, UK)
according to manufacturers instructions. The cells were suspended in lOmls of buffer PI
(RNAase pre-added). lOmls buffer P2 was then added and mixed gently by inverting
four times and incubated at room temperature for 5 minutes. lOmls chilled buffer P3 was
added and mixed gently by inverting four times and then incubated on ice for 20
minutes. The suspension was then centrifuged at 15000G for 30 minutes at 4°C. The
supernatant containing plasmid DNA was then removed promptly. A qiagen-tip was
equilibrated by applying lOmls of buffer QBT and the column allowed to empty by
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gravity flow. The supernatant was then applied to a Qiagen-tip and allowed to enter the
resin by gravity flow. The qiagen tip was washed twice with 30ml of buffer QC. The
DNA was eluted with 15mls buffer QF. DNA was precipitated by adding 10.5 mis
isopropanolol to the eluted DNA. This was mixed and centrifuged at 15,000g for 30
minutes at 4°C. The supernatant was carefully decanted without disturbing the pellet.
The pellet was air-dried for 10 minutes and then solubilised in 1ml of TE buffer.
Quantification of plasmid DNA was performed as follows. 10pl of DNA was diluted in
lOOpl of distilled water and placed into quartz cuvette. The absorbence at 260nm was
measured in a spectrophotometer. DNA quantity (pg/ml) = absorbence at 260nm x 50 x
10. Plasmid DNA was stored at -20°C prior to use.
2.2.3 Physical/chemical gene transfer techniques
2.2.3.1 Electroporation
Cells were harvested when the leukaemia cell lines were in the exponential growth
phase. The cells were pelleted by centrifugation at 400g for 4 minutes and then washed
with 5 mis of room temp RPMI. Following further centrifugation for 4 minutes at 400g
the supernatant was discarded and 1 ml of AIM-V (Gibco-BRL) medium was added. A
viable cell count was performed. A cell suspension of 106 cell/ml was prepared in
2400pl of AIM-V. 50pg of plasmid DNA was added to give a final concentration of
20pg/ml. 800pl of the resulting cell/plasmid DNA mixture was added to 0.4 cm gap
electroporator cuvettes (EquiBio, Monchelsea, UK). Electroporation was performed
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using the Easyject Plus electroporator (EquiBio) with the resistance set at infinite.
Conditions were varied as shown in Table 2.2. Immediately following completion of the
pulse the cell suspension was transferred to the wells of a 6-well plate and 3 mis of pre-
warmed cRPMI was added. Plates were incubated for 48 hours prior to analysis of
reporter gene expression.
DNA (pg) 0 10 10
Voltage (V) 260 260 260
Capacitance (pF) 1500 1500 1800
Table 2.2 Conditions for electroporation of leukaemia cell lines
2.2.2.3 Commercial transfection reagents
Evaluation of gene transfer efficiency of commercial transfection reagents was
performed with cells from the four myeloid leukaemia cell lines. Cells were harvested
when the cell lines were in the exponential growth phase. The cells were pelleted by
centrifugation at 400g for 4 minutes and the resulting supernatant decanted. 1ml of
cRPMI was added and a viable cell count performed. Gene transfer experiments for each
of the commercial reagents was performed according to the manufacturers instructions.
This included performing optimisation of the quantity and proportions of the transfection
reagent and plasmid DNA (see Appendix I).
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i/ Transfast (Promega, Southampton, UK)
A cell suspension of 5x1 CP cells in 500pl AIM-V was prepared for each of the myeloid
leukaemia cell lines. Transfast/DNA mixtures were made up in 6ml Bijoux tubes. AIM-
V medium was added to the Transfast/DNA mixture to give a total volume of 500pl.
The mixture was then vortexed for 10 seconds and incubated for 10 minutes. This
mixture was added drop wise to the leukaemia cell suspension that had been previously
seeded to the wells of a 6-well plate. After 60 minute incubation at 37°C, 5% CO2, the
cells and Transfast/DNA complex were overlain with 5mls of prewarmed cRPMI. The
plates were then incubated for a further 48 hours prior to analysis of reporter gene
expression.
ii/ Fugene 6 (Boehringer Mannheim, Lewes, UK)
A cell suspension was prepared of 5x10" cells/ml in 1600pl cRPMI. Fugene 6 was
diluted to 400pl in AIM-V. The resulting mixture was then incubated for 5 minutes at
room temperature. Plasmid DNA was added to a second bijoux tube. The diluted Fugene
6 was then added drop wise onto the plasmid DNA. The tube was tapped gently to mix
contents and incubated for 15 minutes at room temperature. This mixture was then
added drop wise to the cell suspension previously seeded to the wells of a 6-well plate.
The plates were then incubated for 48 hours with the Fugene 6/DNA complex left with
cells until analysis of reporter gene expression.
iii/ Effectene (Qiagen)
A cell suspension was prepared of SxlO5 cells/ml in 1600pl cRPMI. Plasmid DNA was
diluted in lOOpl buffer EC in a bijoux tube. Enhancer was added at a 1:8 ratio and the
resulting solution was mixed by vortexing for 10 seconds. Following incubation at room
temperature for 2-5 minutes the Effectene reagent was added to DNA/enhancer solution
and mixed by vortexing for 10 seconds. The resulting mixture was then incubated for 10
minutes at room temperature. 600 pi AIM-V was added to transfection complexes and
mixed by pipetting up and down twice. Transfection complexes were than added drop
wise onto the cell suspension that had been previously seeded into wells of a 6-well
plate. The plates were then incubated for 48 hours with the transfection complexes left in
contact with cells until analysis of reporter gene expression.
iv/ Superfect (Qiagen)
A cell suspension was prepared of 5X103 cells/ml in 2mls cRPMI. Plasmid DNA was
diluted in lOOpl AIM-V medium in a bijoux tube. The Superfect transfection reagent
was then added to the DNA and the tube vortexed for 10 seconds. The mixture was
incubated for 5 minutes at room temperature to allow complex formation. The
Superfect/DNA complex was then added drop wise onto the cell suspension that had
previously been seeded into the wells of a 6-well plate. The cells and Superfect/DNA
complex were than incubated for 3 hours. The cells were then pelleted by centrifugation
at 400g for 4 minutes and resuspended in 3 mis cRPMI. The cell suspension was
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transferred to the wells of a 6-well plate, which was incubated for 48 hours prior to
analysis of reporter gene expression.
2.2.4 Retroviral vector system
2.2.4.1 Derivation of retroviral producer cell lines
The first step in the generation of stable producer cell lines was the transfection of the
packaging cell lines with the desired retroviral vector, either pBabe.puroEGFP or the
'empty' pBabe.puro vector. This was performed using the commercial transfection
reagent, Superfect. The three packaging cell lines TeflyRD114, TeflyGA and
TeflyMLV-A were grown to 40% confluence in a 25cm2 flask containing 5 mis of
cDMEM. Prior to transfection the monolayer was washed with 5 mis of sterile tissue
culture grade PBS. The plasmid DNA/Superfect transfection complex was prepared as
follows; 10 jug of plasmid DNA (the pBabe.puroEGFP vector or the 'empty' pBabe.puro
vector) was diluted in 150pl of AIM-V medium. To this was added 30pl of Superfect
and the resulting mixture was vortexed for 10 seconds. Following 5 minutes incubation
at room temperature to allow complex formation, 2mls of cDMEM was added to tube
and mixed by vortexing. The Superfect/DNA complex was then added to 25 cm flasks
containing the packaging cell lines. The flasks were then incubated for 4 hours. The
supernatant was then decanted and the monolayer washed twice with sterile tissue
culture grade PBS. 5mls of cDMEM was added to the flask and the cells were allowed to
grow until they had reached confluence. Once this was achieved, usually 48-72 hours
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following the initial transfection, the medium was replaced with cDMEM containing
puromycin 1 pg/ml (Sigma-Aldrich, Gillingham, UK). Medium was replaced every 3-4
days with cDMEM containing puromycin 1 pg/ml. Cells were maintained in selective
medium until a confluent monolayer of puromycin resistant cells was achieved. The
monolayer was then washed with 5 mis of sterile tissue culture PBS. The PBS was then
aspirated and 2mls of 0.1% trypsin was added. After 30 seconds 1.5mls of the trypsin
solution was aspirated and cells were incubated for a further 2 minutes at which point
the monolayer would be starting to lose adherence. The flask was then tapped lightly to
fully detach the cells. 5mls of cDMEM was added and the resulting cell suspension was
centrifuged at 400g for 4 minutes, lml of cDMEM was added and a viable cell count
was performed. These cells were used to reseed a fresh 25cm2 flask containing 5 mis of
cDMEM and puromycin 1 pg/ml. Once cells were approaching confluence the
supernatant was decanted and the monolayer washed twice with PBS. 4 mis of cDMEM
was added. The supernatant was collected daily and replaced with 4 mis cDMEM. The
harvested supernatant was centrifuged at 400g for 4 minutes and then passed through a
45pm filter. This was then stored at -70° C. This supernatant containing retroviral
virions was used to infect newly generated producer cell lines carrying one of the other
two envelope proteins specificities as a means of enhancing the titre, a process known as
shuttling i.e. retroviral supernatant from TeflyGALV.EGFP was used to infect
TeflyRDl 14.EGFP. This was performed by replacing the medium for a 25-40%
confluent producer cell line with neat retroviral supernatant (as prepared above) to
which was added polybrene 8 pg/ml (Sigma-Aldrich). After 4 hours incubation the
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medium was replaced with cDMEM and the flask was incubated for a further 48 hours.
Medium was then replaced with cDMEM containing puromycin 1 pg/ml. This whole
process was then repeated using retroviral supernatant from the other producer cell line
in order to generate high titre retroviral producer cell lines (Figure 2.1).
2.2.4.2 Production of retroviral vector stock
High titre producer cell lines were used for generation of retroviral vector stock. 1CF
cells were used to seed a 25 cm flask containing 5 mis of cDMEM with puromycin 1
pg/ml. Medium was replaced every 3-4 days with cDMEM containing lpg/ml
puromycin. Once the monolayer was fully confluent the cells were harvested as
described above and a viable cell count was performed. 5 x 106 cells were used to reseed
a 75 cm flask in 10 mis cDMEM. Once the monolayer was approaching 70-80%
confluence the medium was replaced with 5mls cDMEM. The flasks were incubated for
24 hours and the supernatant was decanted into a 15 mis conical tube and replaced with
5mls cDMEM. The harvested supernatant, containing the retroviral particles, was
centrifuged at 400g for 4 minutes and then passed through a 45pM filter. The retroviral
supernatant was either used fresh or stored at -70°C prior to use. Small volume aliquots
of supernatant were taken for subsequent titration. This process was repeated on a daily
basis until full confluence was reached.
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Figure 2.1 Retroviral producer cell line.
Photographs taken under fluorescence microscopy demonstrating enhanced GFP
expression by the retroviral producer cell line, Tefly.RD114 packaging the retroviral
vector pBabe.puroEGFP
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2.2.4.3 Concentration of retroviral vector stock
In order to obtain higher titres of retroviral vectors two methods of concentration were
used. The first of these employed was the conventional method of concentration, by
ultracentrifugation. The second was a novel concentration method that had been
suggested by David Darling (King's College School ofMedicine and Dentistry, London)
following his observations that mixing retroviral particles with Pansorbin lead to an
enhancement in their titre.
i/ Ultracentrifugation
Retroviral vector stock was produced as described above. 25mls of freshly harvested
pooled retroviral vector stock was added to 40ml sterile round bottomed tubes. The side
of the tube where the retroviral particles were expected to pellet was marked. The tubes
were then centrifuged for 2hrs 20 minutes at 20,000 rpm (SW-27 rotor) at 4°C. The
supernatant was decanted whilst carefully avoiding discarding the pellet. The pellet was
then resuspended in 500pl DMEM. The resulting solution was stored at -70°C. Titration
was performed as described below by the gene transfer unit assay on pooled
unconcentrated and concentrated retroviral vector stock.
ii/ Pansorbin Method
Retroviral vector stock was produced as described above. Freshly harvested pooled
vector stock was used for concentration. 50pl of Pansorbin 5% (Pansorbin 5% in RPMI)
(CN Biosciences, Nottingham, UK) was added to lOmls of retroviral supernatant. The
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mixture was incubated for 3 hours at 4°C on a roller. The Pansorbin and retroviral
particles were then harvested by centrifugation at 500g for 10 minutes. The resulting
pellet was resuspended in 500pl DMEM and stored at -70°C until required. Titration of
pooled vector stock and of pansorbin concentrated vector stock was performed as
described below using the gene transfer unit assay.
2.2.4.4 Titration of retroviral vector stock
For titration of retroviral vector stock two main assays were used. The colony forming
assay is based on the stable transduction of the retroviral vector into cells leading to the
expression of a selectable marker; puromycin resistance in the case of the vectors used
in this study. Following a period of culture, under the selective pressure of puromycin,
new colony growth appears. The titre is calculated by the number of transduced colonies
at a given dilution of retroviral stock, expressed as colony forming units (CFU)/ml. This
assay proved to be laborious and poorly reproducible. Therefore for titration of EGFP
containing retroviral vector stock an assay based on the flow cytometric analysis of
reporter gene expression was adopted. This assay proved to be reliable and reproducible
and had the added advantage of given rapid titration results. MOI calculations were
based upon the results of titrations performed by this gene transfer unit (GTU) assay.
Both assays are described in more detail below.
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i/ Colony-forming unit assay
... 9
The target cell line TE6.71 was grown in cDMEM until confluence in a 25cm flask.
Once at confluence the tissue culture supernatant was decanted and the monolayer was
washed with tissue culture grade PBS. 2mls of trypsin 0.1 % were then added. After 30
seconds 1.5 mis of the trypsin solution was aspirated. The flask was then returned to a
37° C incubator. When the cells were started to lose adherence the flask was tapped on
the bench to detach the monolayer and 3.5 mis of cDMEM were added. From the
resulting cell suspension lOOp.1 was seeded into the wells of a 6-well plate to which 2mls
of cDMEM was then added. The plate was then incubated for 24hrs. Retroviral vector
stock for titration was thawed at 37°C and serial dilutions were made in cDMEM
supplemented with 8pg/ml polybrene. 500pl of each dilution were added to wells of the
6-well plate containing the TE6.71 target cell, which was now at 40-60% confluence.
The plate was then incubated for 3 hours. 2 mis of cDMEM was overlain onto the
retroviral supernatant. Plates were incubated for a further 2 days until the monolayer had
reached confluence. The medium was then aspirated and 2mls of cDMEM supplemented
with lpg/ml puromycin was added. The plates were returned to the incubator. Every 2-3
days the medium was replaced with fresh cDMEM supplemented with puromycin
lpg/ml. When colonies became readily identifiable by microscopy the wells were
stained with Giemsa (BDH, Poole, UK). The number of colonies in each well were
counted with the retroviral vector stock titre (CFU/ml) = number of colonies per well x
dilution factor x 2
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ii/ Gene transfer unit assay
The cells from the target cell line were seeded into the wells of a 6-well plate as
described above in the CFU assay. Once the monolayer had reached 40%-60%
confluence infection with the retroviral vector stock was performed. From two of the
wells the cells were harvested, following trypsinisation, and a viable cell count
performed. Retroviral vector stock for titration was thawed at 37°C and serial dilutions
were made in cDMEM supplemented with 8pg/ml polybrene. 500pl from each of three
dilutions was added to the wells of the 6-well plate containing the TE6.71 target cell. To
the final well was added neat retroviral supernatant harvested from the producer cell
lines containing the 'empty' pBabe.puro vector. The plate was then incubated for 4
hours at 37° C. 4 mis of cDMEM was then overlain over the retroviral supernatant and
the plates incubated at 37°C, 5%C02- Following 48 hours incubation cells were
harvested and analysed for GFP expression by flow cytometry. Cells harvested from the
well that had been infected with the 'empty' pBabe.puro vector acted as a negative
control. Titre (GTU/ml) = % cells expressing GFP/100 x dilution factor x 2 x average
cell number from two wells
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2.2.4.5 Fibronectin coating of plates
Enhancement of retroviral vector GTE into haematopoietic cells has been achieved by
using recombinant fibronectin fragments, which leads to co-localisation of the retrovirus
with the target cells (Hanenberg et al, 1996). In an attempt to improve the GTE into the
leukaemia cell lines 6-well plates were coated with plasma-derived fibronectin. This was
performed as follows: 1ml of RPMI was added to the wells of 6-well plate. To this was
added lOOpl of fibronectin (cold immununoglobulin fraction PFC, SNBTS, Edinburgh)
at a concentration of 500pg/ml. The plates were left for 30 minutes at room temperature.
Medium was then aspirated from the wells and the plates were wrapped in cellophane
and stored at -40°C prior to use.
2.2.4.6 Infection of myeloid leukaemia cell lines
Cells were harvested when leukaemia cell lines were in exponential growth phase. Cells
were pelleted by centrifugation at 400g for 4 minutes and then washed with 5 mis RPMI.
Following further centrifugation at 400g for 4 minutes cells were resuspended in 1 ml of
RPMI and a viable cell count was performed. 2.5 xlO3 cells were suspended in retroviral
supernatant, at a MOI of 10, with added polybrene (4pg/ml) and then added to the wells
of a 6-well plate. For control infections cells were resuspended in retroviral supernatant
containing the 'empty' pBabe.puro vector. After 4 hours incubation cells were pelleted
by centrifugation at 400g for 4 minutes and resuspended in 3 mis complete RPMI and
reseeded into the wells of a 6-well plate. Following 48 hours incubation cells were
harvested for analysis of reporter gene expression by flow cytometry.
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2.2.4.7 Infection of primary AML blasts
Freshly thawed primary AML blasts were washed with 5mls RPMI and then centrifuged
at 400g for 4 minutes. The cells were resuspended in 1ml cRPMI and a viable cell count
was performed. Cells were then resuspended in cRPMI to which was added GM-CSF
200ng/ml (Schering-Plough, Welwyn Garden City, UK) and IL-3 20ng/ml (R&D
systems, Abingdon, UK). Following culture for 48 hours cells were harvested by
centrifugation at 400g for 4 minutes and resuspended in 1ml RPMI. A viable cell count
was performed. 2.5 xlO5 cells were taken and resuspended in retroviral supernatant, at a
MOI of 10, with added polybrene (4pg/ml) and then added to the wells of a 6-well plate.
For control infections cells were resuspended in retroviral supernatant containing the
'empty' pBabe.puro vector. After 4 hours incubation cells were pelleted by
centrifugation at 400g for 4 minutes and resuspended in 3 mis complete RPMI and
reseeded into the wells of a 6-well plate. Following 48 hours incubation cells were
harvested for analysis of reporter gene expression by flow cytometry.
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2.2.5 Adenoviral vector system
2.2.5.1 Production of adenoviral vector stock
HEK 293 cells were seeded into a 25cm flask in 5 mis cDMEM. Medium was replaced
every three to four days. When the monolayer was at 90-95% confluence cells were
infected with either the adenovirus vector AdGFP (D.Curiel, University of Alabama,
USA) or the control 'empty' vector, Ad5AEla, (F.Farzaneh, King's College School of
Medicine and Dentistry, London) diluted in 2 mis cDMEM to give a MOI of 20. Viral
absorption was performed for 90 minutes at 37°C, 5% CO2. The medium then replaced
with cDMEM. After 24-48 hours cells began to show the typical cytopathic effect
caused by intracellular adenoviral replication (Figure 2.2). Cells and supernatant were
harvested once greater than 50% of the monolayer had become detached. The cell
suspension was transferred in 14 ml round bottomed tubes to a -70° freezer. The tubes
were left for one hour and then thawed rapidly to 37°C in a water bath. The tubes were
then returned to the freezer and the process repeated again for a total of three freeze
thaw cycles. The lysed cells were pelleted by centrifugation at 400g for 4 minutes. The
supernatant was aspirated and then passed through ,45pm filter. Small volume aliquots
of supernatant were taken for subsequent titration. The adenoviral vector stock was
stored at -70°C prior to use.
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Figure 2.2 Adenoviral vector propagation in the HEK 293 cell line.
A. Photograph taken under fluorescence microscopy demonstrating GFP expression
by the infected 293 cells
B. In combination with low white light levels demonstrating the cytopathic effect
induced by the intracellular adenoviral multiplication
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2.2.5.2 Titration of adenoviral vector stock
The plaque-forming unit (PFU) assay was used in order to confirm the presence of
adenovirus in vector stock harvested from HEK293 cells infected with the control
Ad5AEla vector and to ensure that the titre was broadly comparable with the titres
obtained using the same assay for AdGFP vector stock. For the purposes of establishing
MOI for comparative gene transfer experiments using AdGFP vector stock the GTU
assay was used.
i/ Plaque-forming unit assay
The target cell line HEK 293 was grown in cDMEM until confluence in a 25cm flask.
Once at confluence the tissue culture supernatant was decanted and the monolayer was
washed with tissue culture grade PBS. 2mls of trypsin 0.1 % were then added. After 30
seconds 1.5 mis of the trypsin solution was aspirated and the flask returned to the
incubator. When the cells were started to lose adherence the flask was tapped on the
bench to detach the monolayer and 3.5 mis of cDMEM were added. From the resulting
cell suspension lOOpl was seeded into the wells of a 6-well plate to which 2mls of
cDMEM was then added. The plate was then incubated 48 hours. Serial dilutions of
adenovirus vector stock were made in cDMEM. 500pl of each dilution was overlain
onto HEK 293 cells at 70% confluence. Plates were incubated for 2 hours at 37°C
following which the viral inoculum was removed by aspiration. Molten 1%
agarose/DMEM was prepared by microwaving Seaplaque (3% in distilled H2O)
(BioWhittaker, Wokingham, UK) for 5 minutes, which was then allowed to cool to
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37°C. This was then mixed with prewarmed cDMEM at a ratio of 1:3. 2mls of the
agarose/DMEM mixture was then overlain over the HEK 293 cells. The
agarose/medium was allowed to set at room temperature for 20 minutes following which
it was overlain with 2mls cDMEM. The plates were then incubated for between 4-7 days
to allow formation of cytopathic plaques. 1ml of neutral red stain (0.1% in distilled
H2OXBDH) was added into the medium and plates left for 2 hours. The supernatant was
then decanted and the plates were left overnight at 4°C. Viral plaques were counted for
each well with the adenoviral vector stock titre (PFU/ml) = number of plaque per well x
2 x dilution factor.
ii/ Gene transfer unit assay
The cells from the target cell line, TE6.71, were seeded into the wells of a 6-well plate.
Once the monolayer had reached 40%-60% confluence infection with the AdGFP vector
stock was performed. From two of the wells the cells were harvested, following
trypsinisation, and a viable cell count performed. AdGFP vector stock for titration was
thawed at 37°C and serial dilutions were made in cDMEM. 500pl from each of three
dilutions was added to the wells of the 6-well plate containing the TE6.71 target cell. To
the final well was added neat vector stock containing the 'empty' adenovirus vector,
Ad5AEla. The plate was then incubated for 90 minutes at 37° C. The supernatant was
then aspirated and 4 mis of cDMEM overlain over the cells. The plates were incubated
at 37°C, 5%C02 for 48 hours following which the cells were harvested (following
trypsinisation) and analysed for GFP expression by flow cytometry. Cells harvested
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from the well that had been infected with the 'empty' adenovirus vector acted as a
negative control. Titre (GTU/ml) = % cells expressing GFP/100 x dilution factor x 2 x
average cell number from two wells
2.2.5.3 Infection of myeloid leukaemia cell lines
Cells were harvested when leukaemia cell lines were in exponential growth phase. Cells
were pelleted by centrifugation at 400g for 4 minutes and then washed with 5 mis RPMI.
Following further centrifugation at 400g for 4 minutes cells were resuspended in 1 ml of
RPMI and a viable cell count was performed. 2.5 x lCk cells were taken and suspended
in 500pl complete RPMI to which was added AdGFP at MOI 40, or control adenovirus,
with polybrene (4pg/ml) and placed in 12x75mm plastic tubes. After 90 minutes
incubation at 37° C cells were washed with 5mls RPMI and then pelleted by
centrifugation at 400g for 4 minutes. The cells were then resuspended in 3 mis cRPMI
and transferred to the wells of a 6-well plate which was incubated for a further 48 hours
prior to analysis of reporter gene expression by flow cytometry.
2.2.5.4 Infection of primary AML blasts
Freshly thawed primary AML blasts were washed with 5mls RPMI and then centrifuged
at 400g for 4 minutes. The cells were resuspended in 1ml cRPMI and a viable cell count
was performed. Cells were then resuspended in cRPMI to which was added GM-CSF
200ng/ml and IL-3 20ng/ml or cRPMI with added GM-CSF 200ng/ml, IL-4 20ng/ml
(R&D systems) and CD40L lpg/ml (Alexis corporation, Nottingham, UK). Primary
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AML blasts were cultured for 48 hours with the GM-CSF/IL-3 cytokine combination
and 7 days with the GM-CSF/IL-4/CD40L combination prior to infection. The cells
were then harvested by centrifugation at 400g for 4 minutes and resuspended in 1ml
RPMI. A viable cell count was performed. 2.5 x 105 cells were taken and suspended in
500pl complete RPMI to which was added AdGFP at a MOI of 40, or control
adenovirus, with polybrene (4pg/ml) and placed in 12x75mm plastic tubes. After 90
minutes incubation at 37° C cells were washed with 5mls RPMI and then pelleted by
centrifugation at 400g for 4 minutes. The cells were then resuspended in 3 mis cRPMI
and transferred to the wells of a 6-well plate which was incubated for a further 48 hours
prior to analysis of reporter gene expression by flow cytometry.
2.2.6 Flow cytometric analysis of gene transfer efficiency
Transfected cells either target cell lines, myeloid leukaemia cells or primary AML
blasts, were analysed for GFP expression by flow cytometry in an identical manner.
Cells were harvested and then centrifuged at 400g for 4 minutes. The supernatant was
discarded and the cells resuspended in 1 ml PBS. A viable cell count was performed.
Cell density was adjusted to 2 x 106/ml with PBS and 1 OOju.1 of the resulting cell
suspension was added to 12x75mm plastic tubes. Cells were then analysed using either a
FACSort or a FACSCalibur flow cytometer (Becton Dickinson, USA). Control cells that
had been transfected either in the absence of plasmid DNA for the purposes of the
physical and chemical transfection methods, or with 'empty' vectors for the viral
systems were run in parallel. Non-viable cells were excluded from analysis on the basis
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of forward and side scatter characteristics. Data was then analysed using WinMDI
software. For experiments using enhanced GFP containing vectors, markers were set on
the FL1 channel to include 99.8% of the control cell population. The GFP contained in
the AdGFP vector was not enhanced and the use of such a stringent exclusion criteria for
positivity generated an unacceptably high false negative rate. Therefore for this vector
markers were set to include 99% of the control cell population. GFP expression was
recorded as the percentage of the viable cell population exceeding the upper boundary of
negative control marker.
2.2.7 Generation of stably transduced cell lines
2.2.7.1 Puromycin dose response curves
In order to determine the optimal concentration of puromycin for selection of
retrovirally transduced AML cell line clones puromycin dose response curves were
generated based on cell viability following treatment with puromycin. A MTT (Sigma-
Aldrich) stock solution of 5mg/ml in RPMI-1640 was prepared, filtered through a ,45pm
filter and stored at -40°C prior to use. The MTT conversion at various cell numbers was
established before performing the puromycin dose response assays. Serial logio dilutions
of cells (106-10J) from each of the four leukaemia cell lines were made. In triplicate
lOOpl was added to wells of a 96-well plate. lOpl MTT solution was added to each well
and the plate incubated at 37°C, 5% CO2 for 4 hours. 100 pi of acidic isopropanolol
(0.1M F1CL) was added to wells and titurated to solubilise the converted dye.
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Absorbence of converted dye was measured at 540nm with subtraction at 620nm using
an ELISA plate reader (multiskan MCC/340 P version 2.20). A graph of MTT
conversion according to cell number was generated by plotting cell number versus
absorbence on a linear scale. For the puromycin dose response curves 107 leukaemia
cells in cRPMI were seeded into the wells of a flat-bottomed 96-well plate. Doubling
dilutions of puromycin ranging from 20 to 0.625pg/ml were added to the wells. The
plates were then incubated for 48 hours at 37°C. lOpl MTT was added to each well and
the plates were incubated for a further 4 hours. 100 pi of acidic isopropanolol (0.1M
HCL) was added to each well and tituration was performed in order to solubilise the
converted dye. Absorbence of the converted dye was measured at 540nm with
subtraction at 620nm using an ELISA plate reader. Plotting puromycin concentration
versus cell number on a linear scale generated dose response curves. The lowest
puromycin concentration that achieved a three-logio reduction in cell number was used
for selection of retrovirally-transduced clones. For the K562 cell line the experiment was
repeated with higher concentrations of puromycin, as a three-logio reduction in cell
number was not achievable over the initial dose range.
2.2.7.2 Infection and selection of retrovirally transduced clones
Transduction of leukaemia cells was performed with the pBabe.puro vectors containing
cDNA for CD40, CD80 and IL-2 respectively with the vectors packaged by the
TeflyRD114 cell line. Cells from the leukaemia cell lines were harvested when in
exponential growth phase. 5x105 cells were suspended in 1 ml of retroviral supernatant
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supplemented with polybrene at 8pg/ml and added to the wells of a 6-well plate.
Following 4 hours incubation at 37°C the cells were transferred to a 15mls conical tube
and centrifuged at 400g for 4 minutes. The supernatant was removed and 3mls of cRPMI
was added. After a further 48 hours culture the cells were harvested and then centrifuged
at 400g for 4 minutes. The supernatant was decanted and replaced with 1 ml of cRPMI.
A viable cell count was performed and cell suspensions of 5 x 104 and 5 x 103 cells/ml
were made up in universal containers in 20mls cRPMI supplemented with puromycin at
the predetermined optimal concentration. 200pl of the cell suspension were added to the
wells of a flat-bottomed 96-well plate, with each plate corresponding to a different cell
concentration. The plates were then incubated for 7-10 days until colony formation
became apparent. The contents of wells containing single colonies were then transferred
to a 24-well plate for further expansion in puromycin containing medium. Following
further expansion in selective medium the transduced clones were transferred to wells of
6-well plates. Individual clones were then tested for the success of retroviral vector
transduction by flow cytometric analysis following staining with appropriate mAb.
Clones with high level of expression of the desired gene were selected for further
expansion.
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2.2.7.3 Analysis of transgene expression
i/ Intracellular staining for IL-2
In order to establish the methodology for measurement of intracellular IL-2 production
experiments were initially performed using activated PBMC as a positive control.
PBMC derived from 1 Ornls of PB taken from a healthy volunteer donor were separated
by centrifugation over Lymphoprep using the method as previously described for
harvesting of primary AML blasts. Cells at the interface were aspirated and transferred
to a 15mls conical tube, washed with 5 mis cRPMI and then centrifuged at 400g for 4
minutes. The supernatant was decanted and cells washed again with 5mls cRPMI.
Following further centrifugation at 400g for 4 minutes cells were resuspended in 5 mis
2 0cRPMI in a 25cm flask and incubated overnight at 37 C. Non-adherent cells were
harvested, centrifuged at 400g x 4 minutes and resuspended in 5 mis cRPMI to which
was added phytohaemagglutinin (PHA) lpg/ml, and phorbol myristate acetate (PMA)
50ng/ml (both Sigma-Aldrich) and added to a 25cm flask which was incubated for 24
hours. Monensin 2pM (GolgiStop™, Pharmingen, High Wycombe, UK) was added for
the final 4 hours of culture period. Cells were then harvested, centrifuged at 400g for 4
minutes and the supernatant decanted. The cell pellet was resuspended in 3 mis PBS,
centrifuged again at 400g for 4 minutes. The supernatant was decanted and 50pi PBS
was added. The cells were permeabilised using a commercial permeabilisation solution
(Fix and Perm™, Caltag, Buckingham, UK) according to the manufacturers instructions.
Briefly lOOpl reagent A was added to 50pl cell suspension in 12x75mm plastic tube.
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Following 15 minutes incubation at room temperature the cells were washed with 5 mis
PBS and pelleted by centrifugation at 400g for 4 minutes. The supernatant was decanted
and 1 OOjlxI reagent B added together with 20pi anti-IL2-PE (Sigma-Aldrich) and lOpl
anti-CD69-FITC (Caltag) and isotype matched controls. Following 30 minutes
incubation at room temperature the cells were washed with 5 mis PBS. The cell
suspension was centrifuged at 400g x 4 minutes, supernatant decanted and the cell pellet
resuspended in 200pl PBS. Cells were analysed by flow cytometry on a FACSort flow
cytometer. Negative controls were run in parallel with conditions altered as summarised
in Table 2.3
Unstimulated control Activation control Intracellular IL-2
No PMA/PHA PHA/PMA PHA/PMA
+ Monensin No monensin + monensin




Isotype controls Isotype controls
CD69-FITC/CD3-PE CD69-FITC/CD3-PE
CD69-FITC/IL2-PE
Table 2.3 Experimental controls for the intracellular IL-2 assay
ii/ Cell surface expression of costimulatory molecules
Expression of cell surface molecules by stably transduced cell lines was confirmed by
flow cytometric analysis following staining of cells with the appropriate mAbs.
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2.3 Immunophenotypic analysis of human myeloid cells
Myeloid cells underwent immunophenotypic analysis using a panel of mAb directed
against costimulatory molecules, HLA molecules, dendritic cell-associated markers,
CD54 (ICAM-1) and CD95 (Fas) prior to and following attempted dendritic cell
differentiation (Table 2.4). Cells were harvested and pelleted by centrifugation at 400g
for 4 minutes. The supernatant was decanted and blocking solution made up of 0.5%
human normal immunoglobulin solution (SNBTS, Edinburgh, UK) with 0.1% sodium
azide (Fisher Scientific, Loughborough, UK), was added to give a cell suspension of 5 x
106 cells/ml. Following 30 minutes incubation at 4°C cells were pelleted by
centrifugation at 400g for 4 minutes and 1 ml of PBS was added. A viable cell count was
performed and 2x10s cells were taken and added to 12x75mm plastic tubes. Cells were
either single stained by adding 10 pi of mAb directed against CD la, CD54, CD80,
CD86, CD95, HLA class II all fluorescein isothiocyanate (FITC)-conjugated (all
Serotec, Oxford, UK) or dual stained by adding 10 pi of mAb directed against FITC-
conjugated CD40 (Serotec) and 20 pi of phycoerythrin (PE)-conjugated CD83
(Beckman Coulter, High Wycombe, UK). PBS was added to give a final volume of
lOOpl. Tubes were then incubated for 30 minutes at 4°C. The cells were washed with 3
mis PBS and then pelleted by centrifugation at 400g for 4 minutes. The supernatant was
decanted and lOOpl phosphate buffered saline (PBS) containing 2pg/ml propidium
iodide (PI)(Bender MedSystems, Middlesex, UK) was added. After 5 minutes incubation
analysis was performed on a FACSCalibur flow cytometer. Viable cells were defined





Dendriticcellassoc atedmark r-involvedipresentationofli dantigtTc l s Dendriticcellassoc atedmarker-highlyre t ictt atureCpopula ions.M yh vr li mediatingadhesiontoonocytesdsub tfctivat da / rtr sTll Costimulatorymolecule-whenboundyD40liga ,presentTc lsind cth upregulationofcostimulatoryandHLAmolecules
-J
CD54(ICAM-1) CD80(B7.1) CD86(B7.2) CD95(Fas) HLAI HLAII
Celladhesionmol cu einvo vedbindi gtTc llsiaLFA-1 Costimulatorymolecule-bindingtD28providese ondgn lf rTc llacti atio Costimulatorymolecule-bindingtD28providesse ondign lf rTc llacti atio ReceptorforFaslig nd.Inducesapo tosissusceptiblellnbind ngyliga d MHCmoleculeinvolvednantigenpres ntationtCD8+Tlymphocy es MHCmoleculeinvolvedantigenpres ntationtCD4+Tlym hocy es
Table2.4Panelforthimmunophenotypicnalysisfle ka miace ls
2.4 Induction of differentiation in human myeloid cells
2.4.1 Cytokine-induced differentiation
2.4.1.1 Peripheral blood monocytes
Buffy coats were obtained from whole blood given by healthy volunteer blood donors at
the SEBTS blood donor center (Edinburgh). The buffy coat was mixed at a 1:1 ratio
with cRPMI and then centrifuged at 650g for 25 minutes over Lymphoprep at a 4:1
ratio. The cells at the interface were aspirated and resuspended in 5 mis cRPMI medium
in 15mls conical tubes. The cells were pelleted by centrifugation at 400g for 4 minutes
and washed again with 5 mis cRPMI medium. Following further centrifugation at 400g
for 4 minutes the supernatant was decanted and 10 mis of cRPMI added. The resultant
cell suspension was transferred to a 75cm flask and incubated overnight. The non¬
adherent cells were decanted and 1 Omls of cRPMI supplemented with IL-4 20ng/ml and
GM-CSF 200ng/ml was added. The flask was then incubated for a further 4 days at
which point there was morphological evidence of DC differentiation. Cells were
harvested and washed with 5 mis cRPMl. Cells were pelleted by centrifugation at 400g
for 4 minutes and resuspended in 1 ml of cRPMI. A viable cell count was then
performed. 5 x 106 cells were taken and used for immunophenotypic analysis as
described above. The remaining cells were resuspended at 106/ml in cRPMI
supplemented with GM-CSF 200 ng/ml and IL-4 20 ng/ml. Analysis of DC maturation
was performed by seeding 106 cells in 1 ml of medium into the wells of a 24-well plate.
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To each well was then added various concentrations of CD40L ranging from 1-1000
ng/ml either with or without a proprietary enhancer (Alexis corporation). The plate was
then incubated for 4 days. Cells were harvested and pelleted by centrifugation at 400g
for 4 minutes. Immunophenotypic analysis of the expression of CD40, CD54. CD80,
CD86 and HLA class II molecules was performed as described above.
2.4.1.2 Myeloid leukaemia cell lines
Cytokine-induced differentiation was attempted in the four leukaemia cell lines and in
the CD40 expressing leukaemia cells generated by the retroviral transduction of the
K562, KGla and U937. Cells were harvested when leukaemia cell lines were in
exponential growth phase. Cells were pelleted by centrifugation at 400g for 4 minutes
and then washed with 5 mis RPMI. Following further centrifugation at 400g for 4
minutes cells were resuspended in 1 ml of RPMI and a viable cell count was performed.
3 x 106 cells were added to the wells of a 6-well plate to which was added cRPMI
supplemented with GM-CSF 200 ng/ml and IL-4 20 ng/ml and CD40L 1 pg/ml
Following incubation for 4 days cells were harvested and pelleted by centrifugation at
400g for 4 minutes. The supernatant was discarded and the cells were resuspended in 3
mis of cRPMI supplemented with GM-CSF 200 ng/ml, IL-4 20 ng/ml and CD40L
lpg/ml or TNF-a 15 ng/ml. The resulting cell suspension was returned to the wells of
the 6-well plate. Following 3 days culture cells were harvested and analysed for
evidence of dendritic cell-like differentiation by flow cytometry as described above.
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2.4.1.3 Primary AML blasts
Freshly thawed primary AML blasts were washed with 5mls RPMI and then centrifuged
at 400g for 4 minutes in a 15mls conical tube. The cells were resuspended in 1ml cRPMI
and a viable cell count was performed. 3 x 106 cells were then resuspended in 3 mis
cRPMI supplemented with GM-CSF 200 ng/ml and IL-4 20 ng/ml and transferred to the
wells of a 6-well plate. The plate was incubated for 4 days. The cells were then
harvested and pelleted by centrifugation at 400g for 4 minutes. The cells were
resuspended in 3mls cRPMI supplemented with GM-CSF 200 ng/ml and IL-4 20 ng/ml
and CD40L lpg/ml or TNFa 15ng/ml. The resulting cell suspension was returned to the
wells of the 6-well plate and incubated for a further 3-7 days. Cells were harvested and
used either for flow cytometric analysis, as described above, or as stimulators in
allogeneic mixed leukaemia lymphocyte reactions (MLLR), or to generate leukaemia-
specific CTL or for FISH analysis, as described below. Supernatant from cultures in
which CD40L had been given for the final 3 days of the culture period were aspirated
and stored at -70° C prior to measurement of IL-12(p70) concentration.
Analysis of various maturational agents was performed using leukaemia cells from a
single AML case. Leukaemia cells were cultured in an identical manner for the first 4
days of the culture period. Cells were then harvested and then resuspended in 3mls
cRPMI supplemented with either GM-CSF/ IL-4 alone or with various combination of
Polyriboinosinic polyribocytidylic acid (polyLC) (Sigma-Aldrich), CD40L and a
proprietary enhancer. After a further 72 hours culture the cell suspension was harvested
and centrifuged at 400g for 4 minutes. Supernatant was aspirated and stored at -70° prior
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to measurement of IL-12(p70) concentration and the cells were used for flow cytometric
analysis of costimulatory molecule expression.
2.4.2 FISH analysis
To determine whether the DLLC were derived from the leukaemic clone two AML cases
that possessed chromosomal rearrangements detectable by FISH were selected for
further study. Primary AML blasts were induced to differentiate to DLLC as described
above. Confirmation of DLLC differentiation was performed by flow cytometric
analysis following staining with the appropriate mAb as described above. In one case
unselected leukaemia cells were used to make cytospin preparations. In the second AML
case DLLC were positively selected based on their expression of CD83 as follows:
5xl06 cells were incubated with 20pl of anti-PE microbeads (Miltenyi Biotec, Surrey,
UK) in lOOpl PBS for 30 minutes at room temperature. Cells were then washed with 5
mis PBS and centrifuged at 400g for 4 minutes. The supernatant was decanted and the
cells resuspended in 500pl PBS. The resulting cell suspension was run through a
miniMACS column placed within a miniMACS magnet (Miltenyi Biotec). 1ml of PBS
was run through the column to ensure complete removal of negative cells. The column
was then removed from the magnet and the positively selected cell fraction was
recovered by adding 3mls of PBS to the column and collecting the resulting cell
suspension in a 15ml conical tube. The cells were centrifuged at 400g for 4 minutes and
the supernatant decanted. 1ml of PBS was added and a viable cell count was performed.
The volume was adjusted with PBS to give a cell density of 2 xl05/ml and 200pl of the
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resulting cell suspension was added to pre-assembled cytospin cups. These were then
centrifuged at 200rpm for 5 minutes in a cytospin centrifuge (Shandon Southern,
Shandon, Runcorn, UK). The slides were then fixed in a 3:1 mix ofmethanol/acetic acid
solution for 10 minutes and allowed to air dry at room temperature. Cytospin slides were
pre-treated in 2 x sodium saline citrate at 37°C for 30 minutes and dehydrated in an
ethanol series. They were denatured in 70% formamide (Fluka, UK)/2xSSC at 72°C for
2 minutes and again dehydrated in a cold ethanol series. The slides were hybridised
overnight at 37°C. For identification of inv(16)(pl3;q22) a CBFp dual colour probe
(Vysis (UK), Ltd., GB-Richmond, Surrey, UK.) was used. The CBFp gene is located at
16q22. A 150Kb 5' region of the CBFp gene centromeric to the breakpoint region of the
gene is directly labeled with SpectrumRed fluorochrome. A 170Kb 3' sequence
telomeric to the breakpoint region is directly labeled with SpectrumGreen fluorochrome.
For identification of t(8;21) a AML1/ETO probe was used. This is mixture of the AML1
probe directly labeled with SpectrumGreen fluorochrome and the ETO probe directly
labeled with SpectrumOrange fluorochrome (Vysis (UK), Ltd.). The 1.3 Mb AML1
probe hybridises to the AML1 gene and encompasses the breakpoint region at intron 5.
The 87Kb ETO gene is centrally located within the 480Kb ETO probe and encompasses
the breakpoint region at introns la and lb. The slides were counterstained with 4',6-
diamidino-2-phenylindole-dihydrochloride (Sigma-Aldrich) and mounted in antifade
medium (glycerol: PBS solution). Fluorescent signals were detected using a Zeiss
Axioskop 50 microscope with a triple band pass filter. Images were captured using a
digital image analysis system. 200 cells were scored for each sample.
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2.4.3 IL-12(p70) production by leukaemia cells following differentiation
IL-12(p70) concentration in tissue culture supernatants was measured by ELISA assay.
Microwells (Medisorb ELISA plate, Greiner) were coated with 1 OOpl per well of capture
antibody, mouse anti huIL-12 (Pharmingen), diluted 1:250 in coating buffer (0.2M
NaPCL, pH 9.0). The plate was then sealed and incubated overnight at 4°C. The wells
were aspirated and washed three times with 300pl/well of wash buffer (PBS with 0.05%
Tween-20). After the last wash the plate was inverted and blotted on absorbent paper to
remove any residual buffer. The plate was then blocked with 200pl/well of assay diluent
(PBS with 10% FCS). Following incubation for 1 hour at room temperature the wells
were aspirated and washed with 300pl of wash buffer two times. Standards were then
prepared from a stock solution of 500pg/ml recombinant IL-12 (Pharmingen). Serial
dilutions of IL-12(p70) were prepared by adding 300pl of each standard to a series of
tubes containing 300pl of assay diluent. The test samples were tissue culture
supernatants collected from the final three days of culture of primary leukaemia cells
(106 cells/ml) with GM-CSF, IL-4 and CD40 ligand. These were stored at -20° and
thawed at 37°C immediately prior to use. lOOpl of each test sample and standard were
added to the appropriate wells, in duplicate, and the plate was sealed and incubated for 2
hours at room temperature. The plate was then washed with wash buffer for a total of 5
washes. lOOpl of the working detector, biotinylated mouse anti-huIL-12 at 1:250
dilution with streptavidin-horseradish peroxidase conjugate at 1:250 dilution in assay
diluent, was added to the wells and the plate was sealed and incubated for 1 hour at
room temperature. The wells were then washed and aspirated as before for a total of 7
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washes. 100|_il of the substrate solution, Sigma fast OPD (Sigma-Aldrich) 1 tablet in
20mls dPEO, was added to each well. The plate was then incubated at room temperature
in the dark for 30 minutes. Absorbance was then read at 490nm with an ELISA reader
(V max kinetic microplate reader, Molecular devices). A standard curve was generated
by plotting the IL-12 concentration on the x-axis and absorbance on the y. Using
Microsoft Excel software an equation of the curve was calculated and IL-12(p70)
concentration of the test samples were determined by using this equation.
2.4.4 Immunostimulatory properties of leukaemia Cells
2.4.4.1 Allogeneic MLLR
Mononuclear cells were prepared by lymphoprep separation of PB taken from healthy
donors as previously described. Responder T cells were obtained by harvesting non-
adherent cells from cell suspensions, following overnight plastic adherence in 25cm"
flasks. Stimulator cells, either differentiated leukaemia cells or unmodified leukaemia
cells, were treated with 25pg/ml mitomycin C (Sigma-Aldrich) for 2 hours prior to use
in MLLR. Stimulator cells were then washed three times with cRPMI and added in
graded doses to 1 x 105 allogeneic T cells in 96-well U-bottomed tissue culture plates in
cRPMI with 5% hiABS.
Initially the read-out of proliferation was performed using a commercial cell
proliferation assay, Cell titre 96® (Promega). This is a non-radioactive, colorimetric
based assay. The assay was performed according to the manufacturers instructions.
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Briefly, following 5 days culture, 20pl of combined MTS/PMS solution was added to
each well. The plates were then incubated for 4 hours at 37°C. Absorbance was read at
490nm using an ELISA reader (V max kinetic microplate reader, Molecular devices).
Because the colorimetric assay did not appear to be sensitive enough to detect cell
proliferation in the MLLR subsequent experiments were performed using a radioisotope
based assay. Cells were incubated for the last 18 hours of 5 days culture with 1 pCi
titriated thymidine (ICN Biochemicals, Basingstoke, UK). The plates were then frozen
at -20°C prior to harvesting. On the day of harvesting the plates were thawed and the
wells were harvested onto filter paper using a cell harvester (Tomtec harvester 96* Mach
III M, Wallac, Finland). The filter was air-dried for 1 hour. Wax paper was warmed on a
heating block and the filter paper was then overlain on top of molten wax. Following
setting the wax embedded filter was loaded into cassette and read with a p scintillation
counter (1450 microbeta trilux liquid scintillation and luminescence counter, Wallac).
2.4.4.2 Generation of autologous leukaemia reactive CTL
Autologous T cells from AML patients were obtained when patients had achieved
documented morphological remission. PBMC were separated by centrifugation over
lymphocyte separation medium (Lymphoprep) as previously described. Following
overnight culture in cRPMI adherent cells were decanted and centrifuged at 400g for 4
minutes. The supernatant was decanted and the cells resuspended in cRPMI
supplemented with anti human CD3 mAb (Serotec) at lpg/ml and IL-2 50u/ml (R&D
systems). After 3 days the medium was replaced with cRPMI containing IL2 50u/ml and
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IL-7 lOu/ml (Peprotech, London). Following a further 4 days culture T cells were
harvested and co-cultured with freshly thawed autologous unmodified leukaemia cells or
DLLC in cRPMI with 5% hiABS at a ratio of T cells to unmodified leukaemia cells, or
DLLC, of 3:1. Unmodified leukaemia cells and DLLC were treated with mitomycin C
2 5 jug/ml for 2 hours and then washed three times prior to co-culture with T cells.
Control T cells were cultured with cRPMI supplemented with IL-2 and IL-7 alone. At
the end of the co-culture period the T cells were harvested, centrifuged at 400g for 4
minutes and the supernatant discarded. The cells were then resuspended in cRPMI
containing IL-2 and IL-7 and cultured for a further 4-7 days prior to performing
cytotoxicity assays.
2.4.4.3 Cytotoxicity assays
Initially cytotoxicity assays were performed with freshly thawed unmanipulated AML
blasts as targets. However it became apparent that a significant proportion of the AML
cells were apoptotic therefore giving a high background spontaneous cell death in both
assays. Therefore in later assays apoptotic cells were removed by MACS separation with
annexin-V microbeads as follows: Freshly thawed AML blasts were washed and
resuspended in 200pl of annexin-V buffer (Bender MedSystems). lOpl of annexin-V
microbeads (Miltenyi Biotec) were added and mixed with cells by vortexing for 10
seconds. Cells and beads were incubated for 15 minutes at room temperature. The cells
were then pelleted by centrifugation at 400g for 4 minutes and resuspended in 500pl of
AIM-V medium. The cell suspension was then added to a miniMACS column placed
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within a miniMACS magnet. The negatively selected fraction was collected, washed
with 2mls cRPMI and centrifuged. These cells were then used as targets in the
cytotoxicity assay
H LDH release assay
The LDH release assay was performing using a commercial kit, CytoTox 96®
(Promega), according to the manufacturers instructions. The AML targets cells were
adjusted to a cell density of 105/ml in cRPMI with 5% hiABS. 1 OOjul of the cell
suspension was added to wells of a U-bottomed 96-well plate. Serial dilutions of
effectors, either T cells cultured with IL-2/IL-7 containing medium alone or with
autologous unmodified AML blasts or DLLC, were made up in cRPMI with 5% hiABS
to give final effector:target ratios of 25:1, 10:1 and 5:1. lOOpl were added to the wells of
the 96-well plate. Controls were set up for target cell maximum and spontaneous release,
effector cell spontaneous release and culture medium background as in the Figure 2.3
below. The plate was incubated for 4 hours at 37°C. 45 minutes prior to the completion
of the incubation period 20pl of cell lysis (9% Triton® X-100) solution was added to the
wells containing targets alone to establish target cell maximum release and to wells for
volume correction control. The plate was then centrifuged at 250g for 4 minutes. 50pl of
supernatant removed from each well and transferred to the wells of a flat-bottomed 96-
well plate. 50pl of substrate mixture was added. The plate was then covered in tin foil
and incubated for 30 minutes at room temperature. 50pl of STOP solution (1M acetic
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acid) was added to the wells. The absorbence was read at 492nm with an ELISA reader
(V max kinetic microplate reader, Molecular devices).




taneous release Target cell maxirr"ium release
Volume correcti on control Culture medium 1nackgrour d
Effectcjr cell spontaneous release Experinnental rele;ase
Figure. 2.3 Plate layout for LDH release cytotoxicity assay
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ii/ Flow cytometric based assay
The principle of flow cytometric assay was based on the identification of apoptosis in
target cells by annexin-V and PI staining with elimination of PKH26 stained effectors
achieved by a FL2 high fluorescence exclusion gate (Aubry et al, 1999). Prior to
performing the cytotoxicity assay the cytometer settings were optimised for three colour
staining as follows: 106 primary AML blasts were stained singly with annexin V-FITC
(1 OjliI), PKH26 (4mM) and PI (2pg/ml). FITC labelled cells were run through a
FACSCalibur flow cytometer using settings already optimised for the forward and side
scatter characteristics of leukaemia cells. On a FL1 versus FL2 dot plot the FL-2-%FL-l
compensation was adjusted so that the FL1 positive population was horizontally aligned
with the FL1 negative population. The PKH26 labelled cells were then run through the
cytometer. The FL1-%FL2 compensation was adjusted so that the FL2 positive
population was vertically aligned with the FL2 negative population on the FL1 versus
FL2 dot plot. Finally the PI stained AML cells were run through whilst monitoring the
FL3 versus FL2 plot. FL2-%FL3 adjusted so that PI was undetectable in the FL2
channel. These settings were used for all dual and triple colour analysis of primary AML
blasts.
For performing the cytotoxicity assays 5x106 T cells, either following co-culture with
DLLC or undifferentiated leukaemia blasts or cultured with IL-2 and IL-7 alone, were
stained with 1 ml of 4pM PKH26-GL solution (Sigma-Aldrich) and then incubated for 3
minutes at room temperature. 1 ml of cRPMI was then added to stop the reaction. Cells
were then pelleted by centrifugation at 400g for 4 minutes, the supernatant discarded and
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the cells washed with 4 mis cRPMI. This was repeated three times to completely remove
any unbound PKH26. The cells were then resuspended in cRPMI with 5% hiABS.
PKH26 labelled T cells were made up in various dilutions in cRPMI with 5% hiABS.
Freshly thawed target cells were resuspended in cRPMI with 5% hiABS at cell density
5xl05/ml and 200pl was added to 12x75mm plastic tubes. 200pl of the effector cell
suspensions was then added to the 12x75mm plastic tubes containing the targets to give
effector:target ratios of 25:1, 10:1 and 5:1. The tubes were then centrifuged at 400g for 2
minutes. Following 4 hours incubation at 37° cells were pelleted by centrifugation at
400g for 2 minutes and the supernatant was discarded. The cells were resuspended in
lOOpl of annexin-V buffer (Bender MedSystems). lOpl of annexin-V-FITC was added
and the tubes were incubated for 15 minutes at 4°C. Cells were washed with 2 mis PBS
and then pelleted by centrifugation at 400g for 4 minutes. The supernatant was discarded
and the cells resuspended in lOOpl annexin-V buffer containing 2pg/ml of PI. Analysis
was then performed within 15 minutes on a FACSCalibur flow cytometer using
instrument settings pre-optimised for three colour analysis of primary AML blasts.
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2.4.5 Differentiating agents
2.4.5.1 Calcium Ionomycin induced differentiation
Attempts to induce DLLC differentiation with calcium ionophore A23187 (Sigma-
Aldrich) were performed with leukaemia cells from the HL60 cell line and primary
AML blasts from selected AML cases. Cells were harvested and resuspended at 106
cells/ml in cRPMI. 3 mis of the cell suspension was transferred to the wells of a 6-well
plate and calcium ionophore A23187 was added to give a final concentration varying
from 0 ng/ml to 400ng/ml. Plates were incubated at 37°C, 5% CO2 for 48 hours
following which the cells were harvested and analysed for expression of costimulatory
molecule expression by flow cytometry.
2.4.5.2 Differentiating agents in combination with cytokines
In those AML cases which had shown resistance to cytokine-induced differentiation to
DLLC the culture was repeated but with differentiating agents given in combination
with the cytokine regimen in an attempt to induce differentiation. AML blasts from nine
differentiation resistant cases were cultured at 106 cells/ml in the wells of a 6-well plate
in cRPMI supplemented with GM-CSF, IL-4 (as described previously), with
differentiating agents trichostatin-A (TSA) 75ng/ml in combination with azacytidine
(AZA) lpM, or bryostatin-1 (BRYO) lOnM alone, added for the first 4 days of the
culture period. The cells were then harvested and pelleted by centrifugation at 400g for 4
minutes. The supernatant was discarded and the cells were resuspended in cRPMI
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containing GM-CSF and TNF-a. The cells suspension was reseeded into the wells of a
6-well plate and the plate was incubated for a further 3 days. Cells were then harvested
and used for either for immunophenotypic analysis of costimulatory molecule
expression, or as stimulators in allogeneic MLLR, as described previously.
2.5 Induction of differentiation in murine myeloid leukaemia cells
2.5.1 Murine AML model
The murine AML (mAML) model is a radiation induced leukaemia in CBA mice
(Fennelly et al, 1997; Major, 1979; Wright, 1991). Cryopreserved mAML cells were
obtained for Eric Wright, Dundee Medical School.
2.5.2 Maintenance of animals
All mice were housed within the animal facilities at ICAPB, Edinburgh, according to the
provisions of the animals (Scientific Procedures) Act (UK) 1986.
2.5.3 Passage of murine AML
A frozen aliquot of murine AML cells (aliquot MC7.3 spleen 14/09/95) was thawed at
37°C. The cells were diluted slowly in 20mls of cRPMI. The cells were then pelleted by
centrifugation at 400g for 7 minutes and the medium replaced with 20mls cRPMI. This
process was then repeated. The cells were centrifuged at 400g for 7 minutes and the
resulting cell pellet was resuspended in 2 mis PBS. A viable cell count was performed.
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A total of llx 106 murine AML cells were recovered. 10 female CBA/Ca mice were
irradiated 200R each and injected intraperitoneally with 106 cells in 200pl of PBS. A
further passage of tumour was performed using spleen cells from a first passage mouse
that had developed overt signs of leukaemia. A single cell suspension was prepared from
homogenised spleen and a further 10 female CBA/Ca mice were injected with 2 x 106
cells in 200pl PBS following 300R irradiation.
2.5.4 Harvesting ofmurine AML cells
To obtain peripheral blood samples the following procedure was performed. The mouse
was anaesthetised with halothane. Using a heparinised capillary tube (Hawksley, Sussex,
UK) 10-15 drops blood were collected by venepuncture of the retro-orbital venous
sinuses and added to lOmls of PBS and then mixed by inversion. The cell suspension
was centrifuged at 400g for 4 minutes and the supernatant removed by aspiration. The
cell pellet was then resuspended by flicking tube. 9ml of distilled H2O was added and
mixed by inversion for 12 seconds. 1ml of 1 Ox PBS was then added and again mixed by
inversion. The cells were then centrifuged at 400g for 4 minutes. The supernatant was
removed by aspiration and the pellet was resuspended by flicking tube. 10 ml of PBS
was added and mixed by inversion. The cells were centrifuged at 400g for 4 minutes.
The supernatant was removed and the pellet was resuspended by flicking tube. 1 ml of
cRPMI was added. A viable cell count was performed and cRPMI with 10% DMSO was
added to give a final cell density of 2 x 10 /ml. The cells were then frozen.
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When mice began to develop overt signs of leukaemia they were sacrificed and
leukaemia cells were harvested from peritoneal exudates and spleen. Mice were killed
by CO2 method and then washed down with 70% alcohol. The mouse was lain on the
right side and the skin pinched up to allowing a skin incision and subsequently peeling
off of skin to be performed whilst leaving the peritoneal membrane intact. With a 5ml
syringe and 21g needle 5mls of PBS was injected into the abdominal cavity. Following
this the hind legs were picked up and the mouse shaken gently. Using the same syringe
and needle the fluid from the peritoneal cavity was carefully removed and transferred to
a 15ml conical tube. Injection of PBS into the peritoneal cavity and its subsequent
aspiration was repeated between 4-6 times more until the total volume in the conical
tube was 15mls. The cells were pelleted by centrifugation at 400g for 4 minutes. The
supernatant was discarded and the cell pellet resuspended by flicking the tube. 1 ml of
cRPMI added and a viable cell count performed. Cell density was adjusted to 5x107 by
addition of cRPMI with 10% DMSO and cell were frozen.
Spleen obtained from a freshly dissected mouse was placed in a glass homogeniser. 1 ml
of PBS was then added. A glass rod was placed into homogeniser and turned 3-4 times
in order to disrupt the tissue. The resulting cell suspension was transferred to a 15ml
conical tube. This was left to stand for 3-5 minutes to allow tissue debris to settle to the
bottom of the tube. The cells were then decanted into a fresh tube. PBS was then added
to give a final volume of 1 Omls. The cells were pelleted by centrifugation at 400g for 4
minutes. The supernatant was discarded and the cell pellet resuspended by flicking tube,
lml of cRPMI was added and a viable cell count was performed. Cell density adjusted to
5x107 by addition of cRPMI with 10% DMSO and cell were frozen.
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2.5.4 Immunophenotypic profile of leukaemia cells
Murine AML cells were analysed for expression of costimulatory molecule expression
before and after attempted differentiation by staining 2x 105 cells in 12x75mm plastic
tubes with 10 pi rat mAb directed against mouse CD40, CD80, CD86, HLA class II (all
Serotec), CDllb (Pharmingen) (all FITC-conjugated) and Gr-1 (Pharmingen) (PE-
conjugated). Cells were also stained with isotype matched control rat antibodies
(Serotec). The tubes were then incubated for 30 minutes at 4 °C. Cells were washed with
2mls PBS and then pelleted by centrifugation at 400g for 4 minutes. The supernatant
was discarded and lOOpl of PBS containing 2pg/ml PI was added. After 5 minutes
incubation analysis was performed on a FACSCalibur flow cytometer using the pre-
optimised 3-colour settings modified for the FSC and SSC characteristics of murine
cells. Viable cells were defined with a forward scatter (FS)/PI gate.
2.5.6 Cytokine-induced differentiation
Freshly thawed murine AML cells were cultured at 5x106 cells/ml in the wells of a 6-
well plate in cRPMI with 5% hiABS and lOOpM 2-Mercaptoethanol (Sigma) to which
was added murine GM-CSF lOng/ml and murine IL-4 50ng/ml for 4 days at 37° C. The
cell suspension was then harvested and the cells pelleted by centrifugation at 400g for 4
minutes. The medium was replaced with fresh cRPMI to which was added GM-CSF
lOng/ml and murine TNFa 25ng/ml and the cell suspension reseeded into the wells of a
6-well plate. Following further culture for 3 days the cells were harvested and were used
for immunophenotypic analysis.
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2.5.7 Bryostatin-1 in combination with cytokines
In an attempt to overcome cytokine-induced differentiation resistance murine AML cells
were cultured under identical conditions except that for the first 4 days of the culture
period BRYO lOnM was used in combination with the cytokine regimen.
2.6 Photomicroscopy
Phase contrast photomicrographs were taken using a Nikon F-301 camera attached to a
Nikon Diaphot phase contrast microscope (Nikon, Japan).
Cytospin preparations for photography purposes were prepared as follows. Cells were
resuspended in PBS to give a cell density of 106/ml. Cytospin cups were assembled with
Shandon glass slides (Cytoslide™, Shandon) and filter cards. 200pl of the cell
suspension was then transferred to the cytospin cups placed within a cytospin centrifuge
(Shandon, Southern). These were then centrifuged at 200rpm for 5 minutes. The slides
were then removed and allowed to air dry for 10 minutes. The slides were then stained
with May-Grunwald-Giemsa stain (BDH, Poole, UK) using an automatic slide stainer
(Varistain 24-2, Shandon). Photomicrographs were taken with a Leica Wild MPS52
camera attached to a Leica Periplan (Leica,Germany) microscope.
2.7 Statistical analysis




3.1 Comparative experiments of gene transfer efficiency
3.1.1 Selection of a GFP containing plasmid vector
A qualitative comparison in the GTE of six GFP containing plasmid vectors,
following calcium phosphate precipitation, into COS and CHO target cell lines was
performed. The pBabe.puroEGFP vector was selected for subsequent experiments, as
under fluorescence microscopy it appeared to infect a greater proportion of cells and
gave higher fluorescence intensity than the other vectors.
3.1.2 Myeloid leukaemia cell lines
3.1.2.1 Electroporation
Electroporation, under the range of conditions tested, gave a low transfection
efficiency in the four leukaemia cell lines tested, <1%, and was associated with a
high degree of cell death (>60%) in all four of the leukaemia cell lines.
3.1.2.2 Commercial transfection reagents
For all the commercial transfection reagents optimisation was performed to establish
the conditions that gave the highest efficiency of gene transfer. An example of this is
illustrated in Figure 3.1. Optimisation of the commercial transfection reagent
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Transfast into the K562 cell lines was performed by varying the plasmid DNA
quantity at two separate charge ratios. GTE was determined by the measuring the
percentage of cells expressing GFP, in comparison to cells transfected in the absence
of plasmid DNA, by flow cytometry.
Despite optimisation the level of gene transfer using commercial transfection
reagents was very low. A GTE of >5% was only achieved in the K562 cell line and
only with the transfection reagents Transfast and Effectene (Fig 3.2). In the
remaining cell lines the level of GTE with all of the commercial transfection reagents
was < 1%.
3.1.2.3 Retroviral vectors
Three packaging cells lines, TeflyMLV-A, TeflyRD114 and TeflyGALV containing
the pBabe.puroEGFP were created (as well as three lines containing the 'empty'
pBabe.puro vector for the purposes of generating control retroviral vectors). A
comparison of the GTE of these packaging cell lines was performed with the four
leukaemia cell lines. The results from this experiment is shown in Table 3.1
% GFP positive
Envelope protein
K562 KG 1a U937 HL60
MLV-A 5~8 7G 1023 0.2
GALV 26.5 6.2 9.2 0.4
RD114 72.7 10.8 30.8 0.9
Table 3.1 Comparison of gene transfer efficiency of a retroviral vector packaged
with three different envelope specificities
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DNA (fig) DNA (jig)
Figure 3.1 Optimisation of gene transfer to K562 cell line with Transfast.





Transfast Effectene Fugene Superfect
Physical /chemical transfection method used
Figure 3.2 Comparison of gene transfer efficiency with commercial transfection
reagents
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Packaging of the retroviral vector by the TeflyRD114 cell line gave consistently
higher levels of GTE than with the other two packaging cell lines. This may have
been due to the fact that the RD114 envelope protein increased the efficiency of
retroviral vector attachment to the myeloid leukaemia cells in comparison with
vectors possessing the other two envelope protein specificities. However as no
physical evaluation of the total number of retroviral particles in the individual vector
stocks was made another possible explanation could be that the
TeflyRDl 14.pBabe.puroEGFP producer cell line generated higher concentrations of
retroviral particles than the other producer cell lines. However as, for whatever
reason, relatively high tire retroviral vector stock could be generated by the
TeflyRDl 14.pBabe.puroEGFP producer cell line all subsequent comparative
experiments of GTE with the retroviral vector were performed with vector stock
harvested from this producer cell line.
Although retroviral stock of reasonable titre could be generated attempts were made
to perform further concentration of this stock in order to allow experiments on
leukaemia cells to be performed at the highest possible MOI. Two methods were
used, either concentration by ultracentrifugation or by mixing with pansorbin.
Concentration of retroviral vector stock by ultracentrifugation led to around a 10-fold
increase in titre based on the GTU assay when compared with pooled unconcentrated
vector stock. However when comparisons were made between the GTE of neat
pooled unconcentrated vector stock with vector stock concentrated by
ultracentrifugation there was no apparent enhancement of GTE despite the higher
titre (data not shown). A similar pattern was observed in experiments comparing
unconcentrated vector stock with vector stock concentrated by the pansorbin method
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Table 3.2 shows the titres obtained at various dilutions for unconcentrated vector






Table 3.2 Comparison of the titres obtained with pansorbin concentrated versus
unconcentrated retroviral vector stock
These experiments showed that enhancement of titre, as measured by the GTU assay,
was highest at the lowest dilution and progressively fell as the degree of dilution
diminished. A possible explanation for this observation is that the pansorbin itself
had a detrimental effect on the GTE, this effect being most marked at the highest
pansorbin concentration. When a comparison of pooled retroviral vector stock was
made with neat pansorbin concentrated vector stock in the four leukaemia cell lines it
was found that there was no significant enhancement of GTE with the pansorbin
concentrated vector stock (Table 3.3).
% GFP positive
Ce" ''ne Pooled Pansorbin concentrated
5\ Ow-i n6\(titre 4x10s) (titre 2x10°)
K562 46.7 38.5
KG 1a 1.3 1.1
U937 29.2 28.2
HL60 0.3 0.2
Table 3.3 Comparison of gene transfer efficiency of pansorbin concentrated versus
unconcentrated retroviral vector stock
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Because concentration of retroviral vector stock led to no apparent benefit in terms
of enhancement in GTE unconcentrated retroviral vector stock was used in all
subsequent experiments.
An alternative approach to increasing the GTE of retroviral vectors, other than by
using a higher MOI, is to enhance the binding of the retrovirus to the target cells by
co-localisation on recombinant fibronectin (Hanenberg et al, 1996). Because of the
availability of plasma-derived fibronectin, sourced from the SNBTS Protein
Fractionation Centre (Edinburgh), fibronectin-coated plates were evaluated as a
means of improving GTE. In parallel infection of human leukaemia cell lines was
performed using 6-well plates that were either uncoated or coated with plasma-
derived fibronectin. High titre retroviral vector stock from the
TeflyRDl 14.pBabe.puroEGFP producer cell line was used for infection of the
leukaemia cells. The results of these experiments showed that there were no apparent









Table 3.4 Comparison of gene transfer efficiency using uncoated and fibronectin
coated plates
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Because of this failure to identify methods to enhance GTE either by concentration
of retroviral vector stock, or by using fibronectin-coated plates, work focused on
generating sufficiently high titre retroviral vector stock to allow a reasonable level of
MOI. The highest titre obtainable, based on the GTU assay, was 2xl06 GTU/ml,
which meant that the highest practicable MOI for infection of the myeloid leukaemia
cell lines was 10. Figure 3.3 shows the mean GTE from three independent
experiments in the four leukaemia cell lines. The K562 cell line was the most
permissive of the cell lines to retroviral vector infection (mean GTE 78.3%),
followed by U937 (mean GTE 39.2%) and then the KGla cell line (mean GTE
8.8%). The HT60 cell line was relatively resistant to retroviral vector infection with a
mean GTE of only 0.96%.
3.1.2.4 Adenoviral vectors
One of the main advantages of using adenoviral vectors is that higher titres of vector
stock can be obtained, in comparison with retroviral vectors, therefore making it
possible to perform infections at higher MOI. AdGFP vector stock titres, based on
the GTU assay, were in the order of 2xl07-5xl07 GTU/ml. In preliminary
experiments it was found that very high MOI (>100) was associated with an
excessive loss of cell viability, presumably due to the toxic effects of the adenovirus.
Therefore subsequent infections were performed at a MOI of 40, which appeared to
give good levels of GTE but was not associated with too much toxicity. Because
there was no difficulty in achieving sufficiently high MOI no purification of
adenoviral vectors was performed. As a number of studies had demonstrated that
combining polycationic lipids with adenoviral vectors enhanced GTE (Clark et al,
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1999; Dietz & Vuk-Pavlovic, 1998; Fasbender et al, 1997) some comparative
experiments of AdGFP with and without polybrene 4pg/ml were performed. These
showed that there was significant enhancement of GTE with polybrene (data not
shown), so in all subsequent infections polybrene was used in combination with the
adenoviral vectors. The GTE of the AdGFP vector in the four leukaemia cell lines is
shown in Figure 3.4. Results represent the mean of three independent experiments.
Three of the myeloid leukaemia cell lines were relatively permissive to adenoviral
infection with mean GTE for the K562, IJ937, and KGla cell lines of 51.1%, 63.1%
and 56% respectively. The HL60 cell line again proved difficult to transfect although




K562 U937 KG1a HL60
AML cell line
Figure 3.3 Comparison of gene transfer efficiency of a retroviral vector, in
leukaemia cells lines.
Experiments performed with the pBabe.puroEGFP vector packaged by the
TeflyRD114 packaging cell line (Represents mean of three independent




Figure 3.4 Comparison of gene transfer efficiency of an adenoviral vector in
leukaemia cell lines.
Experiments performed with the AdGFP vector. (Represents mean of three
independent experiments. Error bars set at one standard deviation from the mean)
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3.1.3 Primary AML blasts
3.1.3.1 Retroviral vector
Infections of primary AML blasts were performed with TeflyRDl 14 vector stock, at
MOI of 10, following 48 hours culture of leukaemia cells with GM-CSF and IL-3
given in an attempt to stimulate cell division. Leukaemia cells from 14 AML cases
were tested. These primary leukaemia cells were resistant to retroviral vector
infection with a mean GTE of only 0.8% (range 0-2.5%).
3.1.3.2 Adenoviral vectors
Infections of primary AML blasts were performed with AdGFP vector stock at a
MOI of 40. Viral absorption was performed either after 48 hours culture with GM-
CSF/IL-3 or after 7 days culture with GM-CSF/IL-4/CD40L, given in an attempt to
increased viral binding and internalisation through upregulation of integrin
expression. The GTE of the AdGFP vectors into primary leukaemia cells showed a
high degree of variability between individual AML samples. For leukaemia cells that
had been cultured with GM-CSF/IL-3 prior to infection the range of GTE was 0.7%-
67.1% (mean GTE 12.1%). AdGFP infections performed after prior culture of the
leukaemia cells with GM-CSF/IL-4/CD40L gave a GTE ranging from 0.7-56.2%
(mean GTE 11%). Overall there was no statistically significant difference between
GTE in leukaemia cells cultured with either of the cytokine combinations (p=0.4).
However if subgroup analysis was performed in the cases that had shown a GTE of
<5% following prior culture with the GM-CSF/IL-3 combination then there did
appear to be a significant enhancement in GTE, in these cases, following culture with
GM-CSF/IL-4/CD40L (mean GTE 9.4%)(p<0.005).
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Table 3.5 Comparison of gene transfer efficiency of an adenoviral vector in primary
leukaemia cells cultured with two different cytokine combinations.
Leukaemia cells derived from 19 AML cases were cultured for either 48 hours with



























Figure 3.5 Comparison of gene transfer efficiency of an adenoviral vector in
primary leukaemia cells cultured with two different cytokine combinations.
Data represented in histogram form
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3.2 Generation of stably transduced cell lines
Stably transduced cell lines were created initially for the purpose of testing whether
gene transfer of costimulatory molecules or immunostimulatory cytokines would
lead to an increase in the immunostimulatory properties of the genetically modified
leukaemia cells. For this purpose CD80 and IL-2 transduced cell lines were created.
However when it became apparent that gene transfer to primary AML blasts, with
the vectors available, was not of a sufficient level to be clinically useful the focus
switched to generating CD40 transduced leukaemia cell lines for the purposes of
their attempted differentiation induction with CD40L.
With the K562 cell line one of the major difficulties in selecting stably transduced
clones was that within the leukaemia cell population there appeared to be a sub-clone
of puromycin resistant cells. This is illustrated by the puromycin response curves that
had been generated prior to the stable transduction of the cell lines. In Figure 3.6 the
puromycin response curve for the K562 cell line is shown alongside that for U937.
Even at very high puromycin concentrations there appears to be a population of
K562 cells that are resistant to the puromycin. It was still possible to generate K562
cell lines transduced with the cDNA of interest by screening multiple clones and
selecting and expanding those that showed high levels of transgene expression.
(Figure 3.7).
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Figure 3.6 Puromycin dose response curves in leukaemia cell lines
A. and B. represent the MTT conversion at various cell number and the puromycin
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Figure 3.7 Stable transduction of leukaemia cell lines with retroviral vectors
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3.2.1 Cell lines expressing costimulatory molecules
As previously described stably transduced cell lines were produced by selecting
clones that showed high levels of transgene expression. For the costimulatory
molecules CD40 and CD80 this involved staining a sample of the cells derived from
individual clones with murine mAb and then performing flow cytometric analysis
(Figure 3.7). Clones with high transgene expression were selected for further
expansion in puromycin containing medium. Transgene expression appeared to be
stable over time with no evidence of transcriptional silencing in any of the
retrovirally transduced cell lines generated.
3.2.2 Cell lines expressing IL-2
Leukaemia cell lines transduced with an IL-2 containing retroviral vector were
produced in an identical manner to that previously described for the cell lines
transduced with cDNA encoding for costimulatory molecules. Screening for high
transgene expressing clones was performed using a flow cytometric method designed
to detect intracellular cytokine production (Prussin & Metcalfe, 1995). However
despite the appearance of puromycin resistant clones no IL-2 production by
apparently transduced leukaemia cells could be detected by this method. Therefore in
order to establish that the methodology was effective at detecting intracellular IL-2
production, activated T cells, derived from healthy volunteer donor PBMC, were
used as an IL-2 producing positive control. PBMC were stimulated with PMA and
PHA and the presence of T cell activation confirmed by dual staining with mAb for
CD3 and the T cell activation marker CD69. Staining of monensin treated PBMC
with anti-IL-2, following permeabilisation, revealed that there was an IL-2 secreting
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population (Figure 3.8). This confirmed the validity of this method for detecting
intracellular cytokine production. However repeated testing of various supposed IL-2
transduced clones, using this method, failed to detect any intracellular IL-2
production. The reason why this method was unsuccessful was not established. A
possible explanation could be that despite successful transduction of leukaemia cells
with cDNA coding for the IL-2 the amount of IL-2 produced by individual cells was
below the level of detection of this particular method. If this were the case then a
more sensitive assay system such as ELISA would probably be better suited for the
detection of cytokine production by retrovirally transduced leukaemia cells.
IL2.PE
Figure 3.8 Measurement of IL-2 production.
Analysis performed by flow cytometric method of detection of intracellular cytokines
A. Expression by PBMC of the T cell activation marker CD69 following stimulation
with PHA and PMA (Gated on the CD3 positive population)
B. Expression of intracellular IL-2 by PBMC following treatment with monensin
(Gated on the CD69 positive population)
C. Expression of intracellular IL-2 by an apparently stably transduced IL2.U937 cell
line using the same method
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3.3 Discussion
The physical and chemical transfection methods evaluated in this study gave a low
efficiency of gene transfer to leukaemic cells and in the case of electroporation was
associated with a high degree of cell death. They therefore do not represent suitable
vectors for gene transfer in a clinical setting. Despite the high transduction efficiency
in the majority of leukaemia cell lines achieved with the pBabe.puro retroviral vector
packaged by the TeflyRD114 cell line, GTE in primary AML blasts was low. The
most probable reason for the low GTE observed using the retroviral vector, in
primary leukaemia cells, is that retroviral vectors require the target cell to be in cycle
in order for transgene expression to take place. Blast cells from patients with AML
tend, however, to be characterised by a low overall proliferation rate due to cell cycle
arrest at G1 (Ferrari et al, 1988). As it is possible to force AML blasts to re-enter the
cell cycle by incubation with GM-CSF and IL-3 leukaemia cells were cultured for 48
hours with these cytokines, prior to infection, in an attempt to improve the efficiency
of retroviral vector transduction (Pebusque et al, 1989). The GTE despite using
cytokines to stimulate cell proliferation was low. Because of the requirement for cell
cycling and the relatively low titres of infectious retroviral particles that can be
obtained, Mo-MLV based retroviral vectors are unlikely to fulfil the requirements of
a clinically useful gene transfer system in this context.
Adenovirus based vectors, in contrast to retroviral vectors, are able to infect non-
dividing cells. In addition it is possible to generate vector stock ofmuch higher titre,
in the range of 1010"11 viral particle/ml. thereby allowing for a greater MOI. Although
transgene expression for the adenovirus vector is not permanent it has been shown to
be sufficiently stable over time to be suitable for use in immunotherapeutic strategies
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(Dietz & Vuk-Pavlovic, 1998; Frey et al, 1998; Gonzalez et al, 1999; Zhong et al,
1999). Using the adenovirus vector, AdGFP, high GTE was obtained in three out of
the four leukaemia cell lines tested. Only the HL60 cell line appeared to be relatively
resistant to adenovirus infection. GTE of the AdGFP vector in primary AML blasts
showed a high degree of variability, regardless of whether the leukaemia cells were
cultured with GM-CSF/IL-3 or GM-CSF/IL-4/CD40L prior to infection. There was
no apparent correlation observed between the FAB subtype of the AML cases and
the individual GTE.
A possible reason for this observed variability between AML samples from different
patients may reflect differential expression of integrins and CAR by the leukaemic
cells. Haematopoietic cells have been shown to have low or absent expression of the
primary adenovirus receptor, CAR, and it's integrins, such as av(33, which appear to
play the major role in adenoviral viral attachment and internalisation (Huang et al,
1996; Wickham et al, 1993). Resting monocytes express low levels of otv integrin
and are relatively resistant to gene transfer by adenovirus vectors (Huang et al,
1995). During terminal differentiation ofmonocytes av integrins become upregulated
and this is associated with an increase in GTE. Similarly during DC maturation a
variety of integrins become upregulated, among them av,, and this is believed to be
the reason for the high efficiency of gene transfer by adenovirus vectors observed in
this cell type (Brown et al, 1995; Dietz & Vuk-Pavlovic, 1998; Zhong et al, 1999).
Based on studies showing that it was possible to induce the differentiation of primary
leukaemia cells into DLLC by culture with cytokine combinations (Boyer et al,
2000; Brouwer et al, 2000a; Brouwer et al, 2000b; Charbonnier et al, 1999;
Choudhury et al, 1999; Cignetti et al, 1999; Costello et al, 2000; Kohler et al, 2000;
Oehler et al, 2000; Robinson et al, 1998), it was hypothesised that DLLC might also
possess the same integrin profile as DC, therefore making them permissive to
adenoviral infection. Therefore a comparison was made between adenoviral infection
of leukaemia cells cultured prior to infection either with the cytokine combination
GM-CSF/IL-3 or with GM-CSF/IL-4/CD40L, given in an attempt to induce DLLC
differentiation. Although in 10 cases GTE was enhanced by prior culture with the
GM-CSF/IL-4/CD40L combination, overall there was no statistically significant
difference in mean GTE between the two cytokine regimens. However if analysis
was restricted to those cases that had only achieved a GTE of <5% with the GM-
CSF/IL-3 combination there was a significant improvement by prior culture of the
leukaemia cells with GM-CSF/IL-4 and CD40L. A possible explanation for this
could be that the leukaemia cells from the AML cases that showed resistance to
adenoviral infection, had low levels of expression of av integrins, or other integrins
involved in adenoviral attachment or internalisation, and following culture with GM-
CSF/IL-4/CD40L showed upregulation in expression of these integrins with
consequent enhancement in GTE. The AML cases that were permissive to adenoviral
infection might be expected to show higher levels of basal expression of the
adenoviral receptors, either integrins or CAR, and therefore would be less likely to
show enhancement of GTE following culture with cytokines aimed at upregulation in
expression of these receptors. In fact in many of these adenoviral permissive cases
GTE was lower with the GM-CSF/IL-4/CD40L combination, which may be as a
consequence of decreasing cell viability over the culture period, itself an important
factor in determining GTE. A further advantage of the GM-CSF/IL-4/CD40L
combination in terms of increasing the immunogenicity of the leukaemia cells, is that
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in addition to achieving genetic modification of the leukaemia cells, in many cases
culture with this cytokine combination was associated with upregulation in
costimulatory and cell adhesion molecule expression by the leukaemia cells.
Although using AdGFP, following one or the other of the cytokine regimes, gave
moderate levels of GTE in the majority of AML cases tested, this levels of gene
transfer is still probably insufficient for the purposes of a clinical gene therapy
strategy.
As it appears that the main limiting factor to achieving high levels of gene transfer
with adenoviral vectors in haematopoietic cells is the lack of adenoviral surface
receptors investigators have sought ways of retargeting adenoviral vectors to
improve their attachment to haematopoietic cells (Douglas et al, 1996; Douglas et al,
1999; Smith et al, 1999; Wickham et al, 1996). Adenoviral vectors have been re-
engineered in a number of ways aimed at increasing their binding to haematopoietic
cells. One group has achieved this by linking the recombinant adenovirus vector to
stem cell factor thereby allowing binding of the vector to the c-kit receptor present
on primitive haematopoietic cells (Smith et al, 1999). Using a different approach
Wickham et al created a recombinant adenoviral vector containing a heparin-binding
domain that targets the virus to broadly expressed, heparan-containing cellular
receptors (Wickham et al, 1996). This vector was found to give a high level of gene
transfer in primary AML blasts (Gonzalez et al, 1999).
Lentiviral vectors were not evaluated as a part of the comparative study of gene
transfer methods in AML, but evidence from recent studies suggests that these
vectors might prove to be efficient at gene transfer to leukaemia cells. In contrast to
Mo-MLV based retroviral vectors, lentiviral vectors are able to transduce non-
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dividing cells (Naldini et al, 1996) and therefore would be more likely to be
successful at gene transfer to the predominately cell-cycle arrested primary AML
blasts. Two groups have independently evaluated a HIV-1 based lentiviral vector
pseudotyped with VSV-G envelope protein in primary AML blasts. Mean GTE of
77.6% (Stripecke et al, 2000) and 19.5% (Biagi et al, 2001) for the lentiviral vector
in leukaemia cells were achieved, respectively for the two groups.
In summary following a comparative analysis of a variety of physical, chemical and
viral transfection systems no method was identified that could be used clinically for
the transfer of immune genes to leukaemia cells for the purpose of creating a cellular
vaccine. However, based on recent studies, adenoviral vectors that have been
retargeted to increase their binding to haematopoietic cells or VSV-G pseudotyped
lentivirus vectors do offer promise as clinically useful gene transfer vectors. This
next generation of vectors may be suitable for the ex vivo transfer of genes encoding





4.1 Differentiation induction in human myeloid leukaemia cells
4.1.1 Immunophenotypic profile of undifferentiated leukaemia cells
Freshly thawed, unmodified, primary AML blasts from 42 patients with newly
diagnosed or relapsed AML were analysed for expression of costimulatory
molecules CD40, CD80 (B7.1) and CD86 (B7.2), cell adhesion molecule CD54
(ICAM-1), CD95 (Fas), HLA class I and II molecules. The results of these studies, in
addition to the clinical features of the AML cases and the routine diagnostic
leukaemia immunophenotype, is summarised in Table 4.1. There was no significant
expression of CD80 by leukaemia cells found in any of the AML cases. In 9 of the
AML cases there was some degree of CD86 expression with 6 of these cases being
of FAB subtypes M4 or M5 i.e. with a monocytic component. CD40 expression was
present in 6 cases, again the majority of these being M4 or M5 AML. Significant Fas
expression was present in 13 cases (31%). All the AML cases were FILA class I
positive with 35 (83%) also class II positive. Primary AML blasts were also analysed
for expression of the dendritic cell associated markers CD la or CD83 prior to
































































































































































































































































































































































































































































































































































































































































































































































Table4.1Clinicalfe turesndimmunophenotypicprofilefAMLcas s. Scoringfoimmunophenotype:<9%10-19%-/+,2 4+,>50+
4.1.2 Cytokine-induced differentiation
4.1.2.1 Peripheral blood monocytes
Culture of peripheral blood monocytes with GM-CSF and IL-4 for 4 days led to the
appearance of a population of cells with the characteristic morphological appearance
of DC. Immunophenotypic analysis of these cells showed them to have expression of
the DC marker CD la and the costimulatory molecule CD40 and to have weak
expression of CD80 and CD86 (Figure 4.1). Following maturation with CD40L the
DC showed an increase in their intensity of expression of CD80 and CD86 consistent
with maturation induction. In order to determine the optimal dose of CD40L to use
for maturation of the DC (and by inference maturation of DLLC), a comparison of
the effect of increasing concentrations of CD40L in DC maturation induction
performed (Figure 4.2). CD40L was use either alone or in combination with a
proprietary enhancer (Alexis corporation), purported to increase the biological
activity of recombinant CD40L. From this data it can be seen that whereas at a
concentrations of lOOOng/ml CD40L had a significant effect on the upregulation of
costimulatory molecule expression, based on the mean fluorescence intensity (MFI),
when the dose was less than lOOOng/ml this effect was much less marked. The
addition of enhancer did however potentiate the effects of the CD40L particularly at
the dose of lOOOng/ml CD40L.
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Figure 4.1 Immunophenotypic profile of immature monocyte-derived dendritic cells.
Dot-plot shows the typical high forward and side scatter characteristics of DC.
Histogram plots demonstrate CD1a, CD40, CD54, HLA class I and II molecule
expression by DC. These Immature DC show weak CD80, CD86 and CD95
expression.
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Figure 4.2 Maturation of dendritic cells.
Upregulation of costimulatory and HLA class II molecule expression by DC following
maturation with CD40L +/- enhancer
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4.1.2.2 Myeloid leukaemia cell lines
Cytokine differentiation to dendritic-like cells was attempted in the four leukaemia
cell lines using the cytokine regimen of GM-CSF, IL-4 and CD40L for 7 days. At the
end of the culture period no morphological or immunophenotypic evidence of DLLC
differentiation was detected. Extending the culture period to 10 days similarly was
ineffective at inducing differentiation. In order to circumvent the apparent resistance
of the leukaemia cell lines to cytokine-induced differentiation, CD40 transduced cell
lines were generated and these were cultured with CD40L in an attempt to induce
costimulatory molecule expression. Three CD40 expressing cell lines were generated
as described earlier. Of the three only a CD40 expressing KG la subline showed
evidence of differentiation. Following 7 days culture with GM-CSF, IL-4 and
CD40L the leukaemia cells from the CD40.KGla cell line showed upregulation of
CD80 and HLA II expression but no CD86 expression (Figure 4.3). This experiment
was repeated on three separate occasions with similar results obtained after each.
Control cells from the CD40 expressing KG la subline were culture in parallel in an
identical manner except that TNFa was substituted for CD40L. The TNFot
containing regimen failed to induce any upregulation of CD80 expression. Despite
the immunophenotypic evidence of differentiation, morphologically the CD40.KGla
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Figure 4.3 Immunophenotypic analysis of CD40.KG1a cell line following culture
with CD40L or TNFa.
Expression of costimulatory molecules, CD95 and HLA I and II molecules on the cell
line CD40.KG1a following 7 days culture in medium containing GM-CSF, IL4 and
CD40L or TNFa.
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4.1.2.3 Primary AML blasts
Leukaemia cells derived from 42 patients with AML were tested for their ability to
undergo cytokine-induced differentiation. Of these 42 cases 22 were deemed to have
successfully undergone DLLC differentiation based on changes in morphology and
immunophenotypic profile. In 4 cases poor viability of the leukaemia cells over the
culture period prevented further evaluation. The remaining 16 cases were deemed to
be resistant to DLLC differentiation. The morphological and immunophenotypic
evidence for DLLC differentiation is presented below. In order to confirm that the
dendritic-like cells generated by cytokine-induced differentiation of leukaemia had
indeed derived from the leukaemic clone FISH analysis was performed in two
informative cases. IL-12(p70) production following maturation with CD40L was
measured by ELISA. The functional properties of DLLC and differentiation resistant
leukaemia cells were tested in allogeneic MLLR. Finally the ability of DLLC to
generate leukaemia reactive autologous CTLs was assessed by cytotoxicity assays.
i/ Morphology
The morphological features that were deemed to represent successful DLLC under
phase contrast microscopy were the appearance of loosely adherent clumps of cells
that on high power examination had characteristic dendritic processes (Figure 4.4).
Morphological features of DLLC following MGG staining of cytospin preparations
were of large cells with a relatively low nuclear:cytoplasmic ratio again showing the
characteristic dendritic processes (Figure 4.5). In contrast leukaemia cells from AML
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Figure 4.5 Comparison of the morphological features of dendritic cells and
dendritic-like leukaemia cells.
MGG stained cytospin preparations of monocyte derived DC and DLLC generated
from primary AML blasts.
A. and B. are DC derived by cytokine-induced differentiation of PB monocytes.
C., D., E., F., G. and H. are DLLC generated from primary AML blasts from AML
cases UPN 3, 22, 31, 32, 38 and 41 respectively
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ii/ Immunophenotypic profile
Successful DLLC differentiation of leukaemia cells was associated with the
appearance of high forward and side scatter population on flow cytometric analysis.
Gating on this population showed it to have expression of CD40 in combination with
CD80 and/or CD86. The flow cytometric profile following gating on the high
forward/side scatter population in one representative case showing DLLC
differentiation is illustrated in Figure 4.6. Leukaemia cells from AML cases that
failed to differentiate to DLLC, following culture with cytokines, showed no
immunophenotypic evidence of DLLC differentiation. A comparison of the
immunophenotypic characteristics of three AML cases that successfully underwent
DLLC differentiation with three cases that were resistant to differentiation is
illustrated in Figure 4.7. The DC marker, CD la, was not found to be helpful in
establishing whether DLLC differentiation had taken place as in only one patient,
UPN 38, was it found to be expressed. The other DC marker CD83 was, however, a
useful marker of DLLC differentiation. Dual-staining of leukaemia cells with CD40
and CD83 following their attempted cytokine-induced differentiation defined three
separate populations: a CD40/CD83 dual negative population believed to correspond
to undifferentiated leukaemia cells, a CD40 positive, CD83 negative population
believed to correspond to leukaemia cells that were committed to differentiation but
had not acquired the features of fully mature DLLC and finally a CD40/CD83 dual
positive population corresponding to mature DLLC.
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Figure 4.6 Immunophenotypic profile of dendritic-like leukaemia cells
Gated on the population with high forward and side scatter characteristics.
DLLC from one representative AML case, UPN 32.
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Figure 4.7 Comparison of immunophenotypic profile of dendritic-like leukaemia
cells and differentiation resistant leukaemia cells.
Expression of Fas (CD95), ICAM-1 (CD54), costimulatory molecules (CD40, 80, 86),
and HLA II molecules by primary leukaemia cells following attempted cytokine-
induced differentiation to DLLC.
A., B. and C. are AML cases UPN 1, 32 and 38 respectively that underwent DLLC
differentiation.
D., E. and F. are AML cases UPN 5, 13 and 20 respectively that failed to undergo
differentiation
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In AML cases where the leukaemia cells were considered to have successfully
undergone DLLC differentiation, > 5% of the total population was CD40/CD83 dual
positive whereas, in resistant cases, <5% of cells showed dual positivity for
CD40/CD83 (Figure 4.8). Although DLLC consistently showed high expression of
CD54 this was not found to be a useful marker for distinguishing differentiation
permissive from differentiation resistant cases, as there was an upregulation in CD54
expression regardless of whether DLLC differentiation had taken place. DLLC did
however show higher levels of CD54 expression, based on MFI, in comparison with
leukaemia cells from differentiation resistant cases. A similar pattern was observed
when analysing HLA class II expression. Although all the leukaemia cells that had
underwent DLLC differentiation had a high levels of HLA class II expression only
two of the differentiation resistant cases were HLA class II negative following
attempted cytokine differentiation, with the majority of the cases showing HLA class
II molecule upregulation. Culture of leukaemia cells with the cytokine regimen did
not appear to have a significant effect on CD95 expression with no particular
differences observed in the pattern of weak or absent expression, between
differentiation permissive and differentiation resistant cases.
Using these immunophenotypic criteria for successful differentiation to DLLC it was
possible to divide AML cases into whether they were permissive or resistant to
cytokine-induced differentiation to DLLC. In Table 4.2 Part A. clinical features of
AML cases permissive to DLLC differentiation are shown. Part B. shows the clinical
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Figure 4.8 Immunophenotypic features characterising dendritic-like leukaemia cell
differentiation.
A, B and C represent AML cases UPN14, UPN32 and UPN35 that underwent DLLC
differentiation. Note the CD40/CD83 dual positive population and associated CD80
and CD86 expression.
D, E and F represent leukaemia cells from AML cases UPN2, UPN5 and UPN20that
failed to show evidence of differentiation. Note the low numbers of CD40/CD83
expressing cells and lack of CD80 or CD86 expression (Quadrant markers set for
isotype matched negative controls)
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A
UPN Age de novo/ AML Karyotype
(yrs) secondary Subtype
UPN1 82 de novo MO 46,XX
UPN3 26 de novo M1 47XY+19
UPN4 64 de novo M1 45XY
UPN6 73 de novo M1 Fail
UPN9 11 de novo M1 47XY.+ 8
UPN11 81 de novo M2 46XX
UPN14 78 de novo M2 46XX
UPN15 61 de novo M2 46XX
UPN17 57 de novo M2 46XY
UPN22 60 de novo M2 46XX,t(8;21)
UPN23 8 de novo M2 46XY,inv(16)
UPN24 64 secondary M2 46XY
UPN30 68 secondary M4 46XX,interstitial del chr9
UPN31 79 de novo M4 46,XX
UPN32 17 de novo M4 46XY
UPN34 86 de novo M4 46XX
UPN35 62 de novo M4 46XY;inv(16)
UPN38 89 de novo M5 47XX + 21
UPN39 51 de novo M5 46XX
UPN40 85 de novo M5 Fail
UPN41 77 de novo M5 Fail
UPN42 53 de novo M5 46XY
B
UP No. Age de novo/ AML Karyotype/ FISH analysis
(yrs) secondary subtype
UPN2 49 de novo M1 Fail
UPN5 77 de novo M1 Complex karyotype
UPN7 62 de novo M1 46XY,del(12p)
UPN10 50 de novo M2 Fail
UPN12 56 de novo M2 46XX
UPN13 29 de novo M2 46XX, partial del 11(q23)/ mil rearrangement
UPN16 65 de novo M2 46XY;t(7;11)(q32;q23)/ mil rearrangement
UPN18 51 secondary M2 Fail
UPN19 68 secondary M2 Complex karyotype
UPN20 67 de novo M2 46XY,del(22q)/ bcr/abl fusion signal
UPN25 64 de novo M2 46XY
UPN26 84 de novo M2 46XX
UPN27 67 secondary M2 46XY
UPN28 71 secondary M2 Fail
UPN33 74 secondary M4 46XY,del(5q),del(12p)
UPN37 23 de novo M5 45X,-Y,del(9)(q21 ),del(22)(q11)
Table 4.2 Comparison of clinical features of differentiation permissive and resistant
AML cases.
A. Cases in which the leukaemia cells were deemed to have undergone cytokine-
induced differentiation to DLLC
B. Cases that were resistant to DLLC differentiation
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There were a range of FAB subtypes in both permissive and resistant cases
suggesting that this was not a critical factor in determining differentiation potential.
In respect of karyotypic features, however, there was a preponderance of poor risk
karyotypic features amongst the differentiation resistant cases. Examples of these
poor risk karyotypic features include the t(9;22) translocation, rearrangements
involving the mil gene and complex karyotypic changes. Clinically leukaemias
possessing these types of karyotypic features are characterised by poorer treatment
outcomes (Grimwade et al, 1998). In contrast, no poor risk karyotypes were present
amongst the differentiation permissive cases and three cases possessed the good risk
karyotypes, either t(8;21) or inv(16), which are associated with better treatment
outcomes (Grimwade et al, 1998).
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iii/ IL-12(p70) production
Tissue culture supernatants were collected from leukaemia cell cultures that had been
cultured for the first 4 days with GM-CSF and IL-4 and the final 3 days of culture
with GM-CSF, IL-4 and CD40L. Figure 4.9 shows the levels of IL-12(p70)
production by leukaemia cells that had undergone DLLC differentiation in
comparison with those that did not. There was no significant production of IL-
12(p70) by leukaemia cells taken from differentiation resistant cases. IL-12(p70)
production by leukaemia cells that had undergo DLLC differentiation was restricted
to five AML cases (UPN 31, 32, 34, 41, 42). All five of these cases were of AML
FAB subtypes M4 or M5 i.e. having a major monocytic component.
The AML case UPN 31 that had the highest level of IL-12(p70) production was
selected for further study of DLLC maturation induction. Following the initial 4 days
of culture with GM-CSF and IL-4 leukaemia cells from AML case UPN 31
underwent maturation using a variety of maturational agents, either alone or in
combination, for the final 3 days of the culture period. Tissue culture supernatants
were measured for IL-12(p70) production by DLLC and cells were analysed for
their level of costimulatory molecule expression. Figure 4.10 shows the IL-12(p70)
production induced by a variety of maturational agents. These results are
representative of four independent experiments. IL-12(p70) production by DLLC in
the absence of any additional maturational stimulus was negligible. Although CD40L
alone did induce significant levels of IL-12(p70) by DLLC there was a marked
potentiation in IL-12(p70) production when the proprietary enhancer was used in
combination with CD40L, and further potentiation when polyLC was added to
CD40L and enhancer. PolyLC when used on its own was associated with minimal
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levels of IL-12(p70) production by DLLC. The best combination of maturational
agents, that of CD40L, enhancer and polyI:C was significantly better at inducing IL-
12(p70) production than GM-CSF, IL-4 alone (p<0.05) or poly:IC alone (p<0.05).
The expression of CD80 and CD86 was similarly enhanced by using the combination
of CD40L, enhancer and poly:IC in comparison with no additional maturational






Figure 4.9 IL-12 production following cytokine-induced differentiation. Comparison
between differentiation resistant and permissive leukaemia cells following 4 days
culture in GM-CSF, IL-4 and then 3 days with GM-CSF, IL-4 and CD40L
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Figure 4.10 Comparison of various maturational agents ability to induce IL-12
production by dendritic-like leukaemia cells.
IL-12(p70) production by dendritic-like leukaemia cells following maturation using
combinations of poly:IC, CD40L and enhancer given in addition to GM-CSF and IL-
4. Dendritic-like leukaemia cells that had no additional maturation stimulus were
cultured in GM-CSF and IL-4 alone. Data shown are mean +/-SD of triplicate




In order to establish that the dendritic-like cells generated by cytokine-induced
differentiation of leukaemia cells had indeed derived from the leukaemic clone FISH
analysis was performed in two potentially informative cases. In both cases induction
of DLLC differentiation was performed by culturing leukaemia cells with the
standard cytokine regimen for 7 days. Successful DLLC differentiation was
confirmed on the basis of morphological changes and characteristic
immunophenotypic profile. Cytospin slide preparations were made of DLLC from
both cases. DLLC from AML case UPN 22 were unselected. This case was
associated with the AML-associated chromosomal translocation t(8;21). FISH
analysis for this rearrangement revealed that 198 of 200 cells counted (99%)
possessed the t(8;21) translocation. Although the DLLC were unselected it was
assumed that as the DLLC comprised greater than 25% of the total population, based
on immunophenotypic analysis, and as the level of positivity by FISH analysis for
t(8;21) was 99%, the DLLC must possess the rearrangement. The second case, UPN
35, had the AML-associated chromosomal rearrangement, inv(16). In this case, prior
to FISH analysis, the DLLC were selected for on the basis of CD83 expression.
FACS analysis of the CD83 positively selected population confirmed dual
expression of CD40 and CD83. FISH analysis of the CD83 positively selected
population revealed that 170 of 200 cells (85%) possessed the inv(16) rearrangement
confirming that the DLLC had indeed derived from the leukaemic clone (Figure
4.11).
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Figure 4.11 FISH analysis of dendritic-like leukaemia cells
Arrows mark the positions of the two probes that have been pulled apart by the
inv(16) chromosomal rearrangement.
Analysis performed on cytospin slides of DLLC, generated from leukaemia cells
from patient UPN 35, following MACS selection on the basis of CD83 expression
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v/ Allogeneic MLLR
MLLR were performed to compare the ability of cytokine cultured leukaemia cells to
stimulate the proliferation of allogeneic T lymphocytes in comparison with
autologous unmodified leukaemia cells. Initially quantification of cellular
proliferation was attempted using a colorimetric assay. This assay is based on the
ability of metabolically active cells to convert a tetrazolium compound, MTS, to a
formazan product. The amount of formazan generated can be determined by
measuring the absorbence at 490nm and is proportional to the number of living cells
in culture. Despite studies showing comparable sensitivity between this assay and the
titriated thymidine assay (Russell & Vindelov, 1998), the colorimetric assay was
unable to detect any differences in proliferation by responder T cells induced by
various stimulators. Therefore this assay was abandoned in favour of a radioisotope-
based assay. Using titriated thymidine uptake as a read out of cell proliferation
DLLC were found to be potent simulators of allogeneic T lymphocyte proliferation
in MLLR (Figure 4.12). In contrast freshly thawed unmodified leukaemia cells, from
the same AML cases, were only weakly immunostimulatory. Leukaemia cells from
differentiation resistant AML cases following attempted cytokine-induced






Fig 4.12 Allostimulatory properties of dendritic-like leukaemia cells.
Allogeneic MLLR. Responders: allogeneic lymphocytes. Stimulators: leukemic cells
either unmodified (AML) or following DLLC differentiation (DLLC) derived from the
same patient. Experiments were performed using leukemic cells from AML cases A.





Fig 4.13 Allostimulatory properties of differentiation resistant leukaemia cells.
Allogeneic MLLR. Responders: allogeneic lymphocytes. Stimulators: leukemic cells
either unmodified (Pre culture) or following attempted DLLC differentiation (Post
culture) from AML cases A. UPN5 B. UPN13 that showed resistance to DLLC
differentiation
- 140 -
vi/ Generation of autologous leukaemia reactive CTL
In order to generate autologous leukaemia reactive CTL, T lymphocytes were
harvested from AML patients in remission and co-cultured with mitomycin-C treated
DLLC. As the number of T lymphocytes obtained from PB was insufficient to
proceed directly to co-culture experiments, it was first necessary to expand T cell
numbers. This was achieved by using anti-CD3 mAb to induce T cell activation
followed by culture of the cells in IL-2 containing medium. Although this was an
effective method of expansion it was found that after a 2-3 weeks culture period
there was a loss in T cell viability. Therefore in later experiments the T lymphocyte
survival factor IL-7 (Tsuda et al, 2000) was used in combination with IL-2 in order
to prevent T cell apoptosis. Because the T cells were stimulated in this non-specific
manner for the purposes of cytotoxicity assays a control was included with T
lymphocytes cultured with cytokines alone acting as effectors. The first cytotoxicity
experiments were performed using the LDH release assay. Although in the first two
AML cases tested, apparent leukaemia specific cytotoxicity by CTL that had been
generated by co-culture with DLLC was detected, there was a high degree of
variability between experimental wells and the difference between target cell
maximum and spontaneous release was very low (Figure 4.14). Therefore a different
assay system was adopted based on flow cytometric analysis of annexin-V/PI
staining as markers of apoptosis. Although it was possible to achieve a good
separation between the PKH26 stained effectors and the PKH26 unstained targets on
the basis of fluorescence intensity in the FL2 channel, for the purposes of analysing
apoptosis in the target population it became apparent that non-target associated
events were falling into the FL2 negative gate and skewing the results by increasing
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the numbers of PI positive cells. This was particularly a problem at high
effector:target ratios. It is likely that these FL2 negative, PI positive events
represented cell fragments and debris derived from the effector cell population. Even
by performing lymphoprep separation prior to the cytotoxicity assay this population
still appeared within the acquisition gate. Because of this limitation to the flow
cytometric assay the LDH assay was revisited. One of the positive findings from the
flow cytometric based assay was that it provided information on the viability of the
target cell population. It became apparent that in many cases the leukaemia cell
targets were apoptotic prior to performing the cytotoxicity assay. Because a high
proportion of the target cell population were non-viable this made detection of CTL
induced cell death more difficult. Therefore in order to improve the assay sensitivity
apoptotic cells were removed by immunomagnetically labelling then with annexin-V
microbeads and running the cells through a miniMACS column. This proved a
highly effective method of generating a target cell population with a very low
proportion of non-viable cells and as a consequence a very low level of spontaneous
LDH release for the purposes of the LDH release assay (Figure 4.15). Unfortunately
very few patients with AML, in whom leukaemia cells had been harvested and
stored, subsequently went on to achieve remission. Therefore in only one case was it
possible to perform the LDH release assay following its optimisation. No leukaemia
specific cytotoxicity was detected in that particular case (Figure 4.14).
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A B C
Figure 4.14 Autologous cytotoxicity assays.
Targets; freshly thawed AML blasts. Effectors; autologous lymphocytes either
cultured with IL2/IL7 alone or co-cultured for 72 hours with unmodified leukaemia
cells or dendritic like leukaemia cells. Assays A, B and C performed using the LDH
release assay, D and E with a flow cytometric based assay. Apoptotic target cells
were removed by magnetic microbead selection with annexin V microbeads prior to
performing the cytotoxicity assay in C, D and E.
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Unselected AML blasts Negative fraction Positive fraction
■* ■*
Annexin V Annexin V Annexin V
Unselected AML blasts Negative fraction Positive fraction
Annexin V -/PI - 29% 88% 17%
Annexin V+/PI - 18% 6% 21%
Annexin V +/PI+ 53% 6% 62%
Figure 4.15 Removal of apoptotic cells by MACS selection
Dot plot showing annexin V and PI staining of target cells either unmanipulated or
following immunomagnetic separation with annexin-V microbeads. The relative
percentages of annexin-V and PI positive and negative cells are illustrated in
accompanying table. The early apoptotic population falls within the annexin-V+/PI-
quadrant, the late apoptotic cells within the annexin-V+/PI+ quadrant and healthy




Despite the published studies presenting evidence that calcium ionomycin induced
dendritic cell differentiation in the HL60 cell line and in primary leukaemia cells
these findings could not be reproduced. After culture of the HL60 cell line with
calcium ionomycin for 48 hours, at doses ranging from 25ng/ml to 400ng/ml, there
was no upregulation of CD40, CD80 or CD86 expression detectable. In addition the
leukaemia cells maintained an undifferentiated morphological appearance. Primary
AML blasts derived from 6 patients were cultured for 3 days with calcium
ionomycin at 375ng/ml in combination with GM-CSF and IL-4. Again there was no
morphological or immunophenotypic evidence of differentiation detected.
4.1.3.2 Trichostatin, Azacytidine and Bryostatin
In nine of the AML cases in which the leukaemia cells were resistant to cytokine -
induced differentiation to DLLC, further experiments were performed in which
differentiating agents were used in combination with cytokines. TSA, AZA and
BRYO were used alone or in combination for the first 72 hours of the culture period.
The doses of TSA and AZA had been previously determined based on their effects
on cell viability of leukaemia cells from a single AML case (UPN20). When used
alone in doses exceeding lOOng/ml for TSA and 2pM for azacytidine there was a
>50% decrease in cell viability, based on flow cytometric analysis following PI
staining. When used in combination, doses of TSA greater than 75ng/ml and AZA
greater than lpM were associated with a >50% decrease in cell viability. The dose of
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BRYO used was based on data from previously published studies on BRYO induced
differentiation in leukaemia cells (Kaneki et al, 1999; Steube & Drexler, 1993). A
comparison of the differentiating effects of TSA, AZA and BRYO, in combination
with cytokines is shown in Figure 4.16. Culture with cytokines alone for the first 4
days was able to induce very little differentiation based upon the percentage of cells
showing either dual expression of CD40/83 or single expression of CD40. The
addition of TSA and AZA alone or in combination was ineffective at allowing
differentiation to proceed. In contrast BRYO was effective at inducing DLLC
differentiation with 25% of the total cell population showing dual expression of
CD40 and CD83 and 31% show single expression of CD40. Using TSA and AZA in
combination with BRYO did not lead to any improvement in the degree of
differentiation but did considerably decrease cell viability. CD80 expression
mirrored the changes in CD40 and CD83 expression. Cytokines alone or in
combination with TSA and AZA failed to induce any upregulation in CD80
expression. BRYO when given alone or in combination led to significantly increased
CD80 expression but was most effective when given alone. Morphologically DLLC
generated by BRYO treatment of leukaemia cells differed from those generated by
cytokine-induced differentiation of permissive leukaemia cells in that they remained
adherent and failed to form clusters when viewed under phase contrast microscopy.
However under phase contrast microscopy BRYO generated DLLC did show the
characteristic dendritic processes of DLLC (Figure 4.17). On MGG stained cytospin
preparations BRYO generated DLLC were indistinguishable from those generated by
cytokines alone.
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Figure 4.16 Differentiating agents given in combination with cytokines to induce
differentiation.
Attempted differentiation induction of leukaemia cells from case UPN20 using
differentiating agents in combination with cytokines.
A. Leukaemia cells cultured with GM-CSF and IL-4 alone for the first for 4 days of
the culture period
B. TSA added to cytokines
C. TSA and AZA added to cytokines
D. BRYO added to cytokines
E. BRYO and TSA added to cytokines
F. BRYO, TSA and AZA added to cytokines
Dot plots represent dual staining for CD40 and CD83. Percentages of CD40/83 dual
positive and CD40 single positive cells located in upper right and lower right
quadrants respectively (Quadrant markers set for isotype matched negative
controls). The histograms plots demonstrate CD80 expression by the total cell
population (Closed histogram CD80 expression, open histogram staining with
isotype matched negative control mAb).
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TSA and AZA were similarly ineffective in inducing differentiation in eight other
differentiation resistant AML cases. When given in combination they failed to lead
to induction in costimulatory expression above that achieved by culturing with
cytokines alone. However BRYO again proved to be effective at overcoming
differentiation resistance. Out of the 9 patients in whom BRYO was used in
combination with cytokines to induce DLLC differentiation 6 showed evidence of
differentiation based on upregulation of CD40, CD83, CD80 or CD86 expression.
Figure 4.18 illustrates the immunophenotypic evidence for DLLC differentiation in
three of these cases.
In addition to showing immunophenotypic and morphological evidence of DLLC
differentiation BRYO treated leukaemia cells were also tested for their ability to
induce allogeneic T lymphocyte proliferation in MLLR. Figure 4.19 shows the
results in two AML cases in which allogeneic T lymphocytes were stimulated with
leukaemia cells that had been cultured with BRYO in combination with cytokines or
with cytokines alone. BRYO treatment of the leukaemia cells significantly enhanced
the allostimulatory capacity of the leukaemia cells in comparison with those cultured
with cytokines alone. In addition the amount of T cell proliferation induced by
BRYO treated leukaemia cells, based on titriated thymidine uptake, was comparable









Fig 4.18 Immunophenotypic profile of Bryostatin-1 treated leukaemia cells.
The effects of combining BRYO with cytokines in overcoming the differentiation
block in resistant AML cases. On the dot plot there is now a significant population of
CD40/CD83 dual expressing cells. This accompanied by upregulation of CD80 and
CD86 expression as shown on the histogram plots. Experiments were performed






Fig 4.19 Allostimulatory properties of Bryostatin-1 treated leukaemia cells.
Allogeneic MLLR. Responders: allogeneic lymphocytes. Stimulators: leukemic cells
cultured with GM-CSF/IL4 with or without BRYO from AML cases A. UPN20 and B.
UPN26 that had previously been shown to be resistant to DLLC differentiation.
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4.2 Discussion
These results confirm the work of previous studies in showing that it is possible to
induce the differentiation of primary leukaemia cells into DLLC by culture with
certain cytokine combinations. It was shown that cytokine-induced DLLC were both
morphologically and immunophenotypically reminiscent of MDDC, that they
produced in a proportion of cases the immunostimulatory cytokine IL-12 and that
they were potent stimulators of allogeneic T lymphocyte proliferation. Confirmation
that the DLLC did in fact derive from the leukaemic clone was established in two
AML cases by FISH analysis for a leukaemia-associated chromosomal
rearrangement. It was not possible, however, to definitively establish that DLLC
were capable of generating leukaemia reactive CTL by co-culture with autologous T
lymphocytes. Although in two AML cases cytotoxicity against unmodified
leukaemia targets was demonstrated, the assay system at that time had not been
optimised and it is possible that the differences observed may have arisen by chance.
Unfortunately although subsequent work led to the establishment of a more reliable
and sensitive assay system, due to the small numbers of patients achieving remission,
there was only one case where both leukaemia cells and remission PBMC were
available with which to perform the assay. In this case no cytotoxicity against
leukaemia targets by T lymphocytes cultured with DLLC could be detected. It
remains, therefore, an importance priority to confirm the results of previous studies
showing that leukaemia reactive CTL can be generated by DLLC.
Although the previous studies of DLLC differentiation had shown that in a
significant proportion of AML cases the leukaemia cells fail to undergo cytokine-
induced differentiation to DLLC these studies had not addressed the reasons for this.
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One of the purposes of this study was to try to identify the factors important in
determining differentiation potential and, in those cases found be resistant to DLLC
differentiation, to try to find ways of overcoming this resistance. In order to achieve
this it was necessary to establish criteria for successful DLLC differentiation. It was
found that the appearance of a dual positive CD40/CD83 population was a useful
marker in confirming that DLLC differentiation had taken place. In differentiation
resistant cases, following attempted cytokine-induced differentiation, the
CD40/CD83 positive population was <5% whereas for cases undergoing DLLC
differentiation it was >5%. Expression of CD80 and/or CD86 invariably
accompanied the presence of this CD40/CD83 population. Using these
immunophenotypic criteria it was possible to divide AML cases into those that were
differentiation permissive and those that were differentiation resistant. Examination
of the clinical features of these two groups showed that there appeared to be a
preponderance of poor risk karyotypic features amongst the differentiation resistant
AML cases. The differentiation permissive AML cases possessed either standard risk
or favourable karyotypic features. An association between differentiation potential
and karyotype is plausible given that several lines of evidence point towards a
common theme in the molecular pathogenesis of AML, namely that the end result of
the majority of the commonest chromosomal translocations is the repression of
transcription of genes involved in haematopoietic differentiation (Redner et al,
1999). The rationale for using the histone deacetylase inhibitor TSA and DNA
demethylase AZA in an attempt to overcome differentiation resistance was based on
evidence demonstrating that changes in histone acetylation and DNA methylation
status are important in mediating transcriptional repression in AML. There may be a
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variety of possible reasons why this approach was not successful. AML cases
possessing complex karyotypic alterations will have multiple molecular
rearrangements, many or all of which might contribute to the differentiation block. In
addition the molecular consequences of these poor risk cytogenetic/molecular
rearrangements may be to repress haematopoietic gene transcription by mechanisms
unrelated to changes in histone acetylation or DNA methylation status. BRYO-1
promotes differentiation by interfering with protein kinase C activity (Steube &
Drexler, 1993). It has been shown to be effective at inhibiting the clonogenicity of
myeloid leukaemia cells (Matsui et al, 2000). The success of BRYO in allowing
differentiation to DLLC in resistant AML cases might be a consequence of its
inhibitory effects on cell cycle progression. Cell cycle arrest in these differentiation
resistant cases may be sufficient to permit the cell to respond positively to
differentiation signals induced by cytokines thereby allowing DLLC differentiation
to proceed. Therefore by using agents such as BRYO, in combination with cytokines,
it should be possible to increase the proportion of AML cases that are capable of
undergoing DLLC differentiation. This is of particular significance because it would
appear that the patients most likely to be excluded from receiving DLLC vaccination
are those with karyotypically poor risk AML. However, it is these patients who are
most in need of alternative therapeutic approaches, as their outlook with
conventional combination chemotherapy regimens is extremely poor. Data from
1711 patients entered into the UK MRC X trial showed that 5 year survival for
patients with karyotypically poor risk AML was only 17% (Wheatley et al, 1999).
Whereas FAB subtype was not considered to be an important factor in predicting
DLLC differentiation potential it did appear to influence subsequent DLLC
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maturation. Only AML cases of FAB subtypes M4/M5 produced appreciable levels
of IL-12(p70) following maturation with CD40L. Whether this represents a true
inability of DLLC generated from AML cases of FAB subtypes other than M4 and
M5 to produce IL-12 or whether additional maturational stimuli are required to fully
mature DLLC derived from these cases remains to be determined. This may be
important if DLLC are to be used in an attempt to generate immunity to leukaemia in
vivo. Data from studies examining maturation ofmonocyte derived DC suggests that
IL-12 production by MDDC plays a crucial role in directing T cells towards a Thl
cytokine phenotype (Cella et al, 1996; Kalinski et al, 1999). Thl type responses are
believed to be more relevant in the development of effective anti tumour immunity
(Terheyden et al, 2000). It will be important therefore to characterise the nature of
any in vivo T cell responses following DLLC vaccination in order to determine
whether these are dependent on the maturational status of the DLLC. These issues




5.1 Differentiation induction in murine myeloid leukaemia cells
5.1.1 Passage of murine leukaemia cells
The initial passage was performed using an aliquot of murine AML cells derived
from the spleen of a CBA mouse with radiation-induced leukaemia, which had been
harvested and cryopreserved in 1995. 10 syngeneic CBA mice were irradiated with
200R and then injected intravenously with 106 murine AML cells. The outcome
from these injections is summarised in Table 5.1. For passage 2 the source of the
leukaemia cells was the spleen of a mouse that had developed frank leukaemia from
passage 1. In the second passage a higher dose of leukaemia cells was injected and
in addition the mice received a slightly higher conditioning dose of irradiation of
300R. The outcome from this passage is also summarised in Table 5.1. The mice
injected in passage 2 had a 100% incidence of acute leukaemia and the natural
history was of a faster rate of disease progression, necessitating earlier sacrifice of
animals than was required in passage 1. Cells harvested from passage 2 mice had
morphological features typical of AML. These features were identical whether the
source of the leukaemia cells was spleen, peritoneal exudate or peripheral blood
(Figure 5.1). Cytochemical staining with combined esterase demonstrated positivity
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for both chloracetate and non-specific esterase thereby classifying the leukaemia as
myelomonocytic (Figure 5.1).
Passage No. of Radiation Source of No. of No. of mice Survival
number mice dose leukaemia cells developing from
injected cells injected AML injection
(days)











Table 5.1 Outcome of injection of CBA mice with passage 1 and passage 2
murine leukaemia cells
5.1.2 Immunophenotypic profile of undifferentiated leukaemia cells
Murine leukaemia cells were stained with a more limited panel of mAb antibodies
than was used in the human studies. This panel consisted of mAb directed against
Gr-1 and CD1 lb, used for the purpose of confirming that the leukaemia cells were
myeloid in origin, and CD40, CD80, CD86 and MHC class II, which were felt to be
the most useful for establishing that DLLC differentiation had taken place.
- 157 -
Figure 5.1 Morphological and cytochemical characteristics of murine AML.
Cytospin slides made from mononuclear cell preparations of murine AML A.
Peripheral blood B. Peritoneal exudate and C. Spleen cells stained with MGG and
D. Spleen cells stained with dual esterase
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The immunophenotypic profile of undifferentiated murine leukaemia cells is shown
in Figure 5.2. The leukaemia cells show expression of Gr-1 and CDllb, which
would be consistent with the morphological and cytochemical features that
suggested a myelomonocytic leukaemia. MHC class II expression was negative (In
6 of the 42 human AML cases tested the leukaemia cells were HLA class II
negative). The murine leukaemia cells showed no expression of costimulatory
molecules CD40, CD80 and CD86.
5.1.3 Cytokine-induced differentiation
Murine leukaemia cells were cultured under similar conditions to human leukaemia
cells. For the first 4 days cells were cultured in complete medium supplemented
with murine GM-CSF and murine IL-4. The cells were then harvested and the
medium replaced with complete medium supplemented by GM-CSF and murine
TNFa. Morphologically cytokine cultured murine leukaemia cells showed none of
the features that characterised human DLLC differentiation but instead maintained
an undifferentiated appearance. In addition the murine leukaemia cells show very
poor viability over the duration of the culture period. Immunophenotypic analysis
of the cultured leukaemia cells confirmed the fact that they had failed to undergo
DLLC differentiation based on their lack of expression of MHC class II and
costimulatory molecules. Despite repeated experiments, using aliquots of murine
leukaemia cells from both passages 1 and 2, cytokine-induced DLLC differentiation
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Fig 5.3 Immunophenotypic profile of murine leukaemia cells following culture with
cytokines GM-CSF/IL-4 for 4 days and then GM-CSF/TNFa for 3 days.
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5.1.4 Bryostatin in combination with cytokines
Because BRYO had proven to be an effective agent in overcoming DLLC
differentiation resistance in human AML cases this approach was attempted with
the murine leukaemia cells. Murine leukaemia cells were culture with GM-CSF and
IL-4 in combination with BRYO lOnM for the first 4 days of the culture period.
Then cells were harvested and the medium replaced with fresh complete medium
supplemented by GM-CSF and TNFa. A similar morphological appearance of these
BRYO treated cells to the human leukaemia cells was observed with the appearance
of an adherent population of cells that had dendritic processes. Immunophenotypic
analysis demonstrated that differentiation had taken place with the appearance of a
population of cells that had expression of CD40, CD80, CD86 and MHC class II
(Figure 5.4). However it is important to note that the viable cell population at the
end of the culture period was only 20% (based on staining with PI). Experiments
performed to confirm this finding were unsuccessful either because poor viability
over the culture period prevented any meaningful evaluation or because, based on
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Figure 5.4 Upregulation of costimulatory molecules and MHC class II expression
following culture with cytokines in combination with bryostatin.
-163 -
5.2 Discussion
The murine leukaemia model used in this study in many ways represents a useful
system for evaluating immunotherapy-based approaches for the treatment of AML
(Rithidech et al, 1999). It is a radiation-induced leukaemia, in CBA mice, that
morphologically and immunophenotypically resembles human AML (Major, 1979).
Cytogenetic abnormalities are reported to parallel those found in human AML
(Rithidech et al, 1999). The leukaemia can be maintained by passage through CBA
mice, which means that immunotherapeutic strategies designed at stimulating host
immunity against leukaemia could be tested for in a syngeneic setting.
Unfortunately the murine leukaemia cells proved to be resistant to DLLC
differentiation. As evidence from the human studies demonstrates that a significant
proportion of AML cases are resistant to cytokine-induced differentiation to DLLC,
the fact that the leukaemia cells from this murine AML model were resistant to
differentiation was not wholly unanticipated. An additional factor that may have
been important in leading to differentiation resistance is that the leukaemia cells had
been passaged. Following each passage of the murine leukaemia cells through a
host animal the AML behaves in a more aggressive manner and the time from
injection to death becomes shorter (Personal Communication, E.Wright). It could
be hypothesised that with each passage the leukaemia cells acquire new cytogenetic
abnormalities culminating in a complex karyotypic picture, which based on the data
from the human studies would decrease the chances of DLLC differentiation
occurring. Mice in passage 2 certainly had a higher incidence and shorter natural
history of their leukaemia than mice in passage 1, although there were other factors
that could have contributed to this, such as the fact that in passage 1 the leukaemia
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cells had been cryopreserved 6 years previously and that the number of leukaemia
cells used for the injection and the dose of conditioning radiation used was higher in
passage 2. A karyotype was not performed on the leukaemia cells from passage 1
and 2 in order to establish whether cytogenetic clonal evolution had taken place.
Although attempts were made to overcome the differentiation resistance using
BRYO this approach was only successful on one occasion. Because of the
difficulties in trying to reproduce the results of this experiment and as the murine
leukaemia cells showed such poor viability over the culture period it was felt to be
logistically impossible to pursue the murine AML model as a means of evaluating
the effectiveness of an in vivo DLLC vaccination strategy. There has been one
previous study in which murine erythroleukaemia cells were induced to
differentiate into DLLC by culture with GM-CSF, which suggests that DLLC
differentiation is possible in at least some types of murine leukaemia (Cao et al,
1998). There may be other murine AML models, therefore, that could be used for
the evaluation of a DLLC vaccination strategy. In the absence of these murine
models, clinical trials would be necessary for the assessment of in vivo anti-




The objective of this study was the development of a leukaemia cell vaccine by the
modification of autologous leukaemia cells, which could be used for the
immunotherapy of AML. At the beginning of this study it was thought that an
immune gene transfer approach would prove to be the most suitable way to achieve
this objective. At that time there were few published studies on gene transfer into
primary AML blasts and none that had used adenoviral vectors for this purpose. It
was therefore considered to be important to perform a comprehensive evaluation of
gene transfer methods into myeloid leukaemia cell line and primary AML blasts for
the purpose of selecting a gene transfer system that could be used for generating
sufficient numbers of genetically modified leukaemia cells to allow further study of
their immunostimulatory properties. Unfortunately it transpired that none of the gene
transfer methods evaluated in this study were sufficiently efficient to be of use in a
clinical setting. The most successful method, based on an adenoviral vector system,
gave high levels of gene transfer in a minority of AML cases, but in a significant
proportion gave only low levels of gene transfer. In addition these experiments were
performed at high MOI with relatively small numbers of target cells. Scaling up
these methods in order to generate clinically relevant numbers of genetically
modified leukaemia cells would have been likely to have led to a fall in GTE, rather
than the converse. Whilst this study was being performed data was published on
novel vectors that appeared to show considerable promise for the transfer of genes to
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primary AML blasts. A recombinant adenoviral vector was engineered with a
modified fibre protein thereby allowing it to bind with much greater efficiency to
haematopoietic cells (Wickham et al, 1996). This vector, when used for gene transfer
to primary AML blasts, gave a mean GTE of 94.3% in 25 AML cases (Gonzalez et
al, 1999). The second vector that shows promise in gene transfer to primary
leukaemia cells is a lentiviral vector pseudotyped with VSV-G (Stripecke et al,
2000). Mean GTE of this vector in leukaemia cells from 5 AML cases was 77.6%.
Based on the evidence from the preliminary studies with these vectors it appears that
it may be possible to generate sufficient numbers of genetically modified leukaemia
cells for clinical use as vaccines for the immunotherapy ofAML.
There are, however other potential problems, with pursuing this form of
immunotherapeutic strategy. Although the gene transfer of single immune genes,
such as CD80, may be sufficient to restore the immunogenicity of leukaemia cells in
vitro, in a clinical setting vaccines based on single immune gene transfer might prove
to be ineffective at generating anti-leukaemia immunity because of their inability to
overcome the effects of the immunosuppressive microenvironment. In order to
enable the genetically modified leukaemia cells to favourably alter the leukaemia
microenviroment it may be necessary to use vectors containing combinations of
immune genes. For example a tumour cell vaccine based on leukaemia cells
transduced with a bicistronic vector containing the cDNA for CD80 and the
immunostimulatory cytokine GM-CSF, was evaluated in a murine leukaemia model
and was found to be more effective at inducing leukaemia eradication than
leukaemia cells transduced with CD80 only containing vector (Stripecke et al, 1999).
Another potential concern with the use of viral based vectors is that immune
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responses may be directed against viral proteins rather than the leukaemia-specific
antigens (Gahery-Segard et al, 1998; Molinier-Frenkel et al, 2000). Although all
non-essential genes, other than those necessary for transgene expression, are
eliminated from viral based gene transfer vectors immune responses can still be
generated against viral proteins (Gahery-Segard et al, 1998; Molinier-Frenkel et al,
2000). For the future development of a vaccination strategy based on immune gene
transfer to leukaemia cells it will be necessary to have vectors that are highly
efficient at gene transfer to primary AML blasts, do not elicit host immune responses
against viral proteins and are capable of supporting transgene expression of
combinations of immune genes.
The second approach that was investigated for the purposes of developing a
leukaemia cell vaccine was the cytokine-induced differentiation of leukaemia cells to
dendritic-like cells. One of the potential advantages of this approach over an immune
gene transfer strategy is that following successful DLLC differentiation the
leukaemia cells express a wide range of costimulatory molecules, have high levels of
expression of ICAM-1 and HLA class I and II molecules and, in a proportion of
cases, produce the immunostimulatory cytokine IL-12 (Boyer et al, 2000; Brouwer et
al, 2000a; Brouwer et al, 2000b; Charbonnier et al, 1999; Choudhury et al, 1999;
Cignetti et al, 1999; Costello et al, 2000; Kohler et al, 2000; Oehler et al, 2000;
Robinson et al, 1998). Therefore DLLC may be better equipped to alter the
microenvironment in such a way as to promote effective immune responses and,
based on their ability to produced IL-12 (Charbonnier et al, 1999), skew T cell
cytokine responses towards a Thl phenotype (Kalinski et al, 1999a; Vieira et al,
2000). A potential concern with this approach is that leukaemia-specific antigens
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may in fact be down regulated during DLLC differentiation. WT1, the product of the
Wilms tumour gene is a leukaemia-specific antigen and therefore a potential target
for CTL recognition (Gaiger et al, 2000; Gao et al, 2000; Inoue et al, 1997; Menssen
et al, 1995; Ohminami et al, 2000). However the expression ofWT1 has been shown
to be down regulated during differentiation of CD34+ haematopoietic progenitors
(Menssen et al, 1997). If the same pattern were to be observed during leukaemia cell
differentiation then DLLC might be incapable of generating CTL specific for WT1,
or for other leukaemia-specific antigens whose expression is dependent on
differentiation status. Although FISH analysis does demonstrate that in selected
cases the leukaemia associated chromosomal rearrangement is still carried by the
DLLC (Boyer et al, 2000; Brouwer et al, 2000b; Choudury et al, 1999; Kohler et al,
2000; Oehler et al, 2000; Robinson et al, 1998) it cannot be assumed that the protein
products of these rearrangements would act as antigenic determinants. Therefore in
developing this strategy it will be necessary to have reliable and sensitive assays for
measuring T cell immune responses directed against leukaemia cells, both in vivo
and ex vivo. There are a number of potential ways of measuring T cell activity in
vivo. These include measuring delayed type hypersensitivity responses to intradermal
injections of leukaemia cells, measuring IFN-y production by leukaemia specific
CTL using the ELISPOT assay and by quantifying CTL specific for known
leukaemia antigens by the use of fluorescence labelled HLA-peptide tetramers. At
the present time it is not known which, if any, of the above assays are the most
appropriate for detecting clinically relevant immune responses to leukaemia in vivo.
Only by performing clinical trials of DLLC vaccination and correlating clinical
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responses with the results obtained from the immunological assays will it be possible
to establish the best methods for monitoring immune responses to leukaemia cells.
Any future clinical trials of DLLC vaccination will need to take into account a
number of important considerations in study design. One of the most serious
potential side effects of this type of strategy is that it could encourage the
development of autoimmunity. Following DLLC differentiation leukaemia cells
become potent APC and therefore, in addition to stimulating T cell responses to
leukaemia-specific antigens, might conceivably stimulate immunity against self-
antigens. Autoimmunity has been observed in a vaccination study using DC that had
been pulsed with leukaemia-derived peptides. Vaccination of leukaemia bearing
mice with pulsed DC, when given in combination with CD40L and IL2 transduced
fibroblasts, led to the development of a severe systemic autoimmune disease
resembling GVHD (Roskrow et al, 1999). Therefore in clinical trials of DLLC
vaccination patients will need to be monitored closely for evidence of loss of
tolerance to self-antigens. Another important consideration is the selection of
patients most likely to benefit from the DLLC vaccination strategy. Based on the
experience with DLI it is assumed that patients with a low leukaemia burden i.e.
following prior chemotherapy induced remission are most likely to derive clinical
benefit from immunotherapy type approaches. It is probably unlikely that
vaccination with DLLC would be able to lead to the eradication of high leukaemia
cell burdens. However as MRD is the major contributor to relapse and subsequent
death in patients with AML eradication ofMRD might well lead to improvements in
leukaemia-free survival rates. Given that recruitment of patients with low leukaemia
burden states seems most appropriate for the purposes of a clinical study it still
-170 -
remains to be determined what would be the best vaccination regimen. Clinical
studies will need to address the questions of DLLC dose, routes of vaccination and
frequency and duration of vaccination in order to determine the most effective
method for generating clinically relevant anti-leukaemia immunity.
Following on from our own in vitro studies in DLLC generation and characterisation
a phase I/II clinical study of DLLC vaccination in AML has now been designed. A
successful application to the Leukaemia Research Fund was made and the clinical
study is to be jointly funded by the Scottish National Blood Transfusion Service and
the Leukaemia Research Fund. A brief outline of the study is that four subcutaneous
injections of autologous DLLC, in escalating doses, will be given to patients with
AML who have undergone prior, successful, remission-induction chemotherapy. In
addition to assessing the tolerability of DLLC vaccination other outcomes to be
measured include the changes in immune function induced by vaccination and the
durations of leukaemia-free and overall survival.
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Appendix I
Optimisation of conditions for commercial transfection-reagents
DNA(pG) 0 3 4 4 6 10
Transfast (pi) 12 9 12 24 18 30
Charge ratio - 1:1 1:1 2:1 1:1 1:1
Table 1.1 Optimisation of conditions for Transfast in the K562 cell line alone
DNA(pg) 0 1 2 3 4 4
Transfast (pi) 1.2 3 6 9 12 24
Charge ratio 1:1 1:1 1:1 1:1 2:1
Table 1.2 Optimisation of conditions for Transfast in the four leukaemia cell lines
DNA (pg) 0 12 12 3
Fugene (pi) 3 3 3 6 6 6
Table 1.3 Optimisation of conditions for Fugene in the four leukaemia cell lines
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DNA(pg) 0 0.5 1 0.5 0.5
Enhancer (pi) 4 4 8 4 4
Effectene (pi) 5 5 10 12.5 25
Ratio 1:10 1:10 1:25 1:50
Table 1.4 Optimisation of conditions for Effectene in the four leukaemia cell lines
DNA (pg) 0 2 4
Superfect (pi) 8 8 16
Ratio 1:4 1:4
Table 1.5 Optimisation of conditions for Superfect in the four leukaemia cell lines
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Appendix II
Publications arising from this work
Roddie, P.H., Paterson, T. & Turner, M.L. (2000) Gene transfer to primary acute




ABS Human AB Serum
ALL Acute Lymphoblastic Leukaemia
AML Acute Myeloid Leukaemia
APC Antigen Presenting Cells
APML Acute Promyelocytic Leukaemia




c.p.m. Counts Per Minute
cDNA Complementary Deoxyribonucleic Acid
CAR Coxsackie virus and adenovirus receptor
CFU Colony Forming Units
CI Calcium Ionomycin
CML Chronic Myeloid Leukaemia
CTL Cytotoxic T Lymphocytes
DLI Donor Lymphocyte Infusion
DLLC Dendritic-like leukaemia cells





FACS Fluorescence Activated Cell Sorting
FasL Fas ligand
FCS Foetal Calf Serum
FISH Fluorescence In Situ Hybridisation
g Relative Centrifugal Force
GM-CSF Granulocyte Macrophage-Colony Stimulating Factor
GTE Gene Transfer Efficiency
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GTU Gene Transfer Unit
GVHD Graft Versus flost Disease
GVL Graft Versus Leukaemia
hi Heat Inactivated
HIV-1 Human Immunodeficiency Virus-1






LTR Long Terminal Repeat
mAb Monoclonal Antibody
MDDC Monocyte-derived dendritic cells
MFI Mean Fluorescence Intensity
MGG May-Grtinwald Giemsa
MHC Major Histocompatibility Complex
MLLR Mixed Leukaemia Lymphocyte Reaction
MLV-A Murine Amphotrophic envelope protein
MOI Multiplicity of Infection
Mo-MLV Moloney-Murine Leukaemia Virus
MRD Minimal Residual Disease
NK Natural Killer
PB Peripheral Blood
PBMC Peripheral Blood Mononuclear Cells
PBS Phosphate Buffered Saline
PE Phycoerythrin
PFU Plaque Forming Units
PHA Phytohaemagglutinin
PI Propidium iodide
PMA Phorbol Myristate Acetate
PolyI:C Polyriboinosinic polyribocytidylic acid
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R Rads
RD114 Feline Endogenous Retrovirus Envelope Protein
SCT Stem Cell Transplantation
TCR T Cell Receptor
TGF-p Transforming Growth Factor beta
Th T helper type
TNF-a Tumour Necrosis Factor alpha
ISA Trichostatin-A
VSV-G Vesicular Stomatitis virus-G envelope protein
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